<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants - Ohlsson, A - 2020 | Cochrane Library</title> <meta content="Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants - Ohlsson, A - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003481.pub8/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants - Ohlsson, A - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003481.pub8/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD003481.pub8" name="dc.identifier" scheme="DOI"/> <meta content="Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants" name="citation_title"/> <meta content="Arne Ohlsson&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="University of Toronto" name="citation_author_institution"/> <meta content="Rajneesh Walia" name="citation_author"/> <meta content="University of Birmingham and Walsall Manor Hospital" name="citation_author_institution"/> <meta content="Sachin S Shah" name="citation_author"/> <meta content="Surya Hospital for Women and Children" name="citation_author_institution"/> <meta content="sshahdoc@gmail.com" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="2" name="citation_issue"/> <meta content="10.1002/14651858.CD003481.pub8" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/02/11" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003481.pub8/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003481.pub8/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003481.pub8/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Infant, Low Birth Weight; Cyclooxygenase Inhibitors [therapeutic use]; Ductus Arteriosus, Patent [*drug therapy]; Enzyme Inhibitors [adverse effects, therapeutic use]; Ibuprofen [adverse effects, *therapeutic use]; Indomethacin [adverse effects, therapeutic use]; Infant, Premature; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003481.pub8&amp;doi=10.1002/14651858.CD003481.pub8&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003481.pub8&amp;doi=10.1002/14651858.CD003481.pub8&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003481.pub8&amp;doi=10.1002/14651858.CD003481.pub8&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003481.pub8&amp;doi=10.1002/14651858.CD003481.pub8&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003481.pub8&amp;doi=10.1002/14651858.CD003481.pub8&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003481.pub8&amp;doi=10.1002/14651858.CD003481.pub8&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003481.pub8&amp;doi=10.1002/14651858.CD003481.pub8&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003481.pub8&amp;doi=10.1002/14651858.CD003481.pub8&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003481.pub8&amp;doi=10.1002/14651858.CD003481.pub8&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003481.pub8&amp;doi=10.1002/14651858.CD003481.pub8&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003481.pub8&amp;doi=10.1002/14651858.CD003481.pub8&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003481.pub8&amp;doi=10.1002/14651858.CD003481.pub8&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003481.pub8&amp;doi=10.1002/14651858.CD003481.pub8&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003481.pub8&amp;doi=10.1002/14651858.CD003481.pub8&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003481.pub8&amp;doi=10.1002/14651858.CD003481.pub8&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003481.pub8&amp;doi=10.1002/14651858.CD003481.pub8&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003481.pub8&amp;doi=10.1002/14651858.CD003481.pub8&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003481.pub8&amp;doi=10.1002/14651858.CD003481.pub8&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003481.pub8&amp;doi=10.1002/14651858.CD003481.pub8&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003481.pub8&amp;doi=10.1002/14651858.CD003481.pub8&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003481.pub8&amp;doi=10.1002/14651858.CD003481.pub8&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003481.pub8&amp;doi=10.1002/14651858.CD003481.pub8&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003481.pub8&amp;doi=10.1002/14651858.CD003481.pub8&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="Ko3zGe0H";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD003481\x2epub8\x26doi\x3d10\x2e1002\x2f14651858\x2eCD003481\x2epub8\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003481\x2epub8\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003481\x2epub8\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","pt","ms","fr","pl","zh_HANT","ja","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD003481.pub8",title:"Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants",firstPublishedDate:"Feb 11, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Neonatal Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Ko3zGe0H&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003481.pub8&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003481.pub8';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD003481.pub8/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD003481.pub8/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003481.pub8%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD003481.PUB8" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD003481.pub8/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD003481.PUB8" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD003481.pub8/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD003481.pub8/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>10454 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD003481.pub8" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003481.pub8/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003481.pub8/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003481.pub8/full#CD003481-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003481.pub8/full#CD003481-sec-0183"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003481.pub8/full#CD003481-sec-0036"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003481.pub8/full#CD003481-sec-0037"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003481.pub8/full#CD003481-sec-0042"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003481.pub8/full#CD003481-sec-0043"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003481.pub8/full#CD003481-sec-0067"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003481.pub8/full#CD003481-sec-0177"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003481.pub8/appendices#CD003481-sec-0188"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/table_n/CD003481StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/table_n/CD003481StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003481.pub8/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003481.pub8/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003481.pub8/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003481.pub8/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003481.pub8/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD003481.pub8/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author custom-tooltip" title="Deceased"><a href="/cdsr/doi/10.1002/14651858.CD003481.pub8/information#CD003481-cr-0002">Arne Ohlsson</a><sup>a</sup></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003481.pub8/information#CD003481-cr-0003">Rajneesh Walia</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003481.pub8/information#CD003481-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Sachin S Shah</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/information/en#CD003481-sec-0195">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 11 February 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD003481.pub8">https://doi.org/10.1002/14651858.CD003481.pub8</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD003481-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003481-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003481-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003481-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD003481-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/pt#CD003481-abs-0002">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003481-abs-0016">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD003481-abs-0001" lang="en"> <section id="CD003481-sec-0001"> <h3 class="title" id="CD003481-sec-0001">Background</h3> <p>Indomethacin is used as standard therapy to close a patent ductus arteriosus (PDA) but is associated with reduced blood flow to several organs. Ibuprofen, another cyclo‐oxygenase inhibitor, may be as effective as indomethacin with fewer adverse effects. </p> </section> <section id="CD003481-sec-0002"> <h3 class="title" id="CD003481-sec-0002">Objectives</h3> <p>To determine the effectiveness and safety of ibuprofen compared with indomethacin, other cyclo‐oxygenase inhibitor(s), placebo, or no intervention for closing a patent ductus arteriosus in preterm, low‐birth‐weight, or preterm and low‐birth‐weight infants. </p> </section> <section id="CD003481-sec-0003"> <h3 class="title" id="CD003481-sec-0003">Search methods</h3> <p>We used the standard search strategy of Cochrane Neonatal to search the Cochrane Central Register of Controlled Trials (CENTRAL 2017, Issue 10), MEDLINE via PubMed (1966 to 30 November 2017), Embase (1980 to 30 November 2017), and CINAHL (1982 to 30 November 2017). We searched clinical trials databases, conference proceedings, and the reference lists of retrieved articles for randomised controlled trials and quasi‐randomised trials. </p> </section> <section id="CD003481-sec-0004"> <h3 class="title" id="CD003481-sec-0004">Selection criteria</h3> <p>Randomised or quasi‐randomised controlled trials of ibuprofen for the treatment of a PDA in preterm, low birth weight, or both preterm and low‐birth‐weight newborn infants. </p> </section> <section id="CD003481-sec-0005"> <h3 class="title" id="CD003481-sec-0005">Data collection and analysis</h3> <p>Data collection and analysis conformed to the methods of the Cochrane Neonatal Review Group. We used the GRADE approach to assess the quality of evidence. </p> </section> <section id="CD003481-sec-0006"> <h3 class="title" id="CD003481-sec-0006">Main results</h3> <p>We included 39 studies enrolling 2843 infants.</p> <p><b>Ibuprofen (IV) versus placebo:</b> IV Ibuprofen (3 doses) reduced the failure to close a PDA compared with placebo (typical relative risk (RR); 0.62 (95% CI 0.44 to 0.86); typical risk difference (RD); ‐0.18 (95% CI ‐0.30 to ‐0.06); NNTB 6 (95% CI 3 to 17); I<sup>2</sup> = 65% for RR and I<sup>2</sup> = 0% for RD; 2 studies, 206 infants; moderate‐quality the evidence). One study reported decreased failure to close a PDA after single or three doses of oral ibuprofen compared with placebo (64 infants; RR 0.26, 95% CI 0.11 to 0.62; RD ‐0.44, 95% CI ‐0.65 to ‐0.23; NNTB 2, 95% CI 2 to 4; I<sup>2</sup> test not applicable). </p> <p><b>Ibuprofen (IV or oral) compared with indomethacin (IV or oral):</b> Twenty‐four studies (1590 infants) comparing ibuprofen (IV or oral) with indomethacin (IV or oral) found no significant differences in failure rates for PDA closure (typical RR 1.07, 95% CI 0.92 to 1.24; typical RD 0.02, 95% CI ‐0.02 to 0.06; I<sup>2</sup> = 0% for both RR and RD; moderate‐quality evidence). A reduction in NEC (necrotising enterocolitis) was noted in the ibuprofen (IV or oral) group (18 studies, 1292 infants; typical RR 0.68, 95% CI 0.49 to 0.94; typical RD ‐0.04, 95% CI ‐0.07 to ‐0.01; NNTB 25, 95% CI 14 to 100; I<sup>2</sup> = 0% for both RR and RD; moderate‐quality evidence). There was a statistically significant reduction in the proportion of infants with oliguria in the ibuprofen group (6 studies, 576 infants; typical RR 0.28, 95% CI 0.14 to 0.54; typical RD ‐0.09, 95% CI ‐0.14 to ‐0.05; NNTB 11, 95% CI 7 to 20; I<sup>2</sup> = 24% for RR and I<sup>2</sup> = 69% for RD; moderate‐quality evidence). The serum/plasma creatinine levels 72 hours after initiation of treatment were statistically significantly lower in the ibuprofen group (11 studies, 918 infants; MD ‐8.12 µmol/L, 95% CI ‐10.81 to ‐5.43). For this comparison, there was high between‐study heterogeneity (I<sup>2</sup> = 83%) and low‐quality evidence. </p> <p><b>Ibuprofen (oral) compared with indomethacin (IV or oral):</b> Eight studies (272 infants) reported on failure rates for PDA closure in a subgroup of the above studies comparing oral ibuprofen with indomethacin (IV or oral). There was no significant difference between the groups (typical RR 0.96, 95% CI 0.73 to 1.27; typical RD ‐0.01, 95% CI ‐0.12 to 0.09; I<sup>2</sup> = 0% for both RR and RD). The risk of NEC was reduced with oral ibuprofen compared with indomethacin (IV or oral) (7 studies, 249 infants; typical RR 0.41, 95% CI 0.23 to 0.73; typical RD ‐0.13, 95% CI ‐0.22 to ‐0.05; NNTB 8, 95% CI 5 to 20; I<sup>2</sup> = 0% for both RR and RD). There was low‐quality evidence for these two outcomes. There was a decreased risk of failure to close a PDA with oral ibuprofen compared with IV ibuprofen (5 studies, 406 infants; typical RR 0.38, 95% CI 0.26 to 0.56; typical RD ‐0.22, 95% CI ‐0.31 to ‐0.14; NNTB 5, 95% CI 3 to 7; moderate‐quality evidence). There was a decreased risk of failure to close a PDA with high‐dose versus standard‐dose of IV ibuprofen (3 studies 190 infants; typical RR 0.37, 95% CI 0.22 to 0.61; typical RD ‐ 0.26, 95% CI ‐0.38 to ‐0.15; NNTB 4, 95% CI 3 to 7); I<sup>2</sup> = 4% for RR and 0% for RD); moderate‐quality evidence). </p> <p>Early versus expectant administration of IV ibuprofen, echocardiographically‐guided IV ibuprofen treatment versus standard IV ibuprofen treatment, continuous infusion of ibuprofen versus intermittent boluses of ibuprofen, and rectal ibuprofen versus oral ibuprofen were studied in too few trials to allow for precise estimates of any clinical outcomes. </p> </section> <section id="CD003481-sec-0007"> <h3 class="title" id="CD003481-sec-0007">Authors' conclusions</h3> <p>Ibuprofen is as effective as indomethacin in closing a PDA. Ibuprofen reduces the risk of NEC and transient renal insufficiency. Therefore, of these two drugs, ibuprofen appears to be the drug of choice. The effectiveness of ibuprofen versus paracetamol is assessed in a separate review. Oro‐gastric administration of ibuprofen appears as effective as IV administration. To make further recommendations, studies are needed to assess the effectiveness of high‐dose versus standard‐dose ibuprofen, early versus expectant administration of ibuprofen, echocardiographically‐guided versus standard IV ibuprofen, and continuous infusion versus intermittent boluses of ibuprofen. Studies are lacking evaluating the effect of ibuprofen on longer‐term outcomes in infants with PDA. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD003481-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003481-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003481-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003481-abs-0015">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD003481-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD003481-abs-0013">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD003481-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD003481-abs-0010">Polski</a> </li> <li class="section-language"> <a class="" href="full/pt#CD003481-abs-0007">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD003481-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003481-abs-0017">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD003481-abs-0012">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD003481-abs-0005" lang="en"> <h3>Ibuprofen for the treatment of patent ductus arteriosus in preterm or low‐birth‐weight (or both) infants </h3> <p><b>Review question</b> </p> <p>Is the use of ibuprofen compared with indomethacin, other cyclo‐oxygenase inhibitors, placebo, or no intervention for closing a patent ductus arteriosus (PDA) safe and effective for improving the rate of ductal closure and other important clinical outcomes in preterm or low‐birth‐weight (or both) infants? </p> <p><b>Background</b> </p> <p>A common complication for very preterm (premature) or very small babies is PDA. PDA is an open vascular channel between the lungs and the heart. It should close after birth, but sometimes remains open because of the baby's immature stage of development. PDA can lead to life‐threatening complications. The usual treatment for PDA has been indomethacin, a medicine that will successfully close the PDA in the majority of babies, but can cause serious side effects such as reduced blood flow to several organs. Another option is the drug ibuprofen. </p> <p><b>Study characteristics</b> </p> <p>We searched scientific databases for randomised controlled trials (clinical studies where people are randomly put into one of two or more treatment groups) in preterm infants (born at less than 37 weeks into pregnancy), low‐birth‐weight (weighing less than 2500 g) infants, or preterm and low‐birth‐weight infants with a PDA. The treatments were ibuprofen, indomethacin, another cyclo‐oxygenase inhibitor, placebo or no treatment. The evidence is current to 30 November 2017. </p> <p><b>Key Results</b> </p> <p>This review of 39 trials (2843 infants) found that ibuprofen was as effective as indomethacin in closing a PDA, caused fewer transient side effects on the kidneys, and reduced the risk of necrotising enterocolitis, a serious condition that affects the gut. Whether ibuprofen confers any important long‐term advantages or disadvantages on development is not known. Additional long‐term follow‐up studies to 18 months of age and to the age of school entry are needed to decide whether ibuprofen or indomethacin is the drug of choice for closing a PDA. </p> <p><b>Quality of Evidence:</b> According to GRADE (a method to score the quality of the trials supporting each outcome), the quality of the evidence varied from very low to moderate but was moderate for the important outcomes of failure to close a PDA, need for surgical closure of the PDA, duration of ventilator support, necrotizing enterocolitis, oliguria and serum/plasma creatinine levels when we compared intravenous or oral ibuprofen with intravenous or oral indomethacin. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD003481-sec-0183" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD003481-sec-0183"></div> <h3 class="title" id="CD003481-sec-0184">Implications for practice</h3> <section id="CD003481-sec-0184"> <p>Ibuprofen is more effective in closing a patent ductus arteriosus (PDA) compared with placebo. We found no statistically significant difference in the effectiveness of ibuprofen compared with indomethacin in closing a PDA. Ibuprofen reduced the risk of necrotising enterocolitis (NEC), time on assisted ventilation, and had fewer negative effects on renal function. Pulmonary hypertension was observed in three infants after the prophylactic use of ibuprofen, in one case in this review and in additional case reports for the treatment of a PDA. Either ibuprofen or indomethacin can be used to close a PDA. Based on currently available information, ibuprofen does appear to confer net benefits over indomethacin for the treatment of a PDA, but the clinician needs to be aware that both drugs are associated with adverse effects. </p> </section> <h3 class="title" id="CD003481-sec-0185">Implications for research</h3> <section id="CD003481-sec-0185"> <p>Future research would benefit from long‐term follow‐up (intact survival) to at least 18 months' corrected age, and preferably to the age of school entry. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD003481-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD003481-sec-0036"></div> <div class="table" id="CD003481-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Intravenous ibuprofen compared with placebo for patent ductus arteriosus</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population: preterm infants with patent ductus arteriosus</b> </p> <p><b>Settings: NICU</b> </p> <p><b>Intervention: intravenous ibuprofen</b> </p> <p><b>Comparison: placebo</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>IV ibuprofen</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Failure to close a patent ductus arteriosus (after 3 doses)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.62</b> (0.44 to 0.86) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>206<br/> (2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bias: there was unclear bias for random sequence generation and allocation concealment in the two included studies. The blinding of personnel was unclear in both studies and the blinding of outcome assessments was low risk in one study and unclear in the other study. We did not downgrade the evidence. </p> <p>Heterogeneity/consistency: we noted moderate heterogeneity (65%) for RR but no heterogeneity (0%) for RD. We downgraded the evidence by one step. </p> <p>Directness of evidence: studies were conducted in the target population.</p> <p>Precision: the confidence intervals around the point estimates for RR and RD were quite narrow </p> <p>Presence of publication bias: this category was not applicable as only two studies were included in the analysis. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>471 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>294 per 1000</b><br/> 29 to 432 </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Necrotising enterocolitis</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.84</b> (0.87 to 3.90) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>264<br/> (2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bias: the information about random sequence generation, allocation concealment, blinding of personnel and blinding of outcome assessments was unclear in one of the two studies. In the second study there were no concerns about these items. We did not downgrade the evidence. </p> <p>Heterogeneity/consistency: we noted high heterogeneity (77%) for RR and moderate heterogeneity (67%) for RD. We downgraded the evidence by one step. </p> <p>Directness of evidence: studies were conducted in the target population.</p> <p>Precision: the confidence intervals around the point estimates for RR and RD were quite narrow. </p> <p>Presence of publication bias: this category was not applicable as only two studies were included in the analysis. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>68 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>129 per 1000</b><br/> (119 to 139) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>IV:</b> intravenous; <b>NICU:</b> Neonatal intensive care unit: <b>RD:</b> risk difference; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD003481-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Intravenous or oral ibuprofen compared with intravenous or oral indomethacin for patent ductus arteriosus</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population: preterm infants with patent ductus arteriosus</b> </p> <p><b>Settings: NICU</b> </p> <p><b>Intervention: intravenous or oral ibuprofen</b> </p> <p><b>Comparison: intravenous or oral indomethacin</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Indomethacin (IV or oral)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Ibuprofen (IV or oral)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Failure to close a patent ductus arteriosus (PDA) (after single or 3 doses)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.07</b> (0.92 to 1.24) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1590<br/> (24) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bias: there was low risk of bias for random sequence generation in 7 of the studies and there was unclear risk in the remaining 17 studies.There was low risk of bias for allocation concealment in 13 studies, high risk of bias in one study and unclear risk in the remaining 10 studies. The blinding of personnel was adequate in three studies, unclear in six studies and there was high risk of bias in 15 studies. Blinding of outcome assessments was at low risk of bias in 11 studies, unclear in six studies and there was high risk of bias in seven studies. We downgraded the evidence by one step. </p> <p>Heterogeneity/consistency: there was no heterogeneity (0%) for either RR or for RD.</p> <p>Directness of evidence: studies were conducted in the target population.</p> <p>Precision: the confidence intervals around the point estimates for RR and RD were narrow. </p> <p>Presence of publication bias: the funnel plot was symmetric based on 24 studies.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>280 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>305 per 1000</b><br/> (0 to 708) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Need for surgical closure of the PDA</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.06</b> (0.81 to 1.39) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1275<br/> (16) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bias: there was low risk of bias for random sequence generation in seven of the studies and there was unclear risk in the remaining 9 studies.There was low risk of bias for allocation concealment in 10 studies, high risk of bias in one study and unclear risk in the remaining 5 studies. The blinding of personnel was adequate in three studies, unclear in two studies and there was high risk of bias in 11 studies. Blinding of outcome assessments was at low risk of bias in 9 studies, unclear in three studies and there was high risk of bias in four studies. We downgraded the evidence by one step. </p> <p>Heterogeneity/consistency: there was no heterogeneity (0%) for either RR or for RD.</p> <p>Directness of evidence: studies were conducted in the target population.</p> <p>Precision: the confidence intervals around the point estimates for RR and RD were narrow. </p> <p>Presence of publication bias: the funnel plot was symmetric based on 16 studies.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>135 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>144 per 1000</b><br/> (0 to 250) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of ventilator support (days)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean duration of ventilator support (days) ranged across control groups from 8 to 26 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean duration of ventilator support (days) in the intervention groups was 2.35 days lower (3.71 to 0.99 days lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD ‐2.35</b> (‐3.71 to ‐0.99) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>471<br/> (6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bias: there was low risk of bias for random sequence generation in two of the studies and there was unclear risk in the remaining four studies.There was low risk of bias for allocation concealment in five studies, and unclear risk in one study. The blinding of personnel was adequate in two studies, and there was high risk of bias in four studies. Blinding of outcome assessments was at low risk of bias in four studies, and unclear in two studies. We downgraded the evidence by one step. </p> <p>Heterogeneity/consistency: there was no heterogeneity (19%) for MD.</p> <p>Directness of evidence: studies were conducted in the target population.</p> <p>Precision: the confidence intervals around the point estimates for RR and RD were narrow. </p> <p>Presence of publication bias: only 6 studies were included in the analysis so a funnel plot was not constructed. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Necrotising enterocolitis (any stage)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.68</b> (0.49 to 0.94) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1292<br/> (18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bias: there was low risk of bias for random sequence generation in seven of the studies and there was unclear risk in the remaining 11 studies.There was low risk of bias for allocation concealment in eleven studies, high risk in one study and unclear risk in six studies. The blinding of personnel was adequate in two studies, and there was high risk of bias in 13 studies and an unclear risk of bias in three studies. Blinding of outcome assessments was at low risk of bias in ten studies, high risk of bias in five studies and unclear in three studies. We downgraded the evidence by one step. </p> <p>Heterogeneity/consistency: there was no heterogeneity (0%) for RR and RD.</p> <p>Directness of evidence: studies were conducted in the target population.</p> <p>Precision: the confidence intervals around the point estimates for RR and RD were narrow. </p> <p>Presence of publication bias: the funnel plot was symmetric based on 18 studies.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>111 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>73 per 1000</b><br/> (0 to 400) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Oliguria (urine output &lt; 1 mL/kg/hour)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.28</b> (0.14 to 0.54) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>576<br/> (6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bias: there was low risk of bias for random sequence generation in two of the studies and there was unclear risk in the remaining four studies.There was low risk of bias for allocation concealment in four studies, and unclear risk in two studies. The blinding of personnel was adequate in two studies, unclear in one study and there was high risk of bias in three studies. Blinding of outcome assessments was at low risk of bias in all six studies. We did not downgrade the evidence. </p> <p>Heterogeneity/consistency: there was no heterogeneity (24%) for RR and moderate for RD (69%). We downgraded the evidence by one step. </p> <p>Directness of evidence: studies were conducted in the target population.</p> <p>Precision: the confidence intervals around the point estimates for RR and RD were narrow. </p> <p>Presence of publication bias: only 6 studies were included in the analysis so a funnel plot was not constructed. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>124 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>34 per 1000</b><br/> (0 to 68) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serum/plasma creatinine levels (μmol/L) 72 hours after treatment</b> </p> <p>Normal values for male and female newborns 17.7 to 88.4 µmol/L</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean s<b>erum/plasma creatinine level</b> ranged across control groups from 45.97 to 147.63 <b>μmol/L</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean s<b>erum/plasma creatinine level</b> in the intervention groups was<br/> 8.12 <b>μmol/L lower (‐10.81 to ‐ 5.43 lower)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD ‐8.12 μmol/L (‐10.81 to ‐ 5.43)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>918<br/> (11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bias: there was low risk of bias for random sequence generation in four of the studies and there was unclear risk in the remaining seven studies.There was low risk of bias for allocation concealment in seven studies and unclear risk in four studies. The blinding of personnel was adequate in two studies, there was high risk of bias in seven studies, and the risk of bias was unclear in two studies. Blinding of outcome assessments was at low risk of bias in six studies but there was high risk of bias in 5 studies. We downgraded the evidence by one step. </p> <p>Heterogeneity/consistency: there was high heterogeneity (83%) for MD. We downgraded the evidence by one step. </p> <p>Directness of evidence: studies were conducted in the target population.</p> <p>Precision: the confidence intervals around the point estimates for MD were narrow.</p> <p>Presence of publication bias: the funnel plot was symmetric based on 11 studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>IV:</b> intravenous; <b>MD</b> : mean difference; <b>NICU:</b> Neonatal intensive care unit; <b>RD</b> : risk difference; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD003481-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Oral ibuprofen compared with intravenous or oral indomethacin for patent ductus arteriosus</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population: preterm infants with patent ductus arteriosus</b> </p> <p><b>Settings: NICU</b> </p> <p><b>Intervention: oral ibuprofen</b> </p> <p><b>Comparison: intravenous or oral indomethacin</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Intravenous or oral indomethacin</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Oral ibuprofen</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Failure to close a patent ductus arteriosus (PDA) (after 3 doses)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.96</b> (0.73 to 1.27) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>272<br/> (8) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bias: there was low risk of bias for random sequence generation in two of the studies and there was unclear risk in the remaining six studies.There was low risk of bias for allocation concealment in 3 studies, high risk of bias in one study and unclear risk in four studies. The blinding of personnel was inadequate in seven studies and unclear in one study. Blinding of outcome assessments was good in two of the studies but with high risk of bias in six studies. We downgraded the evidence by two steps. </p> <p>Heterogeneity/consistency: we noted no heterogeneity (0%) for RR and RD.</p> <p>Directness of evidence: studies were conducted in the target population.</p> <p>Precision: the confidence interval around the point estimates for MD was quite narrow</p> <p>Presence of publication bias: only 8 studies were included in the analysis so a funnel plot was not constructed. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>386 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>393 per 1000</b><br/> (0 to 708) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Need for surgical closure of the PDA</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.93</b> (0.50 to 1.74) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>174<br/> (4) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bias: there was low risk of bias for random sequence generation in two of the studies and there was unclear risk in two studies.There was low risk of bias for allocation concealment in one study, high risk of bias in one study and unclear risk in two studies. The blinding of personnel was inadequate in all four studies as was blinding of outcome assessments. We downgraded the evidence by two steps. </p> <p>Heterogeneity/consistency: we noted no heterogeneity (0%) for RR and RD.</p> <p>Directness of evidence: studies were conducted in the target population.</p> <p>Precision: the confidence interval around the point estimate for RR and RD was quite narrow. </p> <p>Presence of publication bias: only 4 studies were included in the analysis so a funnel plot was not constructed. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>188 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>181 per 1000</b><br/> (0 to250) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Necrotising enterocolitis (any stage)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.41</b> (0.23 to 0.73) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>249<br/> (7) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bias: there was low risk of bias for random sequence generation in two of the studies and there was unclear risk in the remaining five studies.There was low risk of bias for allocation concealment in 3 studies, high risk of bias in one study and unclear risk in three studies. The blinding of personnel was inadequate in six studies and unclear in one study. Blinding of outcome assessments was good in two of the studies but with high risk of bias in five studies. We downgraded the evidence by two steps. </p> <p>Heterogeneity/consistency: we noted no heterogeneity (0%) for RR and RD.</p> <p>Directness of evidence: studies were conducted in the target population.</p> <p>Precision: the confidence interval around the point estimates for MD was quite narrow.</p> <p>Presence of publication bias: only 7 studies were included in the analysis so a funnel plot was not constructed. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>224 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>83 per 1000</b><br/> (0 to 400) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serum/plasma creatinine levels (µmol/L) 72 hours after treatment</b> </p> <p>Normal values for male and female newborns 17.7 to 88.4 µmol/L</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>The mean serum/plasma creatinine levels ranged across control groups from 45.97 to 106.08 µmol/L</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean <b>serum/plasma creatinine level</b> in the intervention groups was 0.51 <b>µmol/L (‐6.04 to 5.01)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD ‐0.51</b> (‐6.04 to 5.01) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>190<br/> (5) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bias: there was low risk of bias for random sequence generation in one of the studies and there was unclear risk in the remaining 4 studies.There was low risk of bias for allocation concealment in 3 studies, and unclear risk in two studies The blinding of personnel was inadequate in four studies and unclear in one study. Blinding of outcome assessments was good in one of the studies but with high risk of bias in four studies. We downgraded the evidence by two steps. </p> <p>Heterogeneity/consistency: we noted moderate heterogeneity (72%) for MD. We downgraded the evidence by one step. </p> <p>Directness of evidence: studies were conducted in the target population.</p> <p>Precision: the confidence interval around the point estimates for MD was quite narrow.</p> <p>Presence of publication bias: only 5 studies were included in the analysis so a funnel plot was not constructed. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>MD:</b> Mean difference; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD003481-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Oral ibuprofen compared with intravenous ibuprofen for patent ductus arteriosus</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population: preterm infants with patent ductus arteriosus</b> </p> <p><b>Settings: NICU</b> </p> <p><b>Intervention: oral ibuprofen</b> </p> <p><b>Comparison: intravenous ibuprofen</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>intravenous ibuprofen</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>oral ibuprofen</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Failure to close a patent ductus arteriosus (after single or 3 doses)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.38</b> (0.26 to 0.56) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>406<br/> (5) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bias: there was unclear risk of bias for random sequence generation in all 5 studies. There was low risk of bias for allocation concealment in 4 studies, and unclear risk in one study. The blinding of personnel was inadequate in all five studies and blinding of outcome assessments was good in three studies but inadequate in two studies. We downgraded the evidence by one step. </p> <p>Heterogeneity/consistency: we noted no heterogeneity for RR and for RD (0%).</p> <p>Directness of evidence: studies were conducted in the target population.</p> <p>Precision: the confidence intervals around the point estimates for RR and RD were quite narrow. </p> <p>Presence of publication bias: only 5 studies were included in the analysis so a funnel plot was not constructed. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>363 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>139 per 1000</b><br/> (115 to 156) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Need for surgical closure of the ductus</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.41</b> (0.41 to 1.21) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>406<br/> (5) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bias: there was unclear risk of bias for random sequence generation in all 5 studies. There was low risk of bias for allocation concealment in 4 studies, and unclear risk in one study. The blinding of personnel was inadequate in all five studies and blinding of outcome assessments was good in three studies but inadequate in two studies We downgraded the evidence by one step. </p> <p>Heterogeneity/consistency: we noted no heterogeneity for RR and for RD (0%).</p> <p>Directness of evidence: studies were conducted in the target population.</p> <p>Precision: the confidence intervals around the point estimates for RR and RD were quite narrow. </p> <p>Presence of publication bias: only 5 studies were included in the analysis so a funnel plot was not constructed. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>51 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>19 per 1000</b><br/> (0 to 31) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Duration of ventilatory support</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>MD 0.54 (days)</b> (‐0.01 to 1.10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>134</p> <p>(2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Bias: there was unclear risk of bias for random sequence generation in both studies. There was low risk of bias for allocation concealment in one study, and unclear risk in one study. The blinding of personnel was inadequate in both studies and blinding of outcome assessments was good in one study but inadequate in two one study. We downgraded the evidence by one step. </p> <p>Heterogeneity/consistency: we noted no heterogeneity for MD (10%).</p> <p>Directness of evidence: studies were conducted in the target population.</p> <p>Precision: the confidence intervals around the point estimates for RR and RD were quite wide. We downgraded the evidence by one step. </p> <p>Presence of publication bias: only two studies were included in the analysis so a funnel plot was not constructed. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>The mean duration of ventilatory support (days) ranges across control groups from 3 to 5.1 days</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>The mean duration of ventilatory support was 0.54 (days) higher in the in the oral ibuprofen group (‐0.01 to 1.10)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serum/plasma creatinine levels (μmol/L) after treatment</b> </p> <p>Normal values for male and female newborns 17.7 to 88.4 µmol/L</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>The mean serum/plasma creatinine levels ranged across control groups from 69.84 to 76.02 (μmol/L)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>The mean serum/plasma creatinine level in the intervention groups was 22.47 (μmol/L) lower</b> (‐32.40 to ‐12.53) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 22.47</b> (μmol/L) (‐32.40 to ‐12.53) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>170<br/> (2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bias: there was unclear risk of bias for random sequence generation in both studies. There was low risk of bias for allocation concealment in one study, and unclear risk in one study. The blinding of personnel was inadequate in both studies and blinding of outcome assessments was good in one study but inadequate in the other study. We downgraded the evidence by one step. </p> <p>Heterogeneity/consistency: there was high heterogeneity for MD (81%). We downgraded the evidence by one step. </p> <p>Directness of evidence: studies were conducted in the target population.</p> <p>Precision: the confidence intervals around the point estimates for MD were quite narrow.</p> <p>Presence of publication bias: only 2 studies were included in the analysis so a funnel plot was not constructed. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Oliguria (Urine output &lt; 1 mL/kg/hour)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.14</b> (0.01 to 2.66) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>304<br/> (4) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bias: there was unclear risk of bias for random sequence generation in all 4 studies. There was low risk of bias for allocation concealment in three studies, and unclear risk in one study. The blinding of personnel was inadequate in all four studies and blinding of outcome assessments was good in three studies but inadequate in one study. We downgraded the evidence by one step. </p> <p>Heterogeneity/consistency: tests for heterogeneity were not applicable for RR as there were only outcomes in one group in one trial. We noted no heterogeneity for RD (19%). </p> <p>Directness of evidence: studies were conducted in the target population.</p> <p>Precision: the confidence interval around the point estimate for RR was quite wide. We downgraded the evidence by one step. </p> <p>Presence of publication bias: only 4 studies were included in the analysis so a funnel plot was not constructed. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>IV:</b> intravenous; <b>MD</b> : Mean difference; <b>NICU:</b> Neonatal intensive care unit; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD003481-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>High‐dose oral or intravenous ibuprofen compared with standard‐dose oral or intravenous ibuprofen for patent ductus arteriosus</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population: preterm infants</b> with patent ductus arteriosus </p> <p><b>Settings: NICU</b> </p> <p><b>Intervention: high‐dose oral or intravenous ibuprofen</b> </p> <p><b>Comparison: standard‐dose oral or intravenous ibuprofen</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Standard‐dose ibuprofen</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>High‐dose ibuprofen</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Failure to close a patent ductus arteriosus after 3 doses of ibuprofen</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.37</b> (0.22 to 0.61) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>190<br/> (3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bias: there was unclear risk of bias for random sequence generation in all three studies. The allocation was concealed in two of the studies and unclear in one study. The blinding of personnel was unclear in all three studies and blinding of outcome assessments was unclear in one of the three studies, with low risk of bias in the other two studies. We downgraded the evidence by one step. </p> <p>Heterogeneity/consistency: we noted no heterogeneity for RR (4%) or for RD (0%).</p> <p>Directness of evidence: studies were conducted in the target population.</p> <p>Precision: the confidence intervals around the point estimates for RR and RD were quite narrow. </p> <p>Presence of publication bias: only 3 studies were included in the analysis so a funnel plot was not constructed. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>411 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>147 per 1000</b><br/> (0 to 300) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Necrotising enterocolitis</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.00</b> (0.40 to 2.50) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>130<br/> (2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bias: there was unclear risk of bias for random sequence generation in both studies. The allocation was concealed in both studies. The blinding of personnel was unclear in both studies but there was low risk of bias for blinding of outcome assessments. We downgraded the evidence by one step. </p> <p>Heterogeneity/consistency: we noted no heterogeneity for RR or for RD (0% for both).</p> <p>Directness of evidence: studies were conducted in the target population.</p> <p>Precision: the confidence intervals around the point estimates for RR and RD were quite wide as the sample size was small. We downgraded the evidence by one step. </p> <p>Presence of publication bias: only 2 studies were included in the analysis so a funnel plot was not constructed. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>123 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>123 per 1000</b><br/> (114 to 133) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Oliguria</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 1.57</b> (0.44 to 5.63) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>120</p> <p>(2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Bias: there was unclear risk of bias for random sequence generation in both studies. The allocation was concealed in one study. The blinding of personnel was unclear in both studies but there was low risk of bias for blinding of outcome assessments (by cardiologist) in one study. We downgraded the evidence by one step. </p> <p>Heterogeneity/consistency: we noted no heterogeneity for RR or for RD (0% for both).</p> <p>Directness of evidence: studies were conducted in the target population.</p> <p>Precision: the confidence intervals around the point estimates for RR and RD were quite wide as the sample size was small. We downgraded the evidence by one step. </p> <p>Presence of publication bias: only 2 studies were included in the analysis so a funnel plot was not constructed. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>50 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>83 per 1000</p> <p>(33 to 133)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>NICU:</b> Neonatal intensive care unit; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD003481-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD003481-sec-0037"></div> <section id="CD003481-sec-0038"> <h3 class="title" id="CD003481-sec-0038">Description of the condition</h3> <p>Normal fetal circulation is dependent on the placenta and the patency of the ductus arteriosus (PDA) (<a href="./references#CD003481-bbs2-0082" title="MathewR . Development of the pulmonary circulation: metabolic aspects. In: PolinRA , FoxWW editor(s). Fetal and Neonatal Physiology. Vol. 1, Philadelphia: W.B. Saunders Company, 1998:924‐9. ">Mathew 1998</a>). Following birth and with the separation of the placenta and initiation of breathing, the circulation changes and closure of the ductus starts immediately (<a href="./references#CD003481-bbs2-0082" title="MathewR . Development of the pulmonary circulation: metabolic aspects. In: PolinRA , FoxWW editor(s). Fetal and Neonatal Physiology. Vol. 1, Philadelphia: W.B. Saunders Company, 1998:924‐9. ">Mathew 1998</a>). However, in about a third of low‐birth‐weight (LBW; weighing less than 2500 g) infants, the PDA remains open, especially during the early days of life (<a href="./references#CD003481-bbs2-0067" title="EllisonRC , PechamGJ , LangP , TalnerNS , LererTJ , LinL , et al. Evaluation of the preterm infant for patent ductus arteriosus. Pediatrics1983;71(3):364‐72. [PUBMED: 6338474] ">Ellison 1983</a>). In preterm neonates, the PDA often fails to close. The haemodynamic instability caused by the left to right shunt and associated run off causes renal or gastrointestinal effects including spontaneous perforation and necrotising enterocolitis (NEC), chronic lung disease (CLD) and, if not managed, may lead to mortality (<a href="./references#CD003481-bbs2-0063" title="CottonRB , StahlmanMT , KovarI , CattertonWZ . Medical management of small preterm infants with symptomatic patent ductus arteriosus. Journal of Pediatrics1978;92(3):467‐73. [PUBMED: 632994] ">Cotton 1978a</a>). The presence of a PDA is associated with reduced middle cerebral artery blood flow velocity (<a href="./references#CD003481-bbs2-0104" title="WeirFJ , OhlssonA , MyhrTL , FongK , RyanML . A patent ductus arteriosus is associated with reduced middle cerebral artery blood flow velocity. European Journal of Pediatrics1999;158(6):484‐7. [PUBMED: 10378397] ">Weir 1999</a>). </p> <p>The surgical closure of the symptomatic PDA reduces duration of mechanical ventilation, improves haemodynamics, and improves lung compliance (<a href="./references#CD003481-bbs2-0064" title="CottonRB , StahlmanMT , BenderHW , GrahamTP , CattertonWZ , KovarI . Randomized trial of early closure of symptomatic patent ductus arteriosus in small preterm infants. Journal of Pediatrics1978;93(4):647‐51. [PUBMED: 702245] ">Cotton 1978b</a>; <a href="./references#CD003481-bbs2-0084" title="NaultyCM , HornS , ConryJ , AveryGB . Improved lung compliance after ligation of patent ductus arteriosus in hyaline membrane disease. Journal of Pediatrics1978;93(4):682‐4. [PUBMED: 702251] ">Naulty 1978</a>). However, medical treatment is still considered the treatment of choice in the majority of cases because of the risks related to the surgery. In a large Canadian cohort of 3779 very low‐birth‐weight (VLBW, weighing less than 1500 g) infants, 28% required treatment for a PDA; 75% were treated with indomethacin alone, 8% with surgical ligation alone, and 17% required both indomethacin and surgical ligation (<a href="./references#CD003481-bbs2-0079" title="LeeSK , McMillanDD , OhlssonA , PendrayM , SynnesA , WhyteR , et al. Variations in practice and outcomes in the Canadian NICU Network: 1996‐1997. Pediatrics2000;106(5):1070‐9. [PUBMED: 11061777] ">Lee 2000</a>). Infants with lower birth weight (BW) were more likely to be treated surgically (<a href="./references#CD003481-bbs2-0079" title="LeeSK , McMillanDD , OhlssonA , PendrayM , SynnesA , WhyteR , et al. Variations in practice and outcomes in the Canadian NICU Network: 1996‐1997. Pediatrics2000;106(5):1070‐9. [PUBMED: 11061777] ">Lee 2000</a>). </p> </section> <section id="CD003481-sec-0039"> <h3 class="title" id="CD003481-sec-0039">Description of the intervention</h3> <p>Prostaglandins play a significant role in keeping the ductus arteriosus patent (<a href="./references#CD003481-bbs2-0082" title="MathewR . Development of the pulmonary circulation: metabolic aspects. In: PolinRA , FoxWW editor(s). Fetal and Neonatal Physiology. Vol. 1, Philadelphia: W.B. Saunders Company, 1998:924‐9. ">Mathew 1998</a>). PDA‐related morbidity and mortality reduce with the use of indomethacin, which acts as an inhibitor of prostaglandin‐forming cyclo‐oxygenase enzymes (<a href="./references#CD003481-bbs2-0080" title="MahonyL , CarneroV , BrettC , HeymannMA , ClymanRI . Prophylactic indomethacin therapy for patent ductus arteriosus in very‐low‐birth‐weight infants. New England Journal of Medicine1982;306(9):506‐10. [DOI: 10.1056/NEJM198203043060903; PUBMED: 7035955] ">Mahony 1982</a>; <a href="./references#CD003481-bbs2-0100" title="StefanoJL , AbbasiS , PearlmanSA , SpearML , EsterlyKL , BhutaniVK . Closure of the ductus arteriosus with indomethacin in ventilated neonates with respiratory distress syndrome: effects on pulmonary compliance and ventilation. American Review of Respiratory Disease1991;143(2):236‐9. [DOI: 10.1164/ajrccm/143.2.236; PUBMED: 1990934] ">Stefano 1991</a>). However, indomethacin use has been associated with transient or permanent derangement of renal function, NEC, gastrointestinal haemorrhage or perforation, alteration of platelet function and impairment of cerebral blood flow/cerebral blood flow velocity (<a href="./references#CD003481-bbs2-0065" title="EdwardsAD , WyattJS , RichardsonC , PotterA , CopeM , DelpyDT , et al. Effects of indomethacin on cerebral haemodynamics in very preterm infants. Lancet1990;335(8704):1491‐5. [PUBMED: 1972434] ">Edwards 1990</a>; <a href="./references#CD003481-bbs2-0087" title="OhlssonA , BottuJ , GovanJ , RyanML , FongK , MyhrT . The effect of indomethacin on cerebral blood flow velocities in very low birth weight neonates with patent ductus arteriosus. Developmental Pharmacology and Therapeutics1993;20(1‐2):100‐6. [PUBMED: 7924757] ">Ohlsson 1993</a>; <a href="./references#CD003481-bbs2-0099" title="SeyberthHW , RascherW , HackenthalR , WilleL . Effect of prolonged indomethacin therapy on renal function and selected vasoactive hormones in very low birth weight infants with symptomatic ductus arteriosus. Journal of Pediatrics1983;103(6):979‐84. [PUBMED: 6358443] ">Seyberth 1983</a>; <a href="./references#CD003481-bbs2-0105" title="WolfWM , SnoverDC , LeonardAS . Localized intestinal perforation following intravenous indomethacin in premature infants. Journal of Pediatric Surgery1989;24(4):409‐10. [PUBMED: 2732888] ">Wolf 1989</a>). These negative effects of indomethacin are possibly related to mechanisms other than inhibition of prostaglandin synthesis. </p> <p>In one large trial of 1202 extremely low‐birth‐weight infants, indomethacin prophylaxis did not significantly improve the rate of survival without neurosensory impairment at 18 months, despite the fact that it reduced the frequency of PDA and severe periventricular and intraventricular haemorrhage (IVH) (<a href="./references#CD003481-bbs2-0096" title="SchmidtB , DavisP , ModdemanD , OhlssonA , RobertsRS , SaigalS , et al. Trial of Indomethacin Prophylaxis in Preterms Investigators. Long‐term effect of indomethacin prophylaxis in extremely‐low‐birth‐weight infants. New England Journal of Medicine2001;344(26):1966‐72. [DOI: 10.1056/NEJM200106283442602; PUBMED: 11430325] ">Schmidt 2001</a>). One Cochrane review confirmed that prophylactic treatment with indomethacin has a number of short‐term benefits, in particular a reduction in symptomatic PDA, the need for ductal ligation, and severe IVH (<a href="./references#CD003481-bbs2-0068" title="FowliePW , DavisPG , McGuireW . Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. Cochrane Database of Systematic Reviews2010, Issue 7. [DOI: 10.1002/14651858.CD000174.pub2] ">Fowlie 2010</a>). The same review found no evidence of either benefit or harm concerning longer‐term outcomes, including neurodevelopment (<a href="./references#CD003481-bbs2-0068" title="FowliePW , DavisPG , McGuireW . Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. Cochrane Database of Systematic Reviews2010, Issue 7. [DOI: 10.1002/14651858.CD000174.pub2] ">Fowlie 2010</a>). </p> </section> <section id="CD003481-sec-0040"> <h3 class="title" id="CD003481-sec-0040">How the intervention might work</h3> <p>The complications associated with the use of indomethacin have encouraged the search for an alternate drug to treat a PDA. Ibuprofen, a propionic acid derivative and non‐selective cyclo‐oxygenase inhibitor, has been reported to close a PDA, but without gastrointestinal haemodynamic disturbance and potentially harmful cerebral adverse effects (<a href="./references#CD003481-bbs2-0060" title="ChemtobS , BeharryK , BarnaT , VarmaDR , ArandaJV . Differences in the effects in the newborn piglet of various nonsteroidal antiinflammatory drugs on cerebral blood flow but not on cerebrovascular prostaglandins. Pediatric Research1991;30(1):106‐11. [DOI: 10.1203/00006450‐199107000‐00021; PUBMED: 1891274] ">Chemtob 1991</a>; <a href="./references#CD003481-bbs2-0061" title="CoceaniF , WhiteE , BodachE , OlleyPM . Age‐dependent changes in the responses of the lamb ductus arteriosus to oxygen and ibuprofen. Canadian Journal of Physiology and Pharmacology1979;57(8):825‐31. [PUBMED: 497895] ">Coceani 1979</a>; <a href="./references#CD003481-bbs2-0103" title="VarvarigouA , BardinCL , BeharryK , ChemtobS , PapageorgiouA , ArandaJV . Early ibuprofen administration to prevent patent ductus arteriosus in premature newborn infants. JAMA1996;275(7):539‐44. [PUBMED: 8606475] ">Varvarigou 1996</a>). Ibuprofen has some neuro‐protective effects in animal models (<a href="./references#CD003481-bbs2-0059" title="ChemtobS , BeharyK , RexJ , VarmaDR , ArandaJV . Prostanoids determine the range of cerebral blood flow autoregulation of newborn piglets. Stroke1990;21(5):777‐84. [PUBMED: 2339458] ">Chemtob 1990</a>; <a href="./references#CD003481-bbs2-0092" title="PellicerA , AparicioM , CabanasF , ValverdeE , QueroJ , StirisTA . Effect of the cyclo‐oxygenase blocker ibuprofen on cerebral blood volume and cerebral blood flow during normocarbia and hypercarbia in newborn piglets. Acta Pediatrica1999;88(1):82‐8. [PUBMED: 10090554] ">Pellicer 1999</a>). Ibuprofen enhances cerebral autoregulation without affecting cerebral blood flow, cerebral metabolism, or intestinal or renal haemodynamics (<a href="./references#CD003481-bbs2-0071" title="GrosfeldJL , KammanK , GrossK , CikritD , RossD , WolfeM , et al. Comparative effects of indomethacin, prostaglandin E1, and ibuprofen on bowel ischaemia. Journal of Pediatric Surgery1983;18(6):738‐42. [PUBMED: 6686609] ">Grosfeld 1983</a>; <a href="./references#CD003481-bbs2-0072" title="HardyP , PeriKG , LahaieI , VarmaDR , ChemtobS . Increased nitric oxide synthesis and action preclude choroidal vasoconstriction to hyperoxia in newborn pigs. Circulation Research1996;79(3):504‐11. [PUBMED: 8781483] ">Hardy 1996</a>; <a href="./references#CD003481-bbs2-0077" title="KaplanBS , RestainoI , RavalDS , GottliebRP , BernsteinJ . Renal failure in the neonate associated with in utero exposure to non‐steroidal anti‐inflammatory agents. Pediatric Nephrology (Berlin, Germany)1994;8(6):700‐4. [PUBMED: 7696108] ">Kaplan 1994</a>). </p> <p>Another non‐steroidal anti‐inflammatory drug, mefenamic acid, has been reported to close a PDA (<a href="./references#CD003481-bbs2-0076" title="ItoK , NiidaY , SatoJ , OwadaE , ItoK , UmetsuM . Pharmacokinetics of mefenamic acid in preterm infants with patent ductus arteriosus. Acta Paediatrica Japonica; Overseas Edition1994;36(4):387‐91. [PUBMED: 7942001] ">Ito 1994</a>; <a href="./references#CD003481-bbs2-0086" title="NiopasI , MamzoridiK . Determination of indomethacin and mefenamic acid in plasma performance liquid chromatography. Journal of Chromatography. B, Biomedical Applications1994;656(2):447‐50. [PUBMED: 7987501] ">Niopas 1994</a>; <a href="./references#CD003481-bbs2-0095" title="SakhalkarVS , MerchantRH . Therapy of symptomatic patent ductus arteriosus in preterms with mefenemic acid and indomethacin. Indian Pediatrics1992;29(3):313‐8. [PUBMED: 1612672] ">Sakhalkar 1992</a>). Mefenamic acid is currently being used in Japan to close a PDA (<a href="./references#CD003481-bbs2-0101" title="UchiyamaA , NagasawaH , YamamotoY , TatebayashiK , SuzukiH , YamadaK , et al. Clinical aspects of very‐low‐birthweight infants showing reopening of ductus arteriosus. Pediatrics International2011;53(3):322‐7. [DOI: 10.1111/j.1442‐200X.2010.03251.x; PUBMED: 20854286] ">Uchiyama 2011</a>), but, as of July 2014, we have not been able to identify any randomised studies. </p> </section> <section id="CD003481-sec-0041"> <h3 class="title" id="CD003481-sec-0041">Why it is important to do this review</h3> <p>One previous meta‐analysis of three trials of small sample size (<a href="./references#CD003481-bbs2-0026" title="PatelJ , RobertsI , AzzopardiD , HamiltonP , EdwardsAD . Randomized double‐blind controlled trial comparing the effects of ibuprofen with indomethacin on cerebral hemodynamics in preterm infants with patent ductus arteriosus. Pediatric Research2000;47(1):36‐42. [PUBMED: 10625080] ">Patel 2000</a>; <a href="./references#CD003481-bbs2-0037" title="VanOvermeireB , FollensI , HartmannS , CretenWL , VanAckerKJ . Treatment of patent ductus arteriosus with ibuprofen. Archives of Disease in Childhood. Fetal and Neonatal Edition1997;76(3):F179‐84. [PUBMED: 9175948] VanOvermeireB , FollensI , HartmannS , MahieuL , VanReemptsPJ . Intravenous ibuprofen (IBU) for the treatment of patent ductus arteriosus (PDA) in preterm infants with respiratory distress syndrome (RDS). Pediatric Research1996;39:250A. ">Van Overmeire 1997</a>; <a href="./references#CD003481-bbs2-0102" title="VanOvermeireB , LanghendriesJP , VanhasebrouckP , LecoutereD , Van deBroekH . Ibuprofen for early treatment of patent ductus arteriosus, a randomized multicentre trial. Pediatric Research1998;43:200A. ">Van Overmeire 1998</a>) suggested that ibuprofen may be as effective as indomethacin in closing a PDA (<a href="./references#CD003481-bbs2-0088" title="OhlssonA . Back to the drawing board. Pediatric Research2000;47(1):4‐5. [PUBMED: 10625075] ">Ohlsson 2000</a>). The meta‐analysis included 176 neonates who were randomised to either ibuprofen (10 mg/kg followed at 24 and 48 hours later by a dose of 5 mg/kg) or indomethacin (0.2 mg/kg at 12‐hour interval for three doses). The typical risk ratio (RR) for failure of PDA closure using ibuprofen versus indomethacin was 1.0 (95% confidence interval (CI) 0.85 to 1.17) (<a href="./references#CD003481-bbs2-0088" title="OhlssonA . Back to the drawing board. Pediatric Research2000;47(1):4‐5. [PUBMED: 10625075] ">Ohlsson 2000</a>). This meta‐analysis was included in a commentary on a publication of a randomised controlled trial (<a href="./references#CD003481-bbs2-0026" title="PatelJ , RobertsI , AzzopardiD , HamiltonP , EdwardsAD . Randomized double‐blind controlled trial comparing the effects of ibuprofen with indomethacin on cerebral hemodynamics in preterm infants with patent ductus arteriosus. Pediatric Research2000;47(1):36‐42. [PUBMED: 10625080] ">Patel 2000</a>), and the publication type did not allow for detailed description of the methodology used or the inclusion of outcomes other than ductal closure (<a href="./references#CD003481-bbs2-0088" title="OhlssonA . Back to the drawing board. Pediatric Research2000;47(1):4‐5. [PUBMED: 10625075] ">Ohlsson 2000</a>). Additional trials have been published since the year 2000. Therefore, systematic reviews according to Cochrane methodology were justified (<a href="./references#CD003481-bbs2-0106" title="OhlssonA , WaliaR , ShahS . Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database of Systematic Reviews2003, Issue 2. [DOI: 10.1002/14651858.CD003481] ">Ohlsson 2003</a>), as were the current and previous updates (<a href="./references#CD003481-bbs2-0107" title="OhlssonA , WaliaR , ShahS . Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database of Systematic Reviews2005, Issue 4. [DOI: 10.1002/14651858.CD003481.pub2] ">Ohlsson 2005</a>; <a href="./references#CD003481-bbs2-0108" title="OhlssonA , WaliaR , ShahS . Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database of Systematic Reviews2008, Issue 1. [DOI: 10.1002/14651858.CD003481.pub3] ">Ohlsson 2008</a>; <a href="./references#CD003481-bbs2-0109" title="OhlssonA , WaliaR , ShahS . Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database of Systematic Reviews2010, Issue 4. [DOI: 10.1002/14651858.CD003481.pub4] ">Ohlsson 2010</a>; <a href="./references#CD003481-bbs2-0110" title="OhlssonA , WaliaR , ShahS . Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database of Systematic Reviews2013, Issue 4. [DOI: 10.1002/14651858.CD003481.pub5] ">Ohlsson 2013</a>; <a href="./references#CD003481-bbs2-0111" title="OhlssonA , WaliaR , ShahSS . Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants. Cochrane Database of Systematic Reviews2015, Issue 2. [DOI: 10.1002/14651858.CD003481.pub6] ">Ohlsson 2015</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD003481-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD003481-sec-0042"></div> <p><b>Primary objective</b> </p> <p> <ul id="CD003481-list-0001"> <li> <p>To determine the effectiveness and safety of ibuprofen compared with indomethacin, other cyclo‐oxygenase inhibitor(s), placebo, or no intervention for closing a patent ductus arteriosus in preterm, low‐birth‐weight, or preterm and low‐birth‐weight infants. </p> </li> </ul> </p> <p><b>Secondary objectives</b> </p> <p> <ul id="CD003481-list-0002"> <li> <p>To determine the effectiveness and safety of ibuprofen to close a PDA in relation to gestational age, birth weight, method used to diagnose a PDA, and dosing regimen for ibuprofen. </p> </li> </ul> </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD003481-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD003481-sec-0043"></div> <section id="CD003481-sec-0044"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD003481-sec-0045"> <h4 class="title">Types of studies</h4> <p>Randomised or quasi‐randomised controlled trials.</p> </section> <section id="CD003481-sec-0046"> <h4 class="title">Types of participants</h4> <p>Preterm infants less than 37 weeks' gestational age or LBW infants (weighing less than 2500 grams) with a PDA, diagnosed either clinically or by echocardiographically‐guided criteria in the neonatal period (less than 28 days). </p> </section> <section id="CD003481-sec-0047"> <h4 class="title">Types of interventions</h4> <p>The following is a list of the ten interventions/comparisons that were included in this update: </p> <p> <ul id="CD003481-list-0003"> <li> <p>Intravenous ibuprofen verus place</p> </li> <li> <p>Oral ibuprofen versus placebo</p> </li> <li> <p>Intravenous or oral ibuprofen versus intravenous or oral indomethacin</p> </li> <li> <p>Oral ibuprofen versus intravenous or oral indomethacin</p> </li> <li> <p>Oral ibuprofen versus intravenous ibuprofen</p> </li> <li> <p>High‐dose (oral or intravenous) versus standard‐dose ibuprofen (oral or intravenous)</p> </li> <li> <p>Early versus expectant administration of intravenous ibuprofen</p> </li> <li> <p>Echocardiographically (ECHO) ‐ guided intravenous ibuprofen treatment versus standard intravenous ibuprofen treatment </p> </li> <li> <p>Continuous infusion of ibuprofen versus intermittent boluses of ibuprofen</p> </li> <li> <p>Rectal ibuprofen versus oral ibuprofen</p> </li> </ul> </p> <p>For previous versions of this review and for this update, we did not compare ibuprofen to paracetamol, as that is the topic of a separate Cochrane review (<a href="./references#CD003481-bbs2-0090" title="OhlssonA , ShahPS . Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants.. Cochrane Database Systematic Reviews2018, (4). ">Ohlsson 2018</a>). </p> </section> <section id="CD003481-sec-0048"> <h4 class="title">Types of outcome measures</h4> <section id="CD003481-sec-0049"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD003481-list-0004"> <li> <p>Failure of permanent PDA closure within one week of administration of the first dose of ibuprofen (PDA diagnosed either clinically or by ECHO criteria). </p> </li> </ul> </p> </section> <section id="CD003481-sec-0050"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD003481-list-0005"> <li> <p>All‐cause mortality during initial hospital stay.</p> </li> <li> <p>Neonatal mortality (mortality during the first 28 days of life).</p> </li> <li> <p>Infant mortality (mortality during the first year of life).</p> </li> <li> <p>Reopening of the ductus arteriosus.</p> </li> <li> <p>Need for surgical closure of the PDA.</p> </li> <li> <p>Need for treatment with indomethacin to close the PDA*.</p> </li> <li> <p>Duration of ventilator support (days).</p> </li> <li> <p>Duration of need for supplementary oxygen (days).</p> </li> <li> <p>Pneumothorax.</p> </li> <li> <p>Pulmonary haemorrhage*.</p> </li> <li> <p>Pulmonary hypertension*.</p> </li> <li> <p>Chronic lung disease (CLD) (defined as oxygen requirement at 28 days' postnatal age in addition to compatible clinical and roentgenographic findings). </p> </li> <li> <p>CLD (defined as oxygen requirement at 36 weeks' postmenstrual age (PMA) in addition to compatible clinical and roentgenographic findings). </p> </li> <li> <p>CLD (age at diagnosis not stated)*.</p> </li> <li> <p>Intraventricular haemorrhage (IVH) (grades I to IV).</p> </li> <li> <p>Severe IVH (grades III and IV).</p> </li> <li> <p>Periventricular leukomalacia (PVL).</p> </li> <li> <p>Necrotising enterocolitis (NEC) (any stage).</p> </li> <li> <p>Intestinal perforation*.</p> </li> <li> <p>Gastrointestinal bleed.</p> </li> <li> <p>Time to full enteral feeds (postnatal age at time of achieving full enteral feeds).</p> </li> <li> <p>Time to regain birth weight* (days).</p> </li> <li> <p>Retinopathy of prematurity (ROP) (according to the international classification of ROP). </p> </li> <li> <p>Definite sepsis (clinical symptoms and signs of sepsis and a positive bacterial culture in a specimen obtained from normally sterile fluids or tissue obtained at postmortem). </p> </li> <li> <p>Oliguria (defined as less than 1 mL/kg/hour).</p> </li> <li> <p>Serum/plasma levels of creatinine (µmol/L) after treatment*.</p> </li> <li> <p>Increase in serum/plasma levels of creatinine (μmol/L) after treatment*.</p> </li> <li> <p>Cystatin‐C plasma levels (mg/dL) after treatment***.</p> </li> <li> <p>Duration of hospitalisation (total length of hospitalisation from birth to discharge home or mortality) (days). </p> </li> <li> <p>Neurodevelopmental outcome (assessed by a standardised and validated assessment tool, a child developmental specialist or both) at any age reported (outcome data grouped at 12, 18 and 24 months, if available). </p> </li> <li> <p>Bilirubin albumin binding*.</p> </li> <li> <p>Proportion of infants who required rescue treatment for PDA (indomethacin or surgery), died, or dropped out to study day 14**. </p> </li> <li> <p>Other adverse effects reported by the authors.</p> </li> </ul> </p> <p>Outcomes marked with an asterisk (*) were not included in the original protocol but were included in the update of this review in August 2007. These outcomes were included in updates of the review as they were closely related to previous outcomes already included and were considered to be of importance to establish the effectiveness and safety of ibuprofen versus indomethacin. The outcome 'Proportion of infants that required rescue treatment for PDA (indomethacin or surgery), died, or dropped out through study day 14** ' was the primary outcome of the only study (until this update) that compared IV ibuprofen with placebo (<a href="./references#CD003481-bbs2-0005" title="ArandaJV . Multicentre randomized double‐blind placebo controlled trial of ibuprofen L‐Lysine intravenous solution (IV Ibuprofen) in premature infants for the early treatment of patent ductus arteriosus (PDA). Pediatric Academic Societies Annual Meeting; 2005 May 14‐17; Washington DC, United States. 2005. ArandaJV , ClymanR , CoxB , VanOvermeireB , WozniakP , SosenkoI , et al. A randomized, double‐blind, placebo‐controlled trial of intravenous ibuprofen L‐lysine for the early closure of non‐symptomatic patent ductus arteriosus within 72 hours of birth in extremely low‐birth‐weight infants. American Journal of Perinatology2009;26(3):235‐45. [DOI: 10.1055/s‐0028‐1103515; PUBMED: 19067286] ">Aranda 2009</a>), and was, therefore, included from the 2007 update. 'Cystatin‐C plasma levels (mg/dL) after treatment*** ' were included in the 2012 update. </p> </section> </section> </section> <section id="CD003481-sec-0051"> <h3 class="title">Search methods for identification of studies</h3> <p>We used the criteria and standard methods of Cochrane and Cochrane Neonatal (see the Cochrane Neonatal <a href="http://neonatal.cochrane.org/resources-review-authors" target="_blank">search strategy</a> for specialised register). </p> <section id="CD003481-sec-0052"> <h4 class="title">Electronic searches</h4> <p>We conducted a comprehensive search including: Cochrane Central Register of Controlled Trials (CENTRAL 2017, Issue 10) in The Cochrane Library; MEDLINE via PubMed (1966 to 30 November 2017); Embase (1980 to 30 November 2017); and CINAHL (1982 to 30 November 2017) using the following search terms: ((Ibuprofen[MeSH]) OR (Mefenamic Acid[MeSH]) OR ibuprofen OR mefenamic acid) AND ((Ductus Arteriosus, Patent[MeSH]) OR patent ductus arteriosus or PDA), plus database‐specific limiters for RCTs and neonates (see <a href="./appendices#CD003481-sec-0189">Appendix 1</a> for the full search strategies for each database). We did not apply language restrictions. See <a href="./appendices#CD003481-sec-0190">Appendix 2</a> for information on past searches. </p> <p>We searched clinical trials registries for ongoing or recently completed trials (<a href="https://clinicaltrials.gov/" target="_blank">clinicaltrials.gov</a>; the World Health Organization’s International <a href="http://apps.who.int/trialsearch/default.aspx" target="_blank">Trials Registry</a> and Platform, and the ISRCTN <a href="http://www.isrctn.com/" target="_blank">Registry</a>). </p> </section> <section id="CD003481-sec-0053"> <h4 class="title">Searching other resources</h4> <p>We searched the reference lists of any articles selected for inclusion in this review in order to identify additional relevant articles. </p> </section> </section> <section id="CD003481-sec-0054"> <h3 class="title" id="CD003481-sec-0054">Data collection and analysis</h3> <p>We used the standard review methods of the Cochrane Neonatal Review Group (CNRG) in data collection and analysis. One review author (AO) performed the updates conducted in 2005, 2007, and 2010. All three review authors (AO, RW, SS) conducted the 2012, 2014, and 2017 updates. </p> <section id="CD003481-sec-0055"> <h4 class="title">Selection of studies</h4> <p>In the original review, two review authors (AO, SS) assessed all abstracts and published full reports identified as potentially relevant by the literature search for inclusion. For the 2012 and 2014 updates, all three review authors (AO, RW, SS) assessed the articles for possible inclusion. For this update in 2017, two review authors (AO, SS) selected the studies for inclusion. </p> </section> <section id="CD003481-sec-0056"> <h4 class="title">Data extraction and management</h4> <p>Each review author independently extracted data using pre designed data abstraction forms. The review authors compared results and resolved differences. One review author (AO) entered data into Review Manager 5 (<a href="./references#CD003481-bbs2-0093" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>), and the other review authors (RW and SS) cross checked the printout against their own data abstraction forms and corrected errors by consensus. </p> <p>For the studies identified as abstracts, we contacted some primary authors to ascertain whether a full publication was available if the full paper was not identified in an electronic database. </p> <p>We obtained information from the primary author if the published article provided inadequate information for the review. We independently assessed retrieved articles and abstracted the data. </p> </section> <section id="CD003481-sec-0057"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (AO, SS) independently assessed the risk of bias (low, high, or unclear) of all included trials using the Cochrane ‘Risk of bias’ tool (<a href="./references#CD003481-bbs2-0074" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017. Available from training.cochrane.org/handbook. ">Higgins 2017</a>) for the following domains: </p> <p> <ul id="CD003481-list-0006"> <li> <p>Sequence generation (selection bias)</p> </li> <li> <p>Allocation concealment (selection bias)</p> </li> <li> <p>Blinding of participants and personnel (performance bias)</p> </li> <li> <p>Blinding of outcome assessment (detection bias)</p> </li> <li> <p>Incomplete outcome data (attrition bias)</p> </li> <li> <p>Selective reporting (reporting bias)</p> </li> <li> <p>Any other bias</p> </li> </ul> </p> <p>Any disagreements were resolved by discussion or by a third assessor. See <a href="./appendices#CD003481-sec-0191">Appendix 3</a> for a more detailed description of risk of bias for each domain.  </p> </section> <section id="CD003481-sec-0058"> <h4 class="title">Measures of treatment effect</h4> <p>The statistical analyses followed the recommendations of the CNRG. The estimates of treatment effects included RR, risk difference (RD), number needed to treat for an additional beneficial outcome (NNTB) or additional harmful outcome (NNTH) for dichotomous outcomes, and mean difference (MD) for continuous outcomes. All estimates of treatment effects were reported with 95% CI. We considered a P‐value &lt; 0.05 as statistically significant. </p> </section> <section id="CD003481-sec-0059"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of randomisation was the individual infant. We did not include cross‐over or cluster‐randomised trials as those trial designs are unlikely for the intervention studied in this review. No cross‐over or cluster‐randomised trials were identified. An infant was only considered once even if the infant may have been randomised twice by investigators. We planned to contact the authors in order to provide data resulting from the first randomisation. If we could not separate data from the first randomisation, it was planned that the study would be excluded. </p> </section> <section id="CD003481-sec-0060"> <h4 class="title">Dealing with missing data</h4> <p>We requested additional data from the authors of each included trial when data on important outcomes were missing or needed clarification. We received clarifying information from one of the authors or coauthors of the following studies: <a href="./references#CD003481-bbs2-0006" title="BagnoliF , RossettiA , MessinaG , MoriA , CasucciM , TomasiniB . Treatment of patent ductus arteriosus (PDA) using ibuprofen: renal side‐effects in VLBW and ELBW newborns. Journal of Maternal‐Fetal &amp; Neonatal Medicine2013;26(4):423‐9. [DOI: 10.3109/14767058.2012.733775; PUBMED: 23057804] ">Bagnoli 2013</a>; <a href="./references#CD003481-bbs2-0007" title="BravoMC , CabaňasF , RieraJ , Pérez‐FernándezE , QueroJ , Pérez‐RodriguezJ , et al. Randomized controlled clinical trial of standard versus echocardiographically guided ibuprofen treatment for patent ductus arteriosus in preterm infants: a pilot study. Journal of Maternal‐Fetal &amp; Neonatal Medicine2014;27(9):904‐9. [DOI: 10.3109/14767058.2013.846312; PUBMED: 24047189] ">Bravo 2014</a>; <a href="./references#CD003481-bbs2-0010" title="DaniC , VangiV , BertiniG , PratesiS , LoriI , FavelliF , et al. High‐dose ibuprofen for patent ductus arteriosus in extremely preterm infants: a randomized controlled study. Clinical Pharmacology and Therapeutics2012;91(4):590‐6. [PUBMED: 22089267] ">Dani 2012</a>; <a href="./references#CD003481-bbs2-0016" title="FesharakiHJ , NayeriFS , AsbaqPA , AminiE , SedagatM . Different doses of ibuprofen in the treatment of patent ductus arteriosus: a randomized controlled trial. Tehran University Medical Journal2012;70(8):488‐93. ">Fesharaki 2012</a>; <a href="./references#CD003481-bbs2-0025" title="PatelJ , MarksKA , RobertsI , AzzopardiD , EdwardsAD . Ibuprofen treatment of patent ductus arteriosus. Lancet1995;346(8969):255. [PUBMED: 7616831] ">Patel 1995</a>; <a href="./references#CD003481-bbs2-0066" title="ElHassanNO , BirdTM , KingAJ , AmbadwarPB , JaquissRD , KaiserJR , et al. Variation and comparative effectiveness of patent ductus arteriosus pharmacotherapy in extremely low birth weight infants. Journal of Neonatal‐Perinatal Medicine2014;7(3):229‐35. [DOI: 10.3233/NPM‐14814015; PUBMED: 25322995] ">ElHassan 2014</a>. </p> </section> <section id="CD003481-sec-0061"> <h4 class="title">Assessment of heterogeneity</h4> <p>We performed heterogeneity tests including the I<sup>2</sup> test to assess the appropriateness of pooling the data using the following categories for heterogeneity: less than 25% no heterogeneity; 25% to 49% low heterogeneity; 50% to 74% moderate heterogeneity and 75% or greater high heterogeneity (<a href="./references#CD003481-bbs2-0073" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. [DOI: 10.1136/bmj.327.7414.557; PUBMED: 12958120] ">Higgins 2003</a>). </p> </section> <section id="CD003481-sec-0062"> <h4 class="title">Assessment of reporting biases</h4> <p>To ascertain the possibility of publication bias, we produced a funnel plot for the primary outcome of 'failure to close a PDA (after single or three doses)' (<a href="./references#CD003481-fig-0027" title="">Analysis 3.1</a>) and for the outcome of NEC (<a href="./references#CD003481-fig-0043" title="">Analysis 3.17</a>). Both funnel plots were quite symmetric indicating that there was no obvious indication of publication bias (<a href="#CD003481-fig-0001">Figure 1</a>; <a href="#CD003481-fig-0002">Figure 2</a>). </p> <div class="figure" id="CD003481-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, outcome: 3.1 Failure to close a patent ductus arteriosus (PDA) (after single or 3 doses)." data-id="CD003481-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, outcome: 3.1 Failure to close a patent ductus arteriosus (PDA) (after single or 3 doses). </p> </div> </div> </div> <div class="figure" id="CD003481-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, outcome: 3.17 Necrotising enterocolitis (any stage)." data-id="CD003481-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, outcome: 3.17 Necrotising enterocolitis (any stage). </p> </div> </div> </div> </section> <section id="CD003481-sec-0063"> <h4 class="title">Data synthesis</h4> <p>We performed meta‐analyses using Review Manager 5 (<a href="./references#CD003481-bbs2-0093" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). For estimates of typical RR and RD, we used the Mantel‐Haenszel method. We calculated mean difference (MD) for continuous outcomes. For measured quantities, we used the inverse variance method. We used a fixed‐effect model for all meta‐analyses. We used the formulas proposed by Hozo and coworkers to estimate means and standard deviations (SD) from medians and ranges presented by the authors of some of the included studies (<a href="./references#CD003481-bbs2-0075" title="HozoSP , DjulbegovicB , HozoI . Estimating the mean and variance from the median, range, and the size of a sample. BMC Medical Research Methodology2005;5:13. [DOI: 10.1186/1471‐2288‐5‐13; PUBMED: 15840177] ">Hozo 2005</a>). </p> <section id="CD003481-sec-0064"> <h5 class="title">Quality of evidence</h5> <p>We used the GRADE approach, as outlined in the GRADE Handbook (<a href="./references#CD003481-bbs2-0097" title="SchünemannH , BrożekJ , GuyattG , OxmanA , editor(s) . Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. gdt.guidelinedevelopment.org/app/handbook/handbook.html (accessed prior to 31 August 2018). ">Schünemann 2013</a>), to assess the quality of evidence for the following (clinically relevant) outcomes: </p> <p>1. Failure to close a PDA after three doses;</p> <p>2. Need for surgical closure of the PDA;</p> <p>3. Necrotising enterocolitis;</p> <p>4. Duration of ventilatory support;</p> <p>5. Oliguria (urine output &lt; 1mL/kg/hr);</p> <p>6. Serum/plasma creatinine levels (µmol/L) 72 hours after treatment.</p> <p>We included only clinically important outcomes that were reported by at least two trials. </p> <p>Two authors (AO, SS) independently assessed the quality of the evidence for each of the outcomes above. We considered evidence from randomised controlled trials as high quality but downgraded the evidence one level for serious (or two levels for very serious) limitations based upon the following: design (risk of bias), consistency across studies, directness of the evidence, precision of estimates, and presence of publication bias. We used the <a href="./references#CD003481-bbs2-0070" title="McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed 30 November 2017. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. ">GRADEpro GDT</a> Guideline Development Tool to create a ‘Summary of findings’ table to report the quality of the evidence. We developed ‘Summary of findings’ tables for comparisons that included at least two trials. </p> <p>The GRADE approach results in an assessment of the quality of a body of evidence in one of four grades: </p> <p> <ol id="CD003481-list-0007"> <li> <p>High: We are very confident that the true effect lies close to that of the estimate of the effect. </p> </li> <li> <p>Moderate: We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> </li> <li> <p>Low: Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. </p> </li> <li> <p>Very low: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </li> </ol> </p> </section> </section> <section id="CD003481-sec-0065"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned the following subgroup analyses:</p> <p> <ul id="CD003481-list-0008"> <li> <p>gestational age (less than 28 weeks, 28 to 32 weeks, 33 to 36 weeks);</p> </li> <li> <p>BW (less than 1000 grams, 1000 to 1500 grams, 1501 to 2500 grams);</p> </li> <li> <p>method used to diagnose a PDA (by ECHO criteria or only by clinical criteria);</p> </li> <li> <p>a dosing regimen of ibuprofen 10 mg/kg followed by ibuprofen 5 mg/kg 24 and 48 hours later, or indomethacin 0.2 mg/kg at 12‐hour intervals for three doses; </p> </li> <li> <p>oral ibuprofen versus indomethacin (this was added in 2008 as a new comparison as studies now have used oral ibuprofen) (<a href="./references#CD003481-bbs2-0108" title="OhlssonA , WaliaR , ShahS . Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database of Systematic Reviews2008, Issue 1. [DOI: 10.1002/14651858.CD003481.pub3] ">Ohlsson 2008</a>); </p> </li> <li> <p>oral ibuprofen versus IV ibuprofen (this was included as a new comparison in 2013 as studies now have been published assessing this comparison) (<a href="./references#CD003481-bbs2-0110" title="OhlssonA , WaliaR , ShahS . Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database of Systematic Reviews2013, Issue 4. [DOI: 10.1002/14651858.CD003481.pub5] ">Ohlsson 2013</a>); </p> </li> <li> <p>timing of ibuprofen administration as early versus expectant management (this was included as a new comparison in 2013 as one trial studied this intervention) (<a href="./references#CD003481-bbs2-0110" title="OhlssonA , WaliaR , ShahS . Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database of Systematic Reviews2013, Issue 4. [DOI: 10.1002/14651858.CD003481.pub5] ">Ohlsson 2013</a>); </p> </li> <li> <p>higher dosing regimen of ibuprofen 20 mg/kg/day followed by ibuprofen 10 mg/kg/day for two doses compared with the standard‐dose of ibuprofen 10 mg/kg/day followed by ibuprofen 5 mg/kg/day for two doses (this was included in 2013 as a new comparison as one trial studied this intervention) (<a href="./references#CD003481-bbs2-0110" title="OhlssonA , WaliaR , ShahS . Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database of Systematic Reviews2013, Issue 4. [DOI: 10.1002/14651858.CD003481.pub5] ">Ohlsson 2013</a>); </p> </li> <li> <p>ECHO‐guided ibuprofen treatment versus standard ibuprofen treatment (this was included in 2014 as a new comparison as one trial studied this intervention) (<a href="./references#CD003481-bbs2-0111" title="OhlssonA , WaliaR , ShahSS . Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants. Cochrane Database of Systematic Reviews2015, Issue 2. [DOI: 10.1002/14651858.CD003481.pub6] ">Ohlsson 2015</a>); </p> </li> <li> <p>continuous infusion of ibuprofen versus standard boluses of ibuprofen (this was included in 2014 as a new comparison as one trial studied this intervention) (<a href="./references#CD003481-bbs2-0111" title="OhlssonA , WaliaR , ShahSS . Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants. Cochrane Database of Systematic Reviews2015, Issue 2. [DOI: 10.1002/14651858.CD003481.pub6] ">Ohlsson 2015</a>). </p> </li> <li> <p>rectal ibuprofen versus oral ibuprofen (this was included in the 2017 update as a new comparison as one trial studied this intervention). </p> </li> </ul> </p> </section> <section id="CD003481-sec-0066"> <h4 class="title">Sensitivity analysis</h4> <p>The prespecified subgroup analyses excluding studies that used only one dose of medication and studies that were published as abstracts only were abandoned for the updates in 2007, 2010, 2012, 2014 and this 2017 update of the review. Only one study used a single dose and we identified only one abstract. We incorporated the results of these studies with the other studies. All studies used ECHO criteria to diagnose a PDA, so this prespecified subgroup analysis was also abandoned. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD003481-sec-0067" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD003481-sec-0067"></div> <section id="CD003481-sec-0068"> <h3 class="title">Description of studies</h3> <p>We identified one study comparing oral ibuprofen with placebo for the update in 2013 (<a href="./references#CD003481-bbs2-0022" title="LinXZ , ChenHQ , ZhengZ , LiYD , LaiJD , HuangLH . Therapeutic effect of early administration of oral ibuprofen in very low birth weight infants with patent ductus arteriosus. Zhongguo Dang Dai Er Ke za Zhi [Chinese Journal of Contemporary Pediatrics]2012;14(7):502‐5. [PUBMED: 22809601] ">Lin 2012</a>). For the same update, we added a comparison of oral ibuprofen versus IV ibuprofen as three trials studied this comparison (<a href="./references#CD003481-bbs2-0008" title="CherifA , KhroufN , JabnounS , MokraniC , AmaraMB , GuellouzeN , et al. Randomized pilot study comparing oral ibuprofen with intravenous ibuprofen in very low birth weight infants with patent ductus arteriosus. Pediatrics2008;122(6):e1256‐61. [PUBMED: 19047225] ">Cherif 2008</a>; <a href="./references#CD003481-bbs2-0014" title="ErdeveO , YurttutanS , AltugN , OzdemirR , GokmenT , DilmenU , et al. Oral versus intravenous ibuprofen for patent ductus arteriosus closure: a randomised controlled trial in extremely low birthweight infants. Archives of Disease in Childhood. Fetal and Neonatal Edition2012;97(4):F279‐83. [DOI: 10.1136/archdischild‐2011‐300532; PUBMED: 22147286] ">Erdeve 2012</a>; <a href="./references#CD003481-bbs2-0018" title="ErasZ , GokmenT , ErdeveO , OzyurtBM , SaridasB , DilmenU . Impact of oral versus intravenous ibuprofen on neurodevelopmental outcome: a randomized controlled parallel study. American Journal of Perinatology2013;30(10):857‐62. [DOI: 10.1055/s‐0033‐1333667; PUBMED: 23359230] GokmenT , ErdeveO , AltugN , OguzSS , UrasN , DilmenU . Efficacy and safety of oral verus intravenous ibuprofen in very low birth weight infants with patent ductus arteriosus. Journal of Pediatrics2011;158(4):549‐54; Erratum in: Journal of Pediatrics; 2012;160(1):181. [10.1016/j.jpeds.2010.10.008; PUBMED: 21094951] ">Gokmen 2011</a>). We included one study that compared IV high‐dose ibuprofen versus a standard‐dose regimen of ibuprofen (<a href="./references#CD003481-bbs2-0010" title="DaniC , VangiV , BertiniG , PratesiS , LoriI , FavelliF , et al. High‐dose ibuprofen for patent ductus arteriosus in extremely preterm infants: a randomized controlled study. Clinical Pharmacology and Therapeutics2012;91(4):590‐6. [PUBMED: 22089267] ">Dani 2012</a>). We included one additional comparison for early versus expectant administration of IV ibuprofen (<a href="./references#CD003481-bbs2-0033" title="SosenkoIR , FajardoMF , ClaureN , BancalariE . Timing of patent ductus arteriosus treatment and respiratory outcome in premature infants: a double‐blind randomized controlled trial. Journal of Pediatrics2012;160(6):929‐35. [PUBMED: 22284563] ">Sosenko 2012</a>). Thus, we included six additional studies for the update in 2013. For the update in 2014, we identified and included six additional trials (<a href="./references#CD003481-bbs2-0006" title="BagnoliF , RossettiA , MessinaG , MoriA , CasucciM , TomasiniB . Treatment of patent ductus arteriosus (PDA) using ibuprofen: renal side‐effects in VLBW and ELBW newborns. Journal of Maternal‐Fetal &amp; Neonatal Medicine2013;26(4):423‐9. [DOI: 10.3109/14767058.2012.733775; PUBMED: 23057804] ">Bagnoli 2013</a>; <a href="./references#CD003481-bbs2-0007" title="BravoMC , CabaňasF , RieraJ , Pérez‐FernándezE , QueroJ , Pérez‐RodriguezJ , et al. Randomized controlled clinical trial of standard versus echocardiographically guided ibuprofen treatment for patent ductus arteriosus in preterm infants: a pilot study. Journal of Maternal‐Fetal &amp; Neonatal Medicine2014;27(9):904‐9. [DOI: 10.3109/14767058.2013.846312; PUBMED: 24047189] ">Bravo 2014</a>; <a href="./references#CD003481-bbs2-0016" title="FesharakiHJ , NayeriFS , AsbaqPA , AminiE , SedagatM . Different doses of ibuprofen in the treatment of patent ductus arteriosus: a randomized controlled trial. Tehran University Medical Journal2012;70(8):488‐93. ">Fesharaki 2012</a>; <a href="./references#CD003481-bbs2-0021" title="LagoP , SalvadoriS , OpocherF , RicatoS , ChiandettiL , FrigoAC . Continuous infusion of ibuprofen for treatment of patent ductus arteriosus in very low birth weight infants. Neonatology2014;105(1):46‐54. [DOI: 10.1159/000355679; PUBMED: 24281435] ">Lago 2014</a>; <a href="./references#CD003481-bbs2-0028" title="HoxhaA , GjyzariA , TusheE . Renal effects of ibuprofen during the treatment of patent ductus arteriosus in low birth weight premature infants. Nephrology Dialysis Transplantation Conference. 50th ERA‐EDTA Congress; 2013 May 18‐21; Istanbul, Turkey. 2013. PistulliE , HamitiA , BubaS , HoxhaA , KelmendiN , VyshkaG . The association between patent ductus arteriosus and perinatal infection in a group of low birth weight preterm infants. Iranian Journal of Pediatrics2014;24(1):42‐8. [PUBMED: 25793044] PriftiE , EnkeledaP , RubenaM , AlketaH . The impact of antenatal corticosteroids on PDA in low birth weight infants. Journal of Perinatal Medicine2013;41:s1. QosjaA , KuneshkaN , TusheE , TeneqexhiL . Oral versus intravenous ibuprofen for patent ductus arteriosus closure. Giornale Italiano di Cardiologia2012;13(Suppl 1):15S‐6S. ">Pistulli 2014</a>; <a href="./references#CD003481-bbs2-0039" title="YadavS , AgarwalS , MariaA , DudejaA , DubeyNK , AnandP , et al. Comparison of oral ibuprofen with oral indomethacin for PDA closure in Indian preterm neonates: a randomized controlled trial. Pediatric Cardiology2014;35(5):824‐30. [DOI: 10.1007/s00246‐014‐0861‐2; PUBMED: 24435507] ">Yadav 2014</a>), and one study reported on long‐term follow‐up for <a href="./references#CD003481-bbs2-0018" title="ErasZ , GokmenT , ErdeveO , OzyurtBM , SaridasB , DilmenU . Impact of oral versus intravenous ibuprofen on neurodevelopmental outcome: a randomized controlled parallel study. American Journal of Perinatology2013;30(10):857‐62. [DOI: 10.1055/s‐0033‐1333667; PUBMED: 23359230] GokmenT , ErdeveO , AltugN , OguzSS , UrasN , DilmenU . Efficacy and safety of oral verus intravenous ibuprofen in very low birth weight infants with patent ductus arteriosus. Journal of Pediatrics2011;158(4):549‐54; Erratum in: Journal of Pediatrics; 2012;160(1):181. [10.1016/j.jpeds.2010.10.008; PUBMED: 21094951] ">Gokmen 2011</a>. For this update in 2017, we included the following ongoing trials (<a href="./references#CD003481-bbs2-0045" title="ACTRN12616000195459 . Early pharmacological treatment with supportive care versus supportive care alone in preterm infants with a patent ductus arteriosus. anzctr.org.au/ACTRN12616000195459.aspx (first received 08 February 2016). ">ACTRN12616000195459</a>; <a href="./references#CD003481-bbs2-0046" title="ChiCTR‐TRC‐14004559 . Comparison of the dose effect of oral ibuprofen suspension for PDA treatment in premature infants [Developmental pharmacokinetics and pharmacodynamics of chiral ibuprofen associated with the CYP2C8/9 gene polymorphism]. chictr.org.cn/showproj.aspx?proj=5014 (first received 15 April 2014). ">ChiCTR‐TRC‐14004719</a>; <a href="./references#CD003481-bbs2-0047" title="EUCTR2016‐002974‐11‐ES . Clinical trial to evaluate the impact on the intestinal prognosis of 2 ibuprofen administration regimens for the treatment of patent ductus arteriosus, guided by echocardiography [Phase III, randomized, multicenter, double‐blind clinical trial to evaluate two echo‐guided administration regimens of ibuprofen in the treatment of patent ductus arteriosus: impact on intestinal prognosis]. clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2016‐002974‐11 (first received 26 September 2016). ">EUCTR2016‐002974‐11‐ES</a>; <a href="./references#CD003481-bbs2-0048" title="IRCT201205029611N1 . High dose oral ibuprofen in PDA closure in premature infants. en.irct.ir/trial/10178 (first received 25 August 2014). ">IRCT201205029611N1</a>; <a href="./references#CD003481-bbs2-0049" title="IRCT2015111024977N1 . Comparison of oral Ibuprofen and intravenous indomethacin for the treatment of patent ductus arteriosus [Comparison of oral Ibuprofen and intravenous indomethacin for the treatment of patent ductus arteriosus in preterm infants]. en.irct.ir/trial/20973 (first received 16 December 2015). ">IRCT2015111024977N1</a>; <a href="./references#CD003481-bbs2-0054" title="NCT02128191 . No treatment versus ibuprofen treatment for patent ductus arteriosus in preterm infants [Efficacy and safety of no treatment compared with oral ibuprofen treatment for patent ductus arteriosus in preterm infants: a randomized, double‐blind, placebo‐controlled, non‐inferiority clinical trial]. clinicaltrials.gov/show/NCT02128191 (first received 1 May 2014). ">NCT02128191</a>; <a href="./references#CD003481-bbs2-0055" title="NCT02884219 . Early treatment versus expectative management of PDA in preterm infants [Multi‐center, randomized non‐inferiority trial of early treatment versus expectative management of patent ductus arteriosus in preterm infants (BeNeDuctus Trial ‐ Belgium Netherlands Ductus Trial)]. clinicaltrials.gov/ct2/show/record/NCT02884219 (first received 30 August 2016). ">NCT02884219</a>; <a href="./references#CD003481-bbs2-0051" title="NCT01149564 . Comparison of oral and intravenous ibuprofen for PDA treatment in premature infants. clinicaltrials.gov/show/NCT01149564 (first received 23 June 2010). ">NCT01149564</a>; <a href="./references#CD003481-bbs2-0052" title="NCT01630278 . Early ibuprofen treatment of patent ductus arteriosus (PDA) in premature infants (TRIOCAPI) [Impact of early targeted ibuprofene treatment of patent ductus arteriosus (PDA) on long term neurodevelopmental outcome in very premature infants (TRIOCAPI)]. clinicaltrials.gov/show/NCT01630278 (first received 28 June 2012). ">NCT01630278</a>; <a href="./references#CD003481-bbs2-0053" title="NCT01758913 . Closure of patent ductus arteriosus with indomethacin or ibuprofen in extreme low birth weight infants [Pharmacological closure of patent ductus arteriosus in extreme low birth weight infants. A comparison of efficacy, side effects and outcomes between indomethacin and ibuprofen]. clinicaltrials.gov/show/NCT01758913 (first received 1 January 2013). ">NCT01758913</a>; <a href="./references#CD003481-bbs2-0054" title="NCT02128191 . No treatment versus ibuprofen treatment for patent ductus arteriosus in preterm infants [Efficacy and safety of no treatment compared with oral ibuprofen treatment for patent ductus arteriosus in preterm infants: a randomized, double‐blind, placebo‐controlled, non‐inferiority clinical trial]. clinicaltrials.gov/show/NCT02128191 (first received 1 May 2014). ">NCT02128191</a>). The following full‐text reports were included in this 2017 update; one study compared IV ibuprofen to placebo (<a href="./references#CD003481-bbs2-0012" title="DingYJ , HanB , YangB , ZhuM . NT‐proBNP plays an important role in the effect of ibuprofen on preterm infants with patent ductus arteriosus. European Review for Medical and Pharmacological Sciences2014;18(18):2596‐8. [PUBMED: 25317790] ">Ding 2014</a>); two studies compared IV ibuprofen to IV indomethacin (<a href="./references#CD003481-bbs2-0023" title="LinYJ , ChenCM , RehanVK , FlorensA , WuSY , TsaiML , et al. Randomized trial to compare renal function and ductal response between Indomethacin and ibuprofen treatment in extremely low birth weight infants. Neonatology2017;111(3):195–202. [DOI: 10.1159/000450822; PUBMED: 27842315] ">Lin 2017</a>; <a href="./references#CD003481-bbs2-0013" title="El‐MashadAE , El‐MahdyH , ElAmrousyDE , ElgendyM . Comparative study of the efficacy and safety of paracetamol, ibuprofen, and indomethacin in closure of patent ductus arteriosus in preterm neonates. European Journal of Pediatrics2017;176(2):233‐40. [DOI: 10.1007/s00431‐016‐2830‐7; PUBMED: 28004188] ">El‐Mashad 2017</a>); one study compared high versus standard‐dose of ibuprofen (<a href="./references#CD003481-bbs2-0031" title="PourarianS , TakmilF , CherikiS , AmoozgarH . The effect of oral high‐dose ibuprofen on patent ductus arteriosus closure in preterm infants. American Journal of Perinatology2015;32(12):1158‐63. [DOI: 10.1055/s‐0035‐1551671; PUBMED: 26007314] ">Pourarian 2015</a>); one study compared rectal versus oral ibuprofen (<a href="./references#CD003481-bbs2-0011" title="DemirN , PekerE , EceI , BalahorogluR , TuncerO . Efficacy and safety of rectal ibuprofen for ductus arteriosus closure in very low birth weight infants. European Journal of Pediatrics2016;175(11):1705‐6. DemirN , PekerE , EceI , BalahorogluR , TuncerO . Efficacy and safety of rectal ibuprofen for patent ductus arteriosus closure in very low birth weight preterm infants. Journal of Maternal‐Fetal &amp; Neonatal Medicine2017;30(17):2119–25. [DOI: 10.1080/14767058.2016.1238897; PUBMED: 28052714] PekerE , DemirN , EceI , BalahorotluR , TuncerO . Efficacy and safety of rectal ibuprofen for ductus arteriosus closure in very low birth weight infants. Journal of Maternal‐Fetal &amp; Neonatal Medicine2016;29(Suppl 1):114. ">Demir 2017</a>); and one study compared IV ibuprofen to oral ibuprofen (<a href="./references#CD003481-bbs2-0002" title="AkarM , YildirimTG , SandalG , BozdagS , ErdeveO , AltugN , et al. Does ibuprofen treatment in patent ductus arteriosus alter oxygen free radicals in premature infants?. Cardiology in the Young2017;27(3):507–11. [PUBMED: 27319277] ">Akar 2017</a>). </p> <section id="CD003481-sec-0069"> <h4 class="title">Results of the search</h4> <p>The results of the search conducted in November, 2017 are shown in <a href="#CD003481-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD003481-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Study flow diagram: review update" data-id="CD003481-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram: review update</p> </div> </div> </div> </section> <section id="CD003481-sec-0070"> <h4 class="title">Included studies</h4> <section id="CD003481-sec-0071"> <h5 class="title">Intravenous ibuprofen versus placebo or no intervention (Comparison 1)</h5> <p>The study by Aranda and coworkers was a multi centre study conducted at 11 sites in the US and published as an abstract in 2005 (full study published in 2009) (<a href="./references#CD003481-bbs2-0005" title="ArandaJV . Multicentre randomized double‐blind placebo controlled trial of ibuprofen L‐Lysine intravenous solution (IV Ibuprofen) in premature infants for the early treatment of patent ductus arteriosus (PDA). Pediatric Academic Societies Annual Meeting; 2005 May 14‐17; Washington DC, United States. 2005. ArandaJV , ClymanR , CoxB , VanOvermeireB , WozniakP , SosenkoI , et al. A randomized, double‐blind, placebo‐controlled trial of intravenous ibuprofen L‐lysine for the early closure of non‐symptomatic patent ductus arteriosus within 72 hours of birth in extremely low‐birth‐weight infants. American Journal of Perinatology2009;26(3):235‐45. [DOI: 10.1055/s‐0028‐1103515; PUBMED: 19067286] ">Aranda 2009</a>). </p> <p> <ul id="CD003481-list-0009"> <li> <p>Objective: to compare the efficacy and safety of IV ibuprofen (L‐lysine) with placebo for the early closure of a nonsymptomatic PDA within 72 hours of birth in extremely low‐birth‐weight preterm infants with evidence of ductal shunting by ECHO. </p> </li> <li> <p>Population: 136 preterm infants (PMA &lt; 30 weeks, BW 500 to 1000 grams) with evidence of ductal shunting by ECHO within 72 hours after birth. </p> </li> <li> <p>Intervention: infants were allocated to either a three‐day treatment course of IV ibuprofen of 10 mg/kg, 5 mg/kg and 5 mg/kg (68 infants) or placebo (saline) (68 infants). </p> </li> <li> <p>Outcomes: primary outcome measure was the proportion of infants that required rescue treatment for PDA (indomethacin or surgery), died, or dropped out prior to study day 14. Secondary outcomes included mortality, need for PDA ligation, IVH, PVL, NEC, ROP, pulmonary haemorrhage, pulmonary hypertension, ROP, BPD (supplemental oxygen at 28 days), BPD (supplemental oxygen at 36 weeks' PMA). </p> </li> </ul> </p> <p>The study by Bagnoli and coworkers was a single centre study conducted in Siena, Italy (<a href="./references#CD003481-bbs2-0006" title="BagnoliF , RossettiA , MessinaG , MoriA , CasucciM , TomasiniB . Treatment of patent ductus arteriosus (PDA) using ibuprofen: renal side‐effects in VLBW and ELBW newborns. Journal of Maternal‐Fetal &amp; Neonatal Medicine2013;26(4):423‐9. [DOI: 10.3109/14767058.2012.733775; PUBMED: 23057804] ">Bagnoli 2013</a>). </p> <p> <ul id="CD003481-list-0010"> <li> <p>Objective: to evaluate the renal adverse effects of IV ibuprofen.</p> </li> <li> <p>Population: 134 preterm newborns with ECHO‐confirmed PDA (PMA less than 32 weeks, BW less than 1500 grams, postnatal age greater than 72 hours. </p> </li> <li> <p>Intervention: infants were allocated to a three‐day treatment course of IV ibuprofen of 10 mg/kg, 5 mg/kg and 5 mg/kg given IV over 10 minutes (67 infants) or placebo (0.9% NaCl given IV) (67 infants). </p> </li> <li> <p>Outcomes: failure to close a PDA, need for surgical ligation of the PDA, oliguria, NEC, creatinine, and blood urea nitrogen (BUN) before and after treatment, mortality at 28 days of life. </p> </li> </ul> </p> <p>The study by Ding and coworkers was a single‐centre study conducted in a provincial hospital affiliated to Shandong University, Jinan, China (<a href="./references#CD003481-bbs2-0012" title="DingYJ , HanB , YangB , ZhuM . NT‐proBNP plays an important role in the effect of ibuprofen on preterm infants with patent ductus arteriosus. European Review for Medical and Pharmacological Sciences2014;18(18):2596‐8. [PUBMED: 25317790] ">Ding 2014</a>). </p> <p> <ul id="CD003481-list-0011"> <li> <p>Objective: To clarify the role of N‐terminal pro brain natriuretic peptide, (NT‐proBNP) in ibuprofen on preterm infants with patent ductus arteriosus PDA. </p> </li> <li> <p>Population: 72 preterm infants with mean PMA of 30.24 +/‐ 1.49 weeks and an ECHO‐confirmed PDA. </p> </li> <li> <p>Intervention: Ibuprofen group received oral ibuprofen 10 mg/kg, followed by 5 mg/kg after 24 and 48 hours, and the placebo group received the same volume of 5% glucose. </p> </li> <li> <p>Outcomes: PDA and NT‐proBNP were detected at 24 hours, 3 and 7 days of age. We included only rate of failure of PDA closure at 7 days. </p> </li> </ul> </p> </section> <section id="CD003481-sec-0072"> <h5 class="title">Oral ibuprofen versus placebo or no intervention (Comparison 2)</h5> <p>The study by Lin and coworkers was a single centre study conducted in Xiamen City, Xiamen, Fujian, China (<a href="./references#CD003481-bbs2-0022" title="LinXZ , ChenHQ , ZhengZ , LiYD , LaiJD , HuangLH . Therapeutic effect of early administration of oral ibuprofen in very low birth weight infants with patent ductus arteriosus. Zhongguo Dang Dai Er Ke za Zhi [Chinese Journal of Contemporary Pediatrics]2012;14(7):502‐5. [PUBMED: 22809601] ">Lin 2012</a>). The study was published in Chinese and only the information in the abstract published in English was understood by the review authors. We have written to the authors to obtain further details, but we have not received a response as of January 22nd, 2018. </p> <p> <ul id="CD003481-list-0012"> <li> <p>Objective: to study the therapeutic effect and safety of early administration of oral ibuprofen in VLBW infants with a PDA. </p> </li> <li> <p>Population: 64 symptomatic VLBW infants with ECHO‐confirmed PDA were enrolled within 24 hours after birth. </p> </li> <li> <p>Intervention: in the ibuprofen group, 32 infants received oral ibuprofen 10 mg/kg as an initial dose within 24 hours after birth, followed by a second and a third dose of ibuprofen 5 mg/kg 24 and 48 hours after the initial dose. In the placebo group, 32 infants received normal saline 1 mL/kg followed by saline 0.5 mL 24 and 48 hours later. </p> </li> <li> <p>Outcomes: primary outcome was PDA closure rate following the initial course of treatment (three doses). </p> </li> </ul> </p> </section> <section id="CD003481-sec-0073"> <h5 class="title">Intravenous or oral ibuprofen versus intravenous or oral indomethacin (Comparison 3) </h5> <p>The study by Adamska and coworkers was a single centre study conducted in Poland (<a href="./references#CD003481-bbs2-0001" title="AdamskaE , HelwichE , RutkowskaM , ZacharskaE , PiotrowskaA . Comparison of the efficacy of ibuprofen and indomethacin in the treatment of patent ductus arteriosus in prematurely born infants [Porownanie ibuprofenu i indometacyny w leczeniu przetrwalego przewodu tetniczego u noworodkow urodzonych przedwczesnie]. Medycyna Wieku Rozwojowego2005;9(3 Pt 1):335‐54. [PUBMED: 16547381] ">Adamska 2005</a>). </p> <p> <ul id="CD003481-list-0013"> <li> <p>Objective: to assess the efficacy and safety of early treatment with IV ibuprofen or IV indomethacin in preterm infants. </p> </li> <li> <p>Population: 35 preterm (less than 33 weeks' PMA and BW less than 1500 grams) infants with a PDA diagnosed by Doppler ECHO. </p> </li> <li> <p>Intervention: infants were randomised to receive three doses of indomethacin (0.2 mg/kg IV given at 24‐hour intervals, 19 infants) or three doses of ibuprofen (10, 5 and 5 mg/kg IV given at 24‐hour intervals, 16 infants). </p> </li> <li> <p>Outcomes: primary outcome was ductal closure. Other outcomes included: need for surgical ligation, IVH, PVL, NEC, intestinal perforation, oliguria, time to full oral feeds, CLD (at 28 days of age), pulmonary haemorrhage, pulmonary hypertension, duration of mechanical ventilation, and days on supplemental oxygen. </p> </li> </ul> </p> <p>The study by Akisu and coworkers was a single centre study conducted in Turkey (<a href="./references#CD003481-bbs2-0003" title="AkisuM , OzyurekAR , DorakC , ParlarA , KultursayN . Enteral ibuprofen versus indomethacin in the treatment of patent ductus arteriosus in preterm newborn infants [Premature bebeklerde patent duktus arteriozusun tedavisinde enteral ibuprofen ve indometazinin etkinligi ve guvenilirligi]. Cocuk Sagligi ve Hastaliklari Dergisi2001;44(1):56‐60. ">Akisu 2001</a>). </p> <p> <ul id="CD003481-list-0014"> <li> <p>Objective: to investigate the efficacy and safety of enteral ibuprofen for the treatment of PDA and to compare it with enteral indomethacin. </p> </li> <li> <p>Population: 23 preterm infants (less than 35 weeks' PMA) with a PDA diagnosed by Doppler ECHO. </p> </li> <li> <p>Intervention: infants were randomised to receive either enteral ibuprofen 10 mg/kg as the initial dose followed by 5 mg/kg 24 and 48 hours later (12 infants) or three doses of enteral indomethacin (0.2 mg/kg) every 12 hours (11 infants). </p> </li> <li> <p>Outcomes: primary outcome was ductal closure. Other outcomes included need to re‐treat a PDA with indomethacin or ibuprofen, urine output, serum creatinine after treatment, thrombocyte counts, gastrointestinal haemorrhage, IVH, sepsis, and mortality. </p> </li> </ul> </p> <p>The study by Aly and coworkers was a single centre study conducted in Egypt (<a href="./references#CD003481-bbs2-0004" title="AlyH , LotfyW , BadrawiN , GhawasM , Abdel‐MeguidIE , HammadTA . Oral ibuprofen and ductus arteriosus in premature infants: a randomized pilot study. American Journal of Perinatology2007;24(5):267‐70. [PUBMED: 17484080] LotfyW , BadrawiN , GhawasM , EhsanE , AlyH . Oral ibuprofen solution (O) is efficacious for the treatment of patent ductus arteriosus (PDA) in premature infants: a randomized controlled trial. Pediatric Academic Societies Annual Meeting; 2005 May 14‐17; Washington DC, United States. 2005. [PAS2005:1410] ">Aly 2007</a>). </p> <p> <ul id="CD003481-list-0015"> <li> <p>Objective: to evaluate the feasibility of the use of oral ibuprofen suspension versus IV indomethacin in the treatment of PDA in preterm infants. </p> </li> <li> <p>Population: 21 preterm infants (less than 35 weeks' gestation) aged two to seven days with respiratory distress and PDA diagnosed by Doppler ECHO. </p> </li> <li> <p>Intervention: infants were randomised to receive three doses of IV indomethacin 0.2 mg/kg at 12‐hour intervals (nine infants) or an initial oral dose of ibuprofen 10 mg/kg, followed by two doses of 5 mg/kg after 24 and 48 hours (12 infants). </p> </li> <li> <p>Outcomes: primary outcome was ductal closure. Secondary outcomes included pulmonary haemorrhage, gastrointestinal haemorrhage, NEC, gastrointestinal perforation, and change in serum creatinine following treatment. </p> </li> </ul> </p> <p>The study by Chotigeat and coworkers was a single centre study conducted in Thailand (<a href="./references#CD003481-bbs2-0009" title="ChotigeatU , JirapapaK , LayangkoolT . A comparison of oral ibuprofen and intravenous indomethacin for closure of patent ductus arteriosus in preterm infants. Chotmaihet Thangphaet [Journal of the Medical Association of Thailand]2003;86(Suppl 3):S563‐9. [PUBMED: 14700149] ">Chotigeat 2003</a>). </p> <p> <ul id="CD003481-list-0016"> <li> <p>Objective: to compare efficacy and adverse effects of oral ibuprofen versus IV indomethacin treatment for symptomatic PDA in preterm infants. </p> </li> <li> <p>Population: preterm infants with a symptomatic PDA confirmed by ECHO.</p> </li> <li> <p>Intervention: 30 infants were randomised to receive either three oral doses of ibuprofen (dose not stated) given at 24‐hourly intervals (15 infants) or three doses of IV indomethacin (dose not stated) given at 12‐hourly intervals (15 infants) starting within 10 days of life. </p> </li> <li> <p>Outcomes: primary outcome measure was ductal closure. Secondary outcomes included the need for surgical closure of a PDA, the need for re‐treatment with ibuprofen or indomethacin, mortality by 28 days, CLD (at 28 days), sepsis, ROP, and serum creatinine levels after treatment. </p> </li> </ul> </p> <p>The study by El‐Mashad and coworkers was a single centre study conducted in Egypt (<a href="./references#CD003481-bbs2-0013" title="El‐MashadAE , El‐MahdyH , ElAmrousyDE , ElgendyM . Comparative study of the efficacy and safety of paracetamol, ibuprofen, and indomethacin in closure of patent ductus arteriosus in preterm neonates. European Journal of Pediatrics2017;176(2):233‐40. [DOI: 10.1007/s00431‐016‐2830‐7; PUBMED: 28004188] ">El‐Mashad 2017</a>). </p> <p> <ul id="CD003481-list-0017"> <li> <p>Objective: the effectiveness of indomethacin, ibuprofen, and paracetamol in PDA closure in preterm neonates. </p> </li> <li> <p>Population: preterm neonates with haemodynamically significant PDA.</p> </li> <li> <p>Intervention: group I (paracetamol group) received 15 mg/kg/6 H IV paracetamol infusion for 3 days; group II (ibuprofen group) received 10 mg/kg IV ibuprofen infusion followed by 5 mg/kg/day for 2 days; group III (indomethacin group) received 0.2 mg/kg/12 H indomethacin IV infusion for three doses. Each study group included 100 infants. Total sample 300. </p> </li> <li> <p>Outcomes: primary outcome: failure to close the PDA. Secondary outcomes included: surgical ligation, ROP, GI bleeding, NEC, pulmonary haemorrhage, IVH, sepsis, daily urine output, serum creatinine, serum bilirubin, platelet count. </p> </li> </ul> </p> <p>The study by Fakhraee and coworkers was conducted in a single centre in Iran (<a href="./references#CD003481-bbs2-0015" title="FakhraeeSH , BadieeZ , MojtahedzadehS , KazemianM , KelishadiR . Comparison of oral ibuprofen and indomethacin therapy for patent ductus arteriosus in preterm infants. Zhongguo Dang Dai Er Ke za Zhi [Chinese Journal of Contemporary Pediatrics]2007;9(5):399‐403. [PUBMED: 17937843] ">Fakhraee 2007</a>). </p> <p> <ul id="CD003481-list-0018"> <li> <p>Objective: to compare the efficacy and safety of oral ibuprofen and oral indomethacin for the treatment of PDA in preterm infants. </p> </li> <li> <p>Population: 36 preterm infants (less than 34 weeks' PMA).</p> </li> <li> <p>Intervention: 18 infants were randomised to receive three oral doses of indomethacin 0.2 mg/kg at 24‐hour intervals and 18 infants to three doses of oral ibuprofen (first dose of 10 mg/kg, followed by 5 mg/kg/dose at 24‐hour intervals). </p> </li> <li> <p>Outcomes: primary outcome was ductal closure. Secondary outcomes included maximum serum BUN and creatinine levels after treatment, NEC, mortality at one month of age, and IVH (grades III and IV). </p> </li> </ul> </p> <p>The study by Gimeno Navarro and coworkers was a single centre study conducted in Spain (<a href="./references#CD003481-bbs2-0017" title="Gimeno NavarroA , Cano SanchezA , Fernandez GilinoC , Carrasco MorenoJI , Izquierdo MacianI , Gutierrez LasoA , et al. Ibuprofen versus indomethacin in the treatment of patent ductus arteriosus in preterm infants [Ibuprofeno frente a indometacina en el tratamiento del conducto arterioso persistente del prematuro]. Anales de Pediatria2005;63(3):212‐8. [PUBMED: 16219273] ">Gimeno Navarro 2005</a>). </p> <p> <ul id="CD003481-list-0019"> <li> <p>Objective: to compare the safety and efficacy of IV ibuprofen and IV indomethacin in the treatment of PDA in preterm infants. </p> </li> <li> <p>Population: preterm infants (less than 34 weeks' PMA) with a haemodynamically significant PDA, confirmed by ECHO in the first week of life and who required respiratory support. </p> </li> <li> <p>Intervention: during the first week of life (mean of two days of life), 47 ventilated infants were randomised to receive either indomethacin 0.2 mg/kg/dose IV every 12 hours for three doses (24 infants) or an initial dose of IV ibuprofen 10 mg/kg, followed by two doses of ibuprofen IV every 24 hours (23 infants). </p> </li> <li> <p>Outcomes: primary outcome was ductal closure. Other outcomes included mortality, ductal reopening, need for surgical ligation, NEC, isolated bowel perforation, intestinal haemorrhage, pulmonary haemorrhage, CLD (need for supplemental oxygen at 28 days of age), IVH (grades III and IV), days on assisted ventilation, days on supplemental oxygen, and days in neonatal intensive care unit (NICU). </p> </li> </ul> </p> <p>The study by Hammerman was conducted in a single centre in Israel (<a href="./references#CD003481-bbs2-0019" title="HammermanC , ShchorsI , JacobsonS , SchimmelMS , BromikerR , KaplanM , et al. Ibuprofen versus continuous indomethacin in premature neonates with patent ductus arteriosus: is the difference in the mode of administration?. Pediatric Research2008;64(3):291‐7. [DOI: 10.1203/PDR.0b013e31817d9bb0; PUBMED: 18458658] ">Hammerman 2008</a>). </p> <p> <ul id="CD003481-list-0020"> <li> <p>Objective: to show that treating a PDA with continuous IV indomethacin was similar to IV ibuprofen in its effect on urine output, renal function and blood flow velocities. </p> </li> <li> <p>Population: 64 preterm infants (PMA 33 weeks or less, BW 1750 grams or less) with PDA. </p> </li> <li> <p>Intervention: 31 infants received continuous IV infusion of indomethacin for 36 hours at a rate of 17 μg/kg/hour and 32 infants received ibuprofen 10 mg/kg IV followed by two doses of 5 mg/kg at 24‐hour intervals. One boy assigned to the ibuprofen group was withdrawn by his parents before he started therapy and he was not included in the analysis. </p> </li> <li> <p>Outcomes: primary outcome was ductal closure. Other outcomes included need for surgical ligation, need for re‐treatment with either indomethacin or ibuprofen, need for surgical treatment, bronchopulmonary dysplasia (BPD), IVH (grades III and IV), ROP, NEC. </p> </li> </ul> </p> <p>The study by Lago and coworkers was conducted in two centres in Italy (<a href="./references#CD003481-bbs2-0020" title="LagoP , BettiolT , SalvadoriS , PitassiI , VianelloA , ChiandettiL , et al. Safety and efficacy of ibuprofen versus indomethacin in preterm infants treated for patent ductus arteriosus: a randomised controlled trial. European Journal of Pediatrics2002;161(4):202‐7. [PUBMED: 12014386] LagoP , SalvadoriS , BettiolT , PitassiI , ChiandettiL , SaiaOS . Effects of indomethacin and ibuprofen on renal function in preterm infants treated for patent ductus arteriosus: a randomized controlled trial. Pediatric Research2001;49:375A. ZanardoV , VedovatoS , LagoP , PivaD , FaggianD , ChiozzaL . Effects of ibuprofen and indomethacin on urinary antidiuretic hormone excretion in preterm infants treated for patent ductus arteriosus. Fetal Diagnosis and Therapy2005;20(6):534‐9. [DOI: 10.1159/000088046; PUBMED: 16260891] ">Lago 2002</a>). </p> <p> <ul id="CD003481-list-0021"> <li> <p>Objective: to compare IV indomethacin and IV ibuprofen with regard to efficacy and safety for the early treatment of PDA. </p> </li> <li> <p>Population: preterm infants (PMA 34 weeks or less, postnatal age 48 to 72 hours) with respiratory distress syndrome (RDS) treated with mechanical ventilation and ECHO‐confirmed PDA. </p> </li> <li> <p>Intervention: 175 infants were randomised to either IV ibuprofen (94 infants) at an initial dose of 10 mg/kg followed by two doses of 5 mg/kg each after 24 and 48 hours or three doses of IV indomethacin 0.2 mg/kg at 12‐hour intervals (81 infants). When the ductus arteriosus was still patent after the randomly assigned treatment in infants in either group receiving mechanical ventilation, another three doses of the same medication were given as a non‐randomised rescue treatment. If this therapy did not induce ductal closure, the infant continued to receive mechanical ventilation and, if the ductus was judged to be haemodynamically significant or if further pharmacological treatment was contraindicated, surgical ligation of the ductus was performed. </p> </li> <li> <p>Outcomes: primary outcome was ductal closure. Other outcomes included mortality, oliguria, IVH, PVL, surgical ligation of PDA, serum creatinine, CLD at 36 weeks, NEC, sepsis, mortality, duration of ventilator support, days on supplemental oxygen, duration of hospital stay, and time to full feeds. </p> </li> </ul> </p> <p>The study by Mosca and coworkers was conducted in a single centre in Italy (<a href="./references#CD003481-bbs2-0024" title="MoscaF , BrayM , LattanzioM , FumagalliM , ColnaghiM , CastoldiF , et al. Comparison of the effects of ibuprofen and indomethacin on PDA closure and cerebral perfusion and oxygenation. Pediatric Research1997;41:165A. MoscaF , BrayM , LattanzioM , FumagalliM , ColnaghiMR , CompagnoniG . Comparison of the effects of indomethacin (INDO) and ibuprofen (IBU) on cerebral perfusion and oxygenation in preterm infants. Pediatric Research1996;39:231A. MoscaF , BrayM , LattanzioM , FumagalliM , TosettoC . Comparative evaluation of the effects of indomethacin and ibuprofen on cerebral perfusion and oxygenation in preterm infants with patent ductus arteriosus. Journal of Pediatrics1997;131(4):549‐54. [PUBMED: 9386657] ">Mosca 1997</a>). </p> <p> <ul id="CD003481-list-0022"> <li> <p>Objective: to compare the effects of IV indomethacin and IV ibuprofen on cerebral perfusion and oxygenation in preterm infants with PDA. </p> </li> <li> <p>Population: preterm infants (less than 31 weeks' PMA) with PDA and receiving mechanical ventilation. </p> </li> <li> <p>Intervention: 16 infants received either IV ibuprofen 10 mg/kg dissolved in saline 1 mL and infused over one minute or IV indomethacin 0.2 mg/kg (eight infants). A second and third dose of ibuprofen 5 mg/kg at 24‐hour intervals or indomethacin 0.1 mg/kg (eight infants) was administered, provided no significant adverse effect was observed. </p> </li> <li> <p>Outcomes: near‐infrared spectroscopy was used to measure changes in cerebral blood volume and in oxidised cytochrome oxidase concentration. Cerebral blood flow velocity in the pericallosal artery was measured using Doppler ultrasonography. Ductal closure, reopening of a PDA and the need for re‐treatment with indomethacin or ibuprofen were reported. </p> </li> </ul> </p> <p>The study by Lin and coworkers was conducted in one NICU in Chicago, USA and one NICU in Taiwan (<a href="./references#CD003481-bbs2-0023" title="LinYJ , ChenCM , RehanVK , FlorensA , WuSY , TsaiML , et al. Randomized trial to compare renal function and ductal response between Indomethacin and ibuprofen treatment in extremely low birth weight infants. Neonatology2017;111(3):195–202. [DOI: 10.1159/000450822; PUBMED: 27842315] ">Lin 2017</a>). </p> <p> <ul id="CD003481-list-0023"> <li> <p>Objective: to compare renal function and ductal response between indomethacin and ibuprofen. </p> </li> <li> <p>Population: preterm neonates &lt; 1000 grams with ECHO‐proven and clinically significant PDA. </p> </li> <li> <p>Intervention: group I (indomethacin group) received IV indomethacin in an initial dose of 0.2 mg/kg (1.0 ml/kg) followed by 2 doses of 0.1 mg/kg (0.5 ml/kg) at 24‐hour intervals. Group II (ibuprofen group) received 10 mg/kg IV ibuprofen infusion followed by 2 doses of 5 mg/kg/day at 24 hour intervals. Total number of infants enrolled was 144. </p> </li> <li> <p>Outcomes: renal function, ductal closure, surgical ligation, mortality, ROP stage 3‐4, BPD, NEC (stage ≥ 2), IVH (grade ≥ 2). </p> </li> </ul> </p> <p>The study by Patel and coworkers was a single centre pilot study conducted in England (<a href="./references#CD003481-bbs2-0025" title="PatelJ , MarksKA , RobertsI , AzzopardiD , EdwardsAD . Ibuprofen treatment of patent ductus arteriosus. Lancet1995;346(8969):255. [PUBMED: 7616831] ">Patel 1995</a>). </p> <p> <ul id="CD003481-list-0024"> <li> <p>Objective: to compare the cerebral effects of IV ibuprofen with IV indomethacin in preterm infants. </p> </li> <li> <p>Population: 33 infants with a median PMA of 26 weeks (range 23 to 28) and an ECHO‐confirmed PDA. </p> </li> <li> <p>Intervention: infants were randomised to receive either ibuprofen 5 mg/kg (12 infants), ibuprofen 10 mg/kg (six infants) or indomethacin 0.1 mg/kg (15 infants). The drugs were infused IV over 15 minutes. </p> </li> <li> <p>Outcomes: near‐infrared spectroscopy was used to observe the effect of treatment on cerebral perfusion, indicated by changes in cerebral blood volume and cerebral mitochondrial oxygenation, determined by the change in concentration of oxidised cytochrome aa3. Ductal closure was reported. </p> </li> </ul> </p> <p>The second study by Patel and coworkers was conducted in four centres in England (<a href="./references#CD003481-bbs2-0026" title="PatelJ , RobertsI , AzzopardiD , HamiltonP , EdwardsAD . Randomized double‐blind controlled trial comparing the effects of ibuprofen with indomethacin on cerebral hemodynamics in preterm infants with patent ductus arteriosus. Pediatric Research2000;47(1):36‐42. [PUBMED: 10625080] ">Patel 2000</a>). </p> <p> <ul id="CD003481-list-0025"> <li> <p>Objective: to compare the effects of IV ibuprofen to IV indomethacin on cerebral haemodynamics measured using near‐infrared spectroscopy in preterm infants during treatment for PDA. </p> </li> <li> <p>Population: 33 preterm infants (less than 35 weeks' PMA).</p> </li> <li> <p>Intervention: infants were randomly assigned to three IV doses of either ibuprofen 5 to 10 mg/kg every 24 hours (18 infants) or indomethacin 0.20 to 0.25 mg/kg every 12 hours (15 infants) and also received a dose of saline. </p> </li> <li> <p>Outcomes: primary outcomes were the effects of the first dose on cerebral blood flow and cerebral blood volume. The PDA closure rates, need for surgical ligation of PDA, and need for re‐treatment with indomethacin or ibuprofen were reported. </p> </li> </ul> </p> <p>The study by Pezzati and coworkers was conducted in a single centre in Italy (<a href="./references#CD003481-bbs2-0027" title="PezzatiM , BertiniG , VangiV , BiagiottiR , CianciulliD , RubaltelliFF . Mesenteric and renal perfusion in preterm infants with PDA: indomethacin vs ibuprofen. Pediatric Research1999;45:218A. PezzatiM , VangiV , BiagiottiR , BertiniG , CianciulliD , RubatelliFF . Effects of indomethacin and ibuprofen on mesenteric and renal blood flow in preterm infants with patent ductus arteriosus. Journal of Pediatrics1999;135(6):733‐8. [PUBMED: 10586177] ">Pezzati 1999</a>). </p> <p> <ul id="CD003481-list-0026"> <li> <p>Objective: to evaluate the effect of IV ibuprofen and IV indomethacin for treatment of PDA on mesenteric and renal blood flow velocity in preterm infants. </p> </li> <li> <p>Population: preterm mechanically ventilated infants (less than 33 weeks' PMA) with a PDA diagnosed by Doppler ECHO. </p> </li> <li> <p>Intervention: 17 infants were randomised to receive either IV indomethacin 0.2 mg/kg (eight infants) or IV ibuprofen 10 mg/kg (nine infants) as a continuous infusion over 15 minutes. Regardless of ductal closure after the first dose, all infants received a second and third dose of indomethacin 0.1 mg/kg or ibuprofen 5 mg/kg at 24‐hour intervals. </p> </li> <li> <p>Outcomes: primary outcomes were mesenteric and renal blood flow velocity. Secondary outcomes included ductal closure, ductal reopening, and NEC. </p> </li> </ul> </p> <p>The study by Plavka and coworkers was conducted in three centres in the Czech Republic (<a href="./references#CD003481-bbs2-0029" title="PlavkaR , SvihovecP , BorekI , BiolekJ , KostirovaM , LiskaK , et al. Ibuprofen vs. indomethacin in the treatment of patent ductus arteriosus (PDA) in very premature neonates. Pediatric Research2001;49:375A. ">Plavka 2001</a>). </p> <p> <ul id="CD003481-list-0027"> <li> <p>Objective: to compare adverse effects and efficacy of IV ibuprofen with IV indomethacin for treatment of PDA in very preterm infants. </p> </li> <li> <p>Population: 41 preterm infants with clinical and ECHO signs of PDA.</p> </li> <li> <p>Intervention: infants received either IV ibuprofen 8 mg/kg every 24 hours for three doses (21 infants) or IV indomethacin 0.2 mg/kg every 24 hours for three doses (20 infants). If PDA persisted, treatment was repeated at half dose every 24 hours for six doses. Resistant PDA was ligated. </p> </li> <li> <p>Outcomes: primary outcome was PDA closure. Secondary outcomes included reopening of the duct, need for surgical ligation rates, and cerebral blood flow velocities. </p> </li> </ul> </p> <p>The study by Pourarian and coworkers was conducted in a single centre in Iran (<a href="./references#CD003481-bbs2-0030" title="PourarianSH , PishvaN , MadaniA , RastegariM . Comparison of oral ibuprofen and indomethacin on closure of patent ductus arteriosus in preterm infants. Eastern Mediterranean Health Journal2008;14(2):360‐5. [PUBMED: 18561728] ">Pourarian 2008</a>). </p> <p> <ul id="CD003481-list-0028"> <li> <p>Objective: to evaluate the therapeutic effects of oral administration of indomethacin or ibuprofen suspension on closure of PDA in preterm infants. </p> </li> <li> <p>Population: 20 preterm infants with ECHO‐confirmed PDA</p> </li> <li> <p>Intervention: for the indomethacin group, the powder content of a 25 mg indomethacin capsule was freshly prepared by dissolving in 25 mL distilled water. This was given orally as 0.2 mg/kg for three doses at 24‐hour intervals (10 infants). For the ibuprofen group, an ibuprofen oral suspension containing 100 mg/5 mL was given as an initial dose of 10 mg/kg, followed by two further doses of 5 mg/kg at 24‐hour intervals (10 infants). Administration of the second or third doses of each drug was dependent on achievement of ductal closure after the initial doses. </p> </li> <li> <p>Outcomes: primary outcome was ductal closure. Secondary outcomes included need for surgical closure, NEC, change in mean serum creatinine levels before and after treatment, increase in BUN level greater than 14 µmol/L, and thrombocytopenia less than 50,000/mm<sup>3</sup>. </p> </li> </ul> </p> <p>The study by Salama and coworkers was conducted in a single centre in Qatar (<a href="./references#CD003481-bbs2-0032" title="SalamaH , AlsisiA , Al‐RifaiH , ShaddadA , SamawalL , HabboubL , et al. A randomized controlled trial on the use of oral ibuprofen to close patent ductus arteriosus in premature infants. Journal of Neonatal‐Perinatal Medicine2008;1(3):153‐8. ">Salama 2008</a>). </p> <p> <ul id="CD003481-list-0029"> <li> <p>Objective: to compare the efficacy of oral ibuprofen with IV indomethacin for closure of a significant PDA in preterm infants. </p> </li> <li> <p>Population: 41 preterm infants (PMA less than 34 weeks, BW less than 2500 grams) diagnosed with haemodynamically significant PDA. </p> </li> <li> <p>Intervention: 20 infants received IV indomethacin (three doses of 0.2 mg/kg/dose every 24 hours) and 21 received oral ibuprofen (10 mg/kg on the first day followed by 5 mg/kg for two more days). Ibuprofen was mixed with 0.5 mL of milk before its administration via an oro‐gastric tube. </p> </li> <li> <p>Outcomes: primary outcome was complete closure of the PDA. Secondary outcomes included need for surgical ligation, bowel perforation, and mortality. </p> </li> </ul> </p> <p>The study by Su and coworkers was conducted in a single centre in Taiwan (<a href="./references#CD003481-bbs2-0034" title="SuPH , ChenJY , SuCM , HuangTC , LeeHS . Comparison of ibuprofen and indomethacin therapy for patent ductus arteriosus in preterm infants. Pediatrics International2003;45(6):665‐70. [PUBMED: 14651538] ">Su 2003</a>). </p> <p> <ul id="CD003481-list-0030"> <li> <p>Objective: to compare IV ibuprofen and IV indomethacin with regard to efficacy and safety for the early treatment of PDA in preterm infants. </p> </li> <li> <p>Population: 63 preterm infants (PMA 32 weeks or less, BW 1500 grams or less) with ECHO evidence of a significant PDA. </p> </li> <li> <p>Intervention: 32 infants received IV ibuprofen 10 mg/kg initially followed by 5 mg/kg after 24 and 48 hours and 31 received IV indomethacin 0.2 mg/kg every 12 hours for three doses. </p> </li> <li> <p>Outcomes: primary outcome was PDA closure. Secondary outcomes included need for surgical ligation, mortality, NEC, CLD at 36 weeks' PMA, IVH, PVL, ROP, hospital stay, duration of mechanical ventilation, days to full enteral feeds, and gastric haemorrhage. </p> </li> </ul> </p> <p>The study by Su and coworkers was conducted in a single centre in Taiwan (<a href="./references#CD003481-bbs2-0035" title="SuBH , LinHC , ChiuHY , HsiehHY , ChenHH , TsaiYC . Comparison of ibuprofen and indomethacin for early‐targeted treatment of patent ductus arteriosus in extremely premature infants: a randomised controlled trial. Archives of Disease in Childhood. Fetal and Neonatal Edition2008;93(2):F94‐9. [DOI: 10.1136/adc.2007.120584; PUBMED: 17768157] ">Su 2008</a>). </p> <p> <ul id="CD003481-list-0031"> <li> <p>Objective: to ascertain whether ibuprofen was effective and safe in inducing PDA closure in extremely preterm infants. </p> </li> <li> <p>Population: 119 infants (PMA 28 weeks or less) with RDS and PDA confirmed by ECHO.</p> </li> <li> <p>Intervention: 59 infants received IV indomethacin 0.2 mg/kg (1 mL) as the initial dose and then 0.1 mg/kg in infants less than 48 hours old, and 0.2 mg/kg in infants over 48 hours old at 24‐hour intervals as indicated by PDA flow patterns. Sixty infants received IV ibuprofen 10 mg/kg (1 mL) and then 5 mg/kg at 24‐hour intervals, as indicated by PDA flow patterns. </p> </li> <li> <p>Outcomes: PDA closure rate, need for ductal ligation, mortality, NEC, bowel perforation, gastrointestinal haemorrhage, BPD, sepsis, IVH, PVL, days to full enteral feeds, days to regain BW, days on ventilation, days of supplemental oxygen, post‐treatment serum creatinine levels, and oliguria (less than 1 mL/kg/hour). </p> </li> </ul> </p> <p>The study by Supapannachart and coworkers was conducted in a single centre in Thailand (<a href="./references#CD003481-bbs2-0036" title="SupapannachartS , LimrungsikulA , KhowsathitP . Oral ibuprofen and indomethacin for treatment of patent ductus arteriosus in premature infants: a randomized trial at Ramathibodi Hospital. Chotmaihet Thangphaet [Journal of the Medical Association of Thailand]2002;85(Suppl 4):S1252‐8. [PUBMED: 12549803] ">Supapannachart 2002</a>). </p> <p> <ul id="CD003481-list-0032"> <li> <p>Objective: to assess whether oral ibuprofen daily for three days was as effective as indomethacin to treat symptomatic PDA in preterm infants and to compare the adverse effects of oral ibuprofen to oral or IV indomethacin. </p> </li> <li> <p>Population: 18 preterm (less than 34 weeks' PMA) infants with a symptomatic PDA.</p> </li> <li> <p>Intervention: nine infants received oral ibuprofen 10 mg/kg/dose for three doses given at 24‐hourly intervals and nine infants received three doses of oral or IV indomethacin 0.2 mg/kg/dose given at 12‐hourly intervals. </p> </li> <li> <p>Outcomes: primary outcome was PDA closure. Secondary outcomes included mortality, CLD (age not stated), IVH (grade not stated), and NEC. </p> </li> </ul> </p> <p>The study by Van Overmeire and coworkers was conducted in a single centre in Belgium (<a href="./references#CD003481-bbs2-0037" title="VanOvermeireB , FollensI , HartmannS , CretenWL , VanAckerKJ . Treatment of patent ductus arteriosus with ibuprofen. Archives of Disease in Childhood. Fetal and Neonatal Edition1997;76(3):F179‐84. [PUBMED: 9175948] VanOvermeireB , FollensI , HartmannS , MahieuL , VanReemptsPJ . Intravenous ibuprofen (IBU) for the treatment of patent ductus arteriosus (PDA) in preterm infants with respiratory distress syndrome (RDS). Pediatric Research1996;39:250A. ">Van Overmeire 1997</a>). </p> <p> <ul id="CD003481-list-0033"> <li> <p>Objective: to evaluate the efficacy and adverse effects of IV ibuprofen for the early treatment of PDA and compare it with IV indomethacin. </p> </li> <li> <p>Population: preterm infants (PMA less than 33 weeks) with PDA diagnosed by ECHO.</p> </li> <li> <p>Intervention: 40 infants were randomly assigned at two to three days of life to receive either IV ibuprofen (20 infants) with an initial dose of 10 mg/kg followed by 5 mg/kg 24 and 48 hours later or IV indomethacin (20 infants) 0.2 mg/kg every 12 hours for three doses. Presence of a PDA was verified by Doppler ECHO prior to enrolment, after the last dose of the randomised treatment, and at the age of seven days. When a PDA was present after the randomised treatment and the infant required mechanical ventilation, the infant was treated with indomethacin 0.2 mg/kg every 12 hours for three doses. </p> </li> <li> <p>Outcomes: primary outcome was ductal closure. Secondary outcomes included need for surgical ligation of a PDA, need for re‐treatment with indomethacin, mortality, CLD (at 28 days of age), duration of assisted ventilation, duration of supplemental oxygen, sepsis, NEC, age to regain BW, and ROP. </p> </li> </ul> </p> <p>The second study by Van Overmeire and coworkers was conducted in five centres in Belgium (<a href="./references#CD003481-bbs2-0038" title="PezzatiM , VangiV , BiagiottiR , BertiniG , CianciulliD , RubaltelliFF . Effects of indomethacin and ibuprofen on mesenteric and renal blood flow in preterm infants with patent ductus arteriosus. Journal of Pediatrics1999;135(6):733‐8. [PUBMED: 10586177] VanOvermeireB , LanghendriesJP , VanhaesebrouckP , LecoutereD , Van deBroekH . Ibuprofen for early treatment of patent ductus arteriosus, a randomized multicentre trial. Pediatric Research1998;43:200A. VanOvermeireB , SmetsK , LecoutereD , Van deBroekH , WeylerJ , DeGrooteK , et al. A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus. New England Journal of Medicine2000;343(10):674‐81. [DOI: 10.1056/NEJM200009073431001; PUBMED: 10974130] ">Van Overmeire 2000</a>). </p> <p> <ul id="CD003481-list-0034"> <li> <p>Objective: to compare IV ibuprofen and IV indomethacin with regard to efficacy and safety for the early treatment of PDA in preterm infants. </p> </li> <li> <p>Population: 148 infants (PMA 24 to 32 weeks) with RDS and a PDA confirmed by ECHO.</p> </li> <li> <p>Intervention: 74 infants received IV ibuprofen 10 mg/kg as an initial dose followed by two doses of 5 mg/kg at 24 and 48 hours and 74 infants received IV indomethacin 0.2 mg/kg every 12 hours for three doses. When the ductus arteriosus was still patent after the randomly assigned treatment in an infant in either group who was still receiving mechanical ventilation, indomethacin (three doses of 0.2 mg/kg at 12‐hour intervals) was given as non‐randomised rescue treatment. If this therapy did not promote ductal closure and the infant continued to receive mechanical ventilation, or if there was a contraindication to the second pharmacological treatment, surgical ligation of the ductus was performed. </p> </li> <li> <p>Outcomes: primary outcome was ductal closure. Other outcomes included mortality by one month, NEC, localised bowel perforation, extension of IVH during treatment, PVL, CLD (need for supplemental oxygen for more than 28 days), duration of supplemental oxygen, duration of mechanical ventilation, time to regain BW, time to full enteral feeding, urine output, and serum creatinine. </p> </li> </ul> </p> <p>The study by Yadav and coworkers was conducted in two tertiary care institutes in New Delhi, India (<a href="./references#CD003481-bbs2-0039" title="YadavS , AgarwalS , MariaA , DudejaA , DubeyNK , AnandP , et al. Comparison of oral ibuprofen with oral indomethacin for PDA closure in Indian preterm neonates: a randomized controlled trial. Pediatric Cardiology2014;35(5):824‐30. [DOI: 10.1007/s00246‐014‐0861‐2; PUBMED: 24435507] ">Yadav 2014</a>). </p> <p> <ul id="CD003481-list-0035"> <li> <p>Objective: to assess the efficacy and safety of oral ibuprofen for PDA closure in preterm neonates and compare it with oral indomethacin. </p> </li> <li> <p>Population: 83 preterm infants with a haemodynamically significant PDA (PMA less than 37 weeks, BW less than 2500 grams) confirmed by ECHO. </p> </li> <li> <p>Intervention: 48 infants received oral ibuprofen 10 mg/kg on the first day followed by 5 mg/kg every 24 hours for two doses and 35 infants received indomethacin as three doses of 0.20 to 0.25 mg/kg every 24 hours depending on the gestational age (initial dose was 0.2 mg/kg, subsequent doses at two to seven days of age were 0.2 mg/kg/dose every 24 hours for two doses, and at seven days of age were 0.25 mg/kg/dose every 24 hours for two doses). </p> </li> <li> <p>Outcomes: primary outcome was PDA closure. Secondary outcomes included need for a repeat course of medications (after 48 hours of the third dose of treatment), reopening of the duct, need for surgical ligation (after two courses of treatment), oliguria, gastrointestinal bleed, NEC, IVH, derangement of renal functions, and pulmonary hypertension. </p> </li> </ul> </p> </section> <section id="CD003481-sec-0074"> <h5 class="title">Oral ibuprofen versus intravenous or oral indomethacin (Comparison 4)</h5> <p>The study by Akisu and coworkers was conducted in a single centre in Turkey (<a href="./references#CD003481-bbs2-0003" title="AkisuM , OzyurekAR , DorakC , ParlarA , KultursayN . Enteral ibuprofen versus indomethacin in the treatment of patent ductus arteriosus in preterm newborn infants [Premature bebeklerde patent duktus arteriozusun tedavisinde enteral ibuprofen ve indometazinin etkinligi ve guvenilirligi]. Cocuk Sagligi ve Hastaliklari Dergisi2001;44(1):56‐60. ">Akisu 2001</a>). </p> <p> <ul id="CD003481-list-0036"> <li> <p>Objective: to investigate the efficacy and safety of enteral ibuprofen for the treatment of PDA and to compare it with enteral indomethacin. </p> </li> <li> <p>Population: 23 preterm infants (less than 35 weeks' PMA) with a PDA diagnosed by Doppler ECHO. </p> </li> <li> <p>Intervention: 12 infants received enteral ibuprofen 10 mg/kg as the initial dose followed by 5 mg/kg 24 and 48 hours later and 11 infants received three doses of enteral indomethacin 0.2 mg/kg every 12 hours. </p> </li> <li> <p>Outcomes: primary outcome was ductal closure. Other outcomes included need to re‐treat a PDA with indomethacin or ibuprofen, urine output, serum creatinine after treatment, thrombocyte counts, gastrointestinal haemorrhage, IVH, sepsis, and mortality. </p> </li> </ul> </p> <p>The study by Aly and coworkers was a single centre study conducted in Egypt (<a href="./references#CD003481-bbs2-0004" title="AlyH , LotfyW , BadrawiN , GhawasM , Abdel‐MeguidIE , HammadTA . Oral ibuprofen and ductus arteriosus in premature infants: a randomized pilot study. American Journal of Perinatology2007;24(5):267‐70. [PUBMED: 17484080] LotfyW , BadrawiN , GhawasM , EhsanE , AlyH . Oral ibuprofen solution (O) is efficacious for the treatment of patent ductus arteriosus (PDA) in premature infants: a randomized controlled trial. Pediatric Academic Societies Annual Meeting; 2005 May 14‐17; Washington DC, United States. 2005. [PAS2005:1410] ">Aly 2007</a>). </p> <p> <ul id="CD003481-list-0037"> <li> <p>Objective: to evaluate the feasibility of the use of oral ibuprofen suspension versus IV indomethacin in the treatment of PDA in preterm infants. </p> </li> <li> <p>Population: 21 preterm infants (less than 35 weeks' PMA) aged two to seven days with respiratory distress and PDA diagnosed by Doppler ECHO. </p> </li> <li> <p>Intervention: nine infants received three doses of IV indomethacin 0.2 mg/kg at 12‐hour intervals and 12 infants received an initial oral dose of ibuprofen 10 mg/kg, followed by two doses of 5 mg/kg after 24 and 48 hours. </p> </li> <li> <p>Outcomes: primary outcome was ductal closure. Secondary outcomes included biochemical tests (serum creatinine), pulmonary haemorrhage, gastrointestinal bleed, NEC, gastrointestinal perforation, and increase in serum creatinine following treatment. </p> </li> </ul> </p> <p>The study by Chotigeat and coworkers was a single centre study in Thailand (<a href="./references#CD003481-bbs2-0009" title="ChotigeatU , JirapapaK , LayangkoolT . A comparison of oral ibuprofen and intravenous indomethacin for closure of patent ductus arteriosus in preterm infants. Chotmaihet Thangphaet [Journal of the Medical Association of Thailand]2003;86(Suppl 3):S563‐9. [PUBMED: 14700149] ">Chotigeat 2003</a>). </p> <p> <ul id="CD003481-list-0038"> <li> <p>Objective: to compare efficacy and adverse effects of ibuprofen versus indomethacin treatment for symptomatic PDA in preterm infants. </p> </li> <li> <p>Population: preterm infants with a symptomatic PDA confirmed by ECHO.</p> </li> <li> <p>Intervention: 30 infants were randomised to receive either three oral doses of ibuprofen (dose not stated) given at 24‐hourly intervals or three doses of IV indomethacin (dose not stated) given at 12‐hourly intervals starting within 10 days of life. </p> </li> <li> <p>Outcomes: primary outcome measure was ductal closure. Secondary outcomes included the need for surgical closure of a PDA, the need for re‐treatment with ibuprofen or indomethacin, mortality by 28 days, CLD (at 28 days), sepsis, ROP, and serum creatinine levels after treatment. </p> </li> </ul> </p> <p>The study by Fakhraee and coworkers was conducted in a single centre in Iran (<a href="./references#CD003481-bbs2-0015" title="FakhraeeSH , BadieeZ , MojtahedzadehS , KazemianM , KelishadiR . Comparison of oral ibuprofen and indomethacin therapy for patent ductus arteriosus in preterm infants. Zhongguo Dang Dai Er Ke za Zhi [Chinese Journal of Contemporary Pediatrics]2007;9(5):399‐403. [PUBMED: 17937843] ">Fakhraee 2007</a>). </p> <p> <ul id="CD003481-list-0039"> <li> <p>Objective: to compare the efficacy and safety of oral ibuprofen and oral indomethacin for the treatment of PDA in preterm infants. </p> </li> <li> <p>Population: 36 preterm infants (less than 34 weeks' PMA).</p> </li> <li> <p>Intervention: 18 infants were randomised to receive three oral doses of indomethacin 0.2 mg/kg at 24‐hour intervals and 18 infants received three doses of oral ibuprofen (first dose of 10 mg/kg, followed by 5 mg/kg/dose at 24‐hour intervals). </p> </li> <li> <p>Outcomes: primary outcome was ductal closure. Secondary outcomes included maximum serum BUN and creatinine levels after treatment, NEC, mortality at 1 month of age, and IVH (grades III and IV). </p> </li> </ul> </p> <p>The study by Pourarian and coworkers was conducted in a single centre in Iran (<a href="./references#CD003481-bbs2-0030" title="PourarianSH , PishvaN , MadaniA , RastegariM . Comparison of oral ibuprofen and indomethacin on closure of patent ductus arteriosus in preterm infants. Eastern Mediterranean Health Journal2008;14(2):360‐5. [PUBMED: 18561728] ">Pourarian 2008</a>). </p> <p> <ul id="CD003481-list-0040"> <li> <p>Objective: to evaluate the therapeutic effects of oral administration of indomethacin or ibuprofen suspension on closure of PDA in preterm infants. </p> </li> <li> <p>Population: 20 preterm infants with ECHO‐confirmed PDA.</p> </li> <li> <p>Intervention: for the indomethacin group, the powder content of a 25 mg indomethacin capsule was freshly prepared by dissolving in 25 mL distilled water. This was given orally as 0.2 mg/kg for three doses at 24‐hour intervals. For the ibuprofen group, an ibuprofen oral suspension containing 100 mg/5 mL was given as an initial dose of 10 mg/kg, followed by two further doses of 5 mg/kg at 24‐hour intervals. Administration of the second or third doses of each drug was dependent on achievement of ductal closure after the initial doses. </p> </li> <li> <p>Outcomes: primary outcome was ductal closure. Secondary outcomes included need for surgical closure, NEC, change in mean serum creatinine levels before and after treatment, increase in BUN level more than 14 µmol/L, and thrombocytopenia less than 50,000 mm<sup>3</sup>. </p> </li> </ul> </p> <p>The study by Salama and coworkers was conducted in a single centre in Qatar (<a href="./references#CD003481-bbs2-0032" title="SalamaH , AlsisiA , Al‐RifaiH , ShaddadA , SamawalL , HabboubL , et al. A randomized controlled trial on the use of oral ibuprofen to close patent ductus arteriosus in premature infants. Journal of Neonatal‐Perinatal Medicine2008;1(3):153‐8. ">Salama 2008</a>). </p> <p> <ul id="CD003481-list-0041"> <li> <p>Objective: to compare the efficacy of oral ibuprofen with IV indomethacin for closure of a significant PDA in preterm infants. </p> </li> <li> <p>Population: 41 preterm infants (PMA less than 34 weeks, BW less than 2500 grams) diagnosed with haemodynamically significant PDA. </p> </li> <li> <p>Intervention: 20 infants received IV indomethacin 0.2 mg/kg/dose every 24 hours for three doses and 21 infants received oral ibuprofen 10 mg/kg on the first day followed by 5 mg/kg for two more days. Ibuprofen was mixed with 0.5 mL of milk before its administration via an oro‐gastric tube. </p> </li> <li> <p>Outcomes: primary outcome was complete closure of the PDA. Secondary outcomes included need for surgical ligation, bowel perforation, and mortality. </p> </li> </ul> </p> <p>The study by Supapannachart and coworkers was conducted in a single centre in Thailand (<a href="./references#CD003481-bbs2-0036" title="SupapannachartS , LimrungsikulA , KhowsathitP . Oral ibuprofen and indomethacin for treatment of patent ductus arteriosus in premature infants: a randomized trial at Ramathibodi Hospital. Chotmaihet Thangphaet [Journal of the Medical Association of Thailand]2002;85(Suppl 4):S1252‐8. [PUBMED: 12549803] ">Supapannachart 2002</a>). </p> <p> <ul id="CD003481-list-0042"> <li> <p>Objective: to assess whether oral ibuprofen was as effective as indomethacin to treat symptomatic PDA in preterm infants and to compare the adverse effects of oral ibuprofen to indomethacin. </p> </li> <li> <p>Population: 18 preterm (less than 34 weeks' PMA) infants with a symptomatic PDA.</p> </li> <li> <p>Intervention: infants were randomly assigned to receive either oral ibuprofen 10 mg/kg/dose for three doses given at 24‐hourly intervals or three doses of oral or IV indomethacin 0.2 mg/kg/dose given at 12‐hourly intervals. </p> </li> <li> <p>Outcomes: primary outcome was PDA closure. Secondary outcomes included mortality, CLD (age not stated), IVH (grades not stated), and NEC. </p> </li> </ul> </p> <p>The study by Yadav and coworkers was conducted in two tertiary care institutes in New Delhi, India (<a href="./references#CD003481-bbs2-0039" title="YadavS , AgarwalS , MariaA , DudejaA , DubeyNK , AnandP , et al. Comparison of oral ibuprofen with oral indomethacin for PDA closure in Indian preterm neonates: a randomized controlled trial. Pediatric Cardiology2014;35(5):824‐30. [DOI: 10.1007/s00246‐014‐0861‐2; PUBMED: 24435507] ">Yadav 2014</a>). </p> <p> <ul id="CD003481-list-0043"> <li> <p>Objective: to assess the efficacy and safety of oral ibuprofen therapy for PDA closure in preterm neonates and compare it with oral indomethacin. </p> </li> <li> <p>Population: 83 preterm infants with a haemodynamically significant PDA (PMA less than 37 weeks, BW less than 2500 grams) confirmed by ECHO. </p> </li> <li> <p>Intervention: 48 infants received oral ibuprofen 10 mg/kg on the first day followed by 5 mg/kg every 24 hours for two doses and 35 infants received indomethacin as three doses of 0.20 to 0.25 mg/kg every 24 hours depending on the gestational age (initial dose was 0.2 mg/kg, subsequent doses at two to seven days of age were 0.2 mg/kg/dose every 24 hours for two doses, and at seven days of age 0.25 mg/kg/dose every 24 hour for two doses). </p> </li> <li> <p>Outcomes: primary outcome was PDA closure. Secondary outcomes included need for a repeat course of medications (after 48 hours of the third dose of treatment), reopening of the duct, need for surgical ligation (after two courses of treatment), oliguria, gastrointestinal bleed, NEC, IVH, derangement of renal functions, and pulmonary hypertension. </p> </li> </ul> </p> </section> <section id="CD003481-sec-0075"> <h5 class="title">Oral ibuprofen versus intravenous ibuprofen (Comparison 5)</h5> <p>The study by Akar and coworkers was conducted in a single centre in Ankara, Turkey <a href="./references#CD003481-bbs2-0002" title="AkarM , YildirimTG , SandalG , BozdagS , ErdeveO , AltugN , et al. Does ibuprofen treatment in patent ductus arteriosus alter oxygen free radicals in premature infants?. Cardiology in the Young2017;27(3):507–11. [PUBMED: 27319277] ">Akar 2017</a>. </p> <p> <ul id="CD003481-list-0044"> <li> <p>Objective: To evaluate the interaction between oxidative status and the medical treatment of PDA with different forms of ibuprofen. </p> </li> <li> <p>Population: 102 preterm infants of &lt; 32 weeks' PMA, birth weight &lt; 1500 grams, and postnatal age 48 to 96 hours with PDA. </p> </li> <li> <p>Intervention: IV Ibuprofen 10 mg/kg initial dose followed by 5 mg/kg after 24 and 48 hours; PO ibuprofen 10 mg/kg initial dose followed by 5 mg/kg after 24 and 48 hours. </p> </li> <li> <p>Outcomes: The primary outcome of the study was the effect of different forms of ibuprofen treatment on the antioxidant and oxidant status of the patients. Secondary outcomes were the relationship between pretreatment total antioxidant capacity and total oxidant status levels and the success rate of PDA closure and need for surgical ligation. We included PDA closure rates and need for surgical ligation in the analyses. </p> </li> </ul> </p> <p>The study by Cherif and coworkers was conducted in a single centre in Tunis, Tunisia (<a href="./references#CD003481-bbs2-0008" title="CherifA , KhroufN , JabnounS , MokraniC , AmaraMB , GuellouzeN , et al. Randomized pilot study comparing oral ibuprofen with intravenous ibuprofen in very low birth weight infants with patent ductus arteriosus. Pediatrics2008;122(6):e1256‐61. [PUBMED: 19047225] ">Cherif 2008</a>). </p> <p> <ul id="CD003481-list-0045"> <li> <p>Objective: to compare efficacy and tolerance between oral and IV ibuprofen in early closure of PDA in VLBW infants. </p> </li> <li> <p>Population: 64 VLBW infants with ECHO‐confirmed PDA, PMA less than 32 weeks, BW less than 1500 grams, postnatal age 48 to 96 hours, respiratory distress requiring more than 25% oxygen supplementation. </p> </li> <li> <p>Intervention: 32 infants received oral ibuprofen 10 mg/kg as the initial dose and 32 infants received IV ibuprofen 10 mg/kg as the initial dose. After the first dose of treatment in both groups, ECHO evaluation was performed to determine the need for a second or a third dose. In each group, in case the ductus was still open after the third dose, IV ibuprofen (an initial dose of 10 mg/kg followed by two doses of 5 mg/kg each, after 24 and 48 hours) as a non‐randomised rescue treatment was given. If this therapy did not promote ductal closure and the infant continued to receive mechanical ventilation, surgical ligation of the ductus was performed. </p> </li> <li> <p>Outcomes: PDA closure rate, need for surgical ligation, rate of reopening of the ductus, oliguria, increase in serum creatinine level greater than 16 mg/dL, change in creatinine concentrations, IVH grades I or II and grades III or IV, PVL, NEC, bowel perforation, sepsis, duration of intubation, survival at one month, and duration of hospital stay. </p> </li> </ul> </p> <p>The study by Erdeve and coworkers was conducted in a single centre in Ankara, Turkey (<a href="./references#CD003481-bbs2-0014" title="ErdeveO , YurttutanS , AltugN , OzdemirR , GokmenT , DilmenU , et al. Oral versus intravenous ibuprofen for patent ductus arteriosus closure: a randomised controlled trial in extremely low birthweight infants. Archives of Disease in Childhood. Fetal and Neonatal Edition2012;97(4):F279‐83. [DOI: 10.1136/archdischild‐2011‐300532; PUBMED: 22147286] ">Erdeve 2012</a>). </p> <p> <ul id="CD003481-list-0046"> <li> <p>Objective: to compare the efficacy and safety of oral versus IV ibuprofen for the pharmacological closure of PDA in less mature preterm infants. </p> </li> <li> <p>Population: 80 infants with PMA 28 weeks or less, BW less than 1000 grams, postnatal age 48 to 96 hours and with ECHO‐confirmed significant PDA. </p> </li> <li> <p>Intervention: 36 infants received oral ibuprofen and 34 infants received IV ibuprofen at a dose of 10 mg/kg followed by 5 mg/kg at 24 and 48 hours. </p> </li> <li> <p>Outcomes: primary outcome was PDA closure rate. Secondary outcomes included mortality, need for re‐treatment or surgical treatment of the PDA, duration of ventilation, duration of hospital stay, increase in serum bilirubin level after treatment, plasma creatinine after the first course of treatment, rate of ductal reopening, pneumothorax, pulmonary haemorrhage, pulmonary hypertension, BPD (supplemental oxygen at 36 weeks' PMA), IVH (grades I to IV), NEC, ROP, and ROP requiring laser treatment. </p> </li> </ul> </p> <p>The study by Gokmen and coworkers was conducted in a single centre in Ankara, Turkey (<a href="./references#CD003481-bbs2-0018" title="ErasZ , GokmenT , ErdeveO , OzyurtBM , SaridasB , DilmenU . Impact of oral versus intravenous ibuprofen on neurodevelopmental outcome: a randomized controlled parallel study. American Journal of Perinatology2013;30(10):857‐62. [DOI: 10.1055/s‐0033‐1333667; PUBMED: 23359230] GokmenT , ErdeveO , AltugN , OguzSS , UrasN , DilmenU . Efficacy and safety of oral verus intravenous ibuprofen in very low birth weight infants with patent ductus arteriosus. Journal of Pediatrics2011;158(4):549‐54; Erratum in: Journal of Pediatrics; 2012;160(1):181. [10.1016/j.jpeds.2010.10.008; PUBMED: 21094951] ">Gokmen 2011</a>). </p> <p> <ul id="CD003481-list-0047"> <li> <p>Objective: to compare oral ibuprofen versus IV ibuprofen for closure of PDA in VLBW infants. </p> </li> <li> <p>Population: 108 VLBW infants with PDA, verified by ECHO (PMA 32 weeks or less, BW 1500 grams or less, postnatal age 48 to 96 hours). </p> </li> <li> <p>Intervention: 54 infants received either IV ibuprofen and 54 infants received oral ibuprofen at an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 hours. Six infants (four in the IV group and two in the oral group) died before they completed the treatment and were excluded from the analyses except for the outcome of mortality during hospital stay. </p> </li> <li> <p>Outcomes: renal tolerance, mean plasma creatinine after treatment, urine output after treatment, cystatin‐C levels, failure to close a PDA, need for second course of ibuprofen, need for surgical ligation, oliguria, hospital stay, NEC, gastrointestinal bleed, sepsis, pneumothorax, BPD (supplemental oxygen at 36 weeks' PMA or at discharge, which ever came first), ROP requiring laser treatment, and mortality during hospital stay. </p> </li> <li> <p>Notes: in 2013, 57 children (56%) of the original 102 infants enrolled in this study were followed to an age of 18 to 24 months' corrected age; 30 infants in the oral ibuprofen group and 27 infants in the IV ibuprofen group were assessed for long‐term outcomes. The following outcomes were reported; Mental (MDI) and Psychomotor (PDI) Developmental Index on Bayley Scales of Infant Development II, moderate/severe cerebral palsy with functional deficits that required rehabilitation services, bilateral hearing loss (requiring amplification), blindness in either eye, MDI less than 70, and PDI less than 70. </p> </li> </ul> </p> <p>The study by Pistulli and coworkers was conducted in a single centre in Tirana, Albania (<a href="./references#CD003481-bbs2-0028" title="HoxhaA , GjyzariA , TusheE . Renal effects of ibuprofen during the treatment of patent ductus arteriosus in low birth weight premature infants. Nephrology Dialysis Transplantation Conference. 50th ERA‐EDTA Congress; 2013 May 18‐21; Istanbul, Turkey. 2013. PistulliE , HamitiA , BubaS , HoxhaA , KelmendiN , VyshkaG . The association between patent ductus arteriosus and perinatal infection in a group of low birth weight preterm infants. Iranian Journal of Pediatrics2014;24(1):42‐8. [PUBMED: 25793044] PriftiE , EnkeledaP , RubenaM , AlketaH . The impact of antenatal corticosteroids on PDA in low birth weight infants. Journal of Perinatal Medicine2013;41:s1. QosjaA , KuneshkaN , TusheE , TeneqexhiL . Oral versus intravenous ibuprofen for patent ductus arteriosus closure. Giornale Italiano di Cardiologia2012;13(Suppl 1):15S‐6S. ">Pistulli 2014</a>). </p> <p> <ul id="CD003481-list-0048"> <li> <p>Objective: to compare the efficacy and safety of oral ibuprofen versus IV ibuprofen in LBW preterm infants. </p> </li> <li> <p>Population: 80 preterm LBW infants with PMA 28 to 32 weeks, BW 2000 grams or less, postnatal age 48 to 96 hours, RDS treated with mechanical ventilation with oxygen requirement greater than 30%, and PDA verified by ECHO. Twelve infants were excluded from the analysis. </p> </li> <li> <p>Intervention: 44 infants received ibuprofen at an initial dose of 10 mg/kg via an oro‐gastric tube and 36 infants received 10 mg/kg of ibuprofen infused IV over a 15‐minute period with a syringe pump followed by 5 mg/kg for two consecutive days. When the PDA was still haemodynamically significant 24 hours after the third dose, as demonstrated by ECHO, and there was no evidence of deterioration in brain ultrasonography, a second course of ibuprofen with three other doses was administered. Infants with persistent PDA even after the second course were treated surgically. In the oral ibuprofen group, seven infants were excluded because of mortality before the complete treatment course and one infant was excluded because of pulmonary haemorrhage (total, eight infants). Outcomes were reported for 36 infants in the oral ibuprofen group. In the IV ibuprofen group, three infants were excluded because of a gastrointestinal bleed and one infant was excluded because only two doses of ibuprofen were administered (total, four infants). Outcomes were reported for 32 infants. </p> </li> <li> <p>Outcomes: failure to close a PDA, need for a second course of ibuprofen, need for surgical ligation, plasma creatinine following treatment, and oliguria. </p> </li> </ul> </p> </section> <section id="CD003481-sec-0076"> <h5 class="title">High‐dose ibuprofen (IV or PO) versus standard‐dose regimen of ibuprofen (IV or PO)(Comparison 6) </h5> <p>The study by Dani and coworkers was conducted as a multi centre study in four NICUs in Italy (<a href="./references#CD003481-bbs2-0010" title="DaniC , VangiV , BertiniG , PratesiS , LoriI , FavelliF , et al. High‐dose ibuprofen for patent ductus arteriosus in extremely preterm infants: a randomized controlled study. Clinical Pharmacology and Therapeutics2012;91(4):590‐6. [PUBMED: 22089267] ">Dani 2012</a>). </p> <p> <ul id="CD003481-list-0049"> <li> <p>Objective: to assess whether a high‐dose of IV ibuprofen versus a standard‐dose IV ibuprofen was more effective in closing a PDA, without increasing adverse effects. </p> </li> <li> <p>Population: 95 infants underwent randomisation; 48 were allocated to standard ibuprofen and 47 to high‐dose ibuprofen. There were 70 infants with PMA less than 29 weeks, ECHO evidence of significant PDA, age 12 to 24 hours and RDS necessitating respiratory support. </p> </li> <li> <p>Intervention: 35 infants received a high‐dose of IV ibuprofen (20‐10‐10 mg/kg/day) and 35 infants received a standard‐dose of IV ibuprofen (10‐5‐5 mg/kg/day). Thirty‐five infants (mean (SD) PMA 25.6 (1.8) weeks; BW 781 (225) grams) were randomised to a high‐dose ibuprofen and 35 infants (mean (SD) PMA 26.0 (1.7) weeks; BW 835 (215) grams) were randomised to standard‐dose ibuprofen. </p> </li> <li> <p>Outcomes: ductal closure, serum creatinine on day three of treatment, oliguria (1 mL/kg/hour or less during a 24‐hour collection period), peak total serum bilirubin during the first week of life, IVH (all grades and grades III and IV), PVL, ROP (all stages, stage greater than 2), NEC, BPD (oxygen requirement at 36 weeks' PMA), sepsis, mortality, and hospital stay (days). </p> </li> </ul> </p> <p>The study by Fesharaki and coworkers was conducted in a single centre in Tehran, Iran (<a href="./references#CD003481-bbs2-0016" title="FesharakiHJ , NayeriFS , AsbaqPA , AminiE , SedagatM . Different doses of ibuprofen in the treatment of patent ductus arteriosus: a randomized controlled trial. Tehran University Medical Journal2012;70(8):488‐93. ">Fesharaki 2012</a>). </p> <p> <ul id="CD003481-list-0050"> <li> <p>Objective: to compare the effects of high‐dose ibuprofen versus standard ibuprofen.</p> </li> <li> <p>Population: 60 preterm infants with a haemodynamically significant PDA confirmed by ECHO (PMA 29 weeks 6/7 to 35 weeks 6/7; BW 1000 to 2500 grams; postnatal age 72 to 120 hours). </p> </li> <li> <p>Intervention: 30 infants received ibuprofen 15 mg/kg on the first day followed by two doses of 7.5 mg/kg on next two days and 30 infants received 10 mg/kg ibuprofen on the first day followed by 5 mg/kg on next two days. </p> </li> <li> <p>Outcomes: failure to close a PDA, urine output less than 0.5 mL/kg after the onset of treatment, and gastrointestinal bleed. </p> </li> </ul> </p> <p>The study by Pourarian and coworkers was conducted in two NICUs in Shiraz, Iran (<a href="./references#CD003481-bbs2-0031" title="PourarianS , TakmilF , CherikiS , AmoozgarH . The effect of oral high‐dose ibuprofen on patent ductus arteriosus closure in preterm infants. American Journal of Perinatology2015;32(12):1158‐63. [DOI: 10.1055/s‐0035‐1551671; PUBMED: 26007314] ">Pourarian 2015</a>). </p> <p> <ul id="CD003481-list-0051"> <li> <p>Objective: to compare the efficacy and possible adverse effects of oral high‐dose ibuprofen to that of standard regimen in closing a PDA </p> </li> <li> <p>Population: 60 preterm infants &lt; 37 weeks' PMA and postnatal age of 3 to 7 days with ECHO diagnosis of haemodynamically significant PDA </p> </li> <li> <p>Intervention: high‐dose ibuprofen group received 20 mg/kg of ibuprofen orally followed by 10 mg/kg/dose after 24 and 48 hours. The normal‐dose ibuprofen group received 10mg/kg of ibuprofen followed by 5 mg/kg/dose after 24 and 48 hours. </p> </li> <li> <p>Outcomes: primary outcome: failure to close the PDA after the first course of ibuprofen. Secondary outcomes included bleeding disorders, GI bleeding, NEC, pulmonary haemorrhage, mortality, oliguria (≤ 1 ml/kg/H), serum creatinine, urine output (ml/kg/hour), and platelet count after treatment. </p> </li> </ul> </p> </section> <section id="CD003481-sec-0077"> <h5 class="title">Early versus expectant administration of intravenous ibuprofen (Comparison 7)</h5> <p>The study by Sosenko and coworkers was conducted in a single NICU in Miami, Florida, USA (<a href="./references#CD003481-bbs2-0033" title="SosenkoIR , FajardoMF , ClaureN , BancalariE . Timing of patent ductus arteriosus treatment and respiratory outcome in premature infants: a double‐blind randomized controlled trial. Journal of Pediatrics2012;160(6):929‐35. [PUBMED: 22284563] ">Sosenko 2012</a>). </p> <p> <ul id="CD003481-list-0052"> <li> <p>Objective: to determine whether early ibuprofen treatment at the onset of subtle PDA symptoms would improve respiratory outcome in preterm infants compared with expectant management, with ibuprofen treatment only when the PDA became haemodynamically significant. </p> </li> <li> <p>Population: infants born with BW 500 to 1250 grams and PMA 23 to 32 weeks, who were more than 24 hours but 14 days or less old and who had ECHO for subtle PDA symptoms (metabolic acidosis, murmur, bounding pulses). </p> </li> <li> <p>Intervention: infants were randomised to 'early' treatment (54 infants received blinded ibuprofen) or 'expectant' management (51 infants received blinded placebo). If the PDA became haemodynamically significant (pulmonary haemorrhage, hypotension, respiratory deterioration), infants received open‐label ibuprofen. Infants with haemodynamically significant PDA at enrolment were excluded from the study. </p> </li> <li> <p>The dosing schedule for ibuprofen was an initial dose of 10 mg/kg, followed by two doses of 5 mg/kg each, every 24 hours, by slow IV infusion; dosing of placebo involved equivalent volumes of dextrose by slow IV infusion on the same schedule. </p> </li> <li> <p>Outcomes: days on supplemental oxygen during the first 28 days of life, mortality during hospital stay, supplemental oxygen at 36 weeks' PMA, intestinal perforation, NEC requiring surgery, IVH (grades III and IV), PVL, sepsis, and ROP (stage 3 or greater). </p> </li> </ul> </p> </section> <section id="CD003481-sec-0078"> <h5 class="title">Echocardiographically guided intravenous ibuprofen versus standard intravenous ibuprofen (Comparison 8) </h5> <p>The study by Bravo and coworkers was conducted in a single NICU in Madrid, Spain (<a href="./references#CD003481-bbs2-0007" title="BravoMC , CabaňasF , RieraJ , Pérez‐FernándezE , QueroJ , Pérez‐RodriguezJ , et al. Randomized controlled clinical trial of standard versus echocardiographically guided ibuprofen treatment for patent ductus arteriosus in preterm infants: a pilot study. Journal of Maternal‐Fetal &amp; Neonatal Medicine2014;27(9):904‐9. [DOI: 10.3109/14767058.2013.846312; PUBMED: 24047189] ">Bravo 2014</a>). </p> <p> <ul id="CD003481-list-0053"> <li> <p>Objective: to explore the efficacy of ECHO‐guided pharmacological closure of the ductus arteriosus in reducing the number of required ibuprofen doses without increasing the reopening rate. </p> </li> <li> <p>Population: 49 preterm infants with an ECHO‐confirmed PDA measuring 1.5 mm or greater (PMA 24 to 34 weeks). </p> </li> <li> <p>Intervention: infants received the first dose of ibuprofen 10 mg/kg and were then randomised to receive either standard treatment (21 infants) or ECHO‐guided treatment (28 infants). Infants in the standard group received two additional doses of ibuprofen 5 mg/kg at 24‐hour intervals after the initial dose of 10 mg/kg, independently of ductal size, as long as additional doses were not contraindicated. Infants in the ECHO‐guided group received additional doses of ibuprofen 5 mg/kg at 24‐hour intervals only if the PDA was still 1.5 mm or greater at the time of the corresponding ibuprofen dose. Decision on whether to treat the PDA when the diameter was less than 1.5 mm in the ECHO‐guided group was at the discretion of the treating consultant. Additional ibuprofen doses were administered only when the PDA was greater than 1.5 mm 24 hours after a complete ibuprofen course (therapeutic failure) or when a reopening was documented. </p> </li> <li> <p>Outcomes: primary outcome was reopening of PDA; secondary outcomes included failure to close a PDA, number of ibuprofen doses used, need for surgical ligation, mortality, BPD (need for supplemental oxygen at 36 weeks' PMA), IVH (grade II or III), PVL, oliguria, creatinine after treatment, and laser therapy for ROP. </p> </li> <li> <p>Notes: Dr. Bravo clarified that ibuprofen was given IV. She communicated that the random sequence was computer‐generated and that the allocation to one of the two groups was by sequential numbered, opaque and sealed envelopes. </p> </li> </ul> </p> </section> <section id="CD003481-sec-0079"> <h5 class="title">Continuous intravenous infusion of ibuprofen versus standard intravenous ibuprofen (boluses) (Comparison 9) </h5> <p>The study by Lago and coworkers was conducted in a single centre in Padua, Italy (<a href="./references#CD003481-bbs2-0021" title="LagoP , SalvadoriS , OpocherF , RicatoS , ChiandettiL , FrigoAC . Continuous infusion of ibuprofen for treatment of patent ductus arteriosus in very low birth weight infants. Neonatology2014;105(1):46‐54. [DOI: 10.1159/000355679; PUBMED: 24281435] ">Lago 2014</a>). </p> <p> <ul id="CD003481-list-0054"> <li> <p>Objective: to establish whether continuous infusion of ibuprofen was more effective in VLBW infants with no additional adverse effects and reduce the need for surgical ligation compared with infants treated with conventional 15‐minute intermittent boluses. </p> </li> <li> <p>Population: 112 VLBW infants (mean (SD) PMA 27.2 (2) weeks; weight 1019 (330) grams).</p> </li> <li> <p>Intervention: 56 infants were given IV ibuprofen in conventional 15‐minute intermittent boluses, while the other 56 were administered IV ibuprofen as a 24‐hour continuous infusion, both at standard‐doses (10/5/5 mg/kg). One infant in the continuous infusion group was excluded because informed consent was withdrawn, leaving 55 infants in that group. </p> </li> <li> <p>Outcomes: primary outcome: PDA closure rate after two standard‐dose ibuprofen courses. Secondary outcomes included mortality, PDA closure after one ibuprofen course, rate of PDA reopening, need for surgical ligation, oliguria (urine output 1 mL/kg/hour or less), creatinine after treatment, gastrointestinal haemorrhage, isolated intestinal perforation, NEC (according to modified Bell's criteria (all stages), BPD (supplemental oxygen at 36 weeks' PMA), IVH (any grade and grade III or IV), cystic PVL, duration of hospital stay, and survival without morbidity. Brain ultrasound was performed on admission and before starting each ibuprofen course, then twice a month or when clinically indicated. Any IVH was graded according to Papille's classification, and PVL was defined as periventricular white matter cysts. Any other gastrointestinal and pulmonary bleeding disorders due to interference with local prostaglandin metabolism were also recorded. BPD was defined as the need for oxygen supplementation and typical chest X‐ray features at a postconceptional age of 36 weeks. ROP was diagnosed according to international criteria. </p> </li> <li> <p>Notes: Dr Lago clarified that ibuprofen in the continuous infusion group was given continuously IV over 24 hours. </p> </li> </ul> </p> </section> <section id="CD003481-sec-0080"> <h5 class="title">Rectal ibuprofen versus oral ibuprofen (Comparison 10)</h5> <p>The study by Demir and coworkers was conducted in a single centre in Van, Turkey (<a href="./references#CD003481-bbs2-0011" title="DemirN , PekerE , EceI , BalahorogluR , TuncerO . Efficacy and safety of rectal ibuprofen for ductus arteriosus closure in very low birth weight infants. European Journal of Pediatrics2016;175(11):1705‐6. DemirN , PekerE , EceI , BalahorogluR , TuncerO . Efficacy and safety of rectal ibuprofen for patent ductus arteriosus closure in very low birth weight preterm infants. Journal of Maternal‐Fetal &amp; Neonatal Medicine2017;30(17):2119–25. [DOI: 10.1080/14767058.2016.1238897; PUBMED: 28052714] PekerE , DemirN , EceI , BalahorotluR , TuncerO . Efficacy and safety of rectal ibuprofen for ductus arteriosus closure in very low birth weight infants. Journal of Maternal‐Fetal &amp; Neonatal Medicine2016;29(Suppl 1):114. ">Demir 2017</a>). </p> <p> <ul id="CD003481-list-0055"> <li> <p>Objective: to compare rectal ibuprofen with oral ibuprofen for the closure of haemodynamically significant patent ductus arteriosus (hsPDA). </p> </li> <li> <p>Population: 72 VLBW preterm infants.</p> </li> <li> <p>Intervention: A total of three ibuprofen doses were administered; the initial dose was 10 mg/kg and the following two doses at 24 and 48 hours were 5 mg/kg. Both rectal and oral ibuprofen were given via an oro‐gastric tube, which was flushed with 1‐2 ml of sterile water to ensure the delivery of the drug. </p> </li> <li> <p>Outcomes: Failure to close the PDA, need for a 2nd course, need for surgical ligation, plasma bilirubin and plasma creatinine after treatment, urine output after treatment. </p> </li> </ul> </p> </section> </section> <section id="CD003481-sec-0081"> <h4 class="title">Excluded studies</h4> <p>Five studies were excluded (<a href="./references#CD003481-bbs2-0040" title="AlipourMR , ShamsiMM , NamayandehSM , PezeshkpourZ , RezaeipourF , SarebanhassanabadiM . The effects of oral ibuprofen on medicinal closure of patent ductus arteriosus in full‐term neonates in the second postnatal week. Iranian Journal of Pediatrics2016;26(4):e5807. [DOI: 10.5812/ijp.5807; PUBMED: 27729962] ">Alipour 2016</a>; <a href="./references#CD003481-bbs2-0041" title="AmoozgarH , GhodstehraniM , PishvaN . Oral ibuprofen and ductus arteriosus closure in full‐term neonates: a prospective case‐control study. Pediatric Cardiology2010;31(1):40‐3. [DOI: 10.1007/s00246‐009‐9542‐y; PUBMED: 19841966] ">Amoozgar 2010</a>; <a href="./references#CD003481-bbs2-0008" title="CherifA , KhroufN , JabnounS , MokraniC , AmaraMB , GuellouzeN , et al. Randomized pilot study comparing oral ibuprofen with intravenous ibuprofen in very low birth weight infants with patent ductus arteriosus. Pediatrics2008;122(6):e1256‐61. [PUBMED: 19047225] ">Cherif 2008</a>; <a href="./references#CD003481-bbs2-0043" title="DesfrereL , ZoharS , MorvilleP , BrunhesA , ChevretS , PonsG , et al. Dose‐finding study of ibuprofen in patent ductus arteriosus using the continual reassessment method. Journal of Clinical Pharmacy and Therapeutics2005;30(2):121‐32. [DOI: 10.1111/j.1365‐2710.2005.00630.x; PUBMED: 15811164] ">Desfrere 2005</a>; <a href="./references#CD003481-bbs2-0044" title="KalaniM , ShariatM , KhalesiN , FarahaniZ , AhmadiS . A comparison of early ibuprofen and indomethacin administration to prevent intraventricular hemorrhage among preterm infants. Acta Medica Iranica2016;54(12):788‐92. [PUBMED: 28120591] ">Kalani 2016</a>). The studies by <a href="./references#CD003481-bbs2-0040" title="AlipourMR , ShamsiMM , NamayandehSM , PezeshkpourZ , RezaeipourF , SarebanhassanabadiM . The effects of oral ibuprofen on medicinal closure of patent ductus arteriosus in full‐term neonates in the second postnatal week. Iranian Journal of Pediatrics2016;26(4):e5807. [DOI: 10.5812/ijp.5807; PUBMED: 27729962] ">Alipour 2016</a> and <a href="./references#CD003481-bbs2-0041" title="AmoozgarH , GhodstehraniM , PishvaN . Oral ibuprofen and ductus arteriosus closure in full‐term neonates: a prospective case‐control study. Pediatric Cardiology2010;31(1):40‐3. [DOI: 10.1007/s00246‐009‐9542‐y; PUBMED: 19841966] ">Amoozgar 2010</a> were conducted in term infants. <a href="./references#CD003481-bbs2-0008" title="CherifA , KhroufN , JabnounS , MokraniC , AmaraMB , GuellouzeN , et al. Randomized pilot study comparing oral ibuprofen with intravenous ibuprofen in very low birth weight infants with patent ductus arteriosus. Pediatrics2008;122(6):e1256‐61. [PUBMED: 19047225] ">Cherif 2008</a> did not include a control group. The study by <a href="./references#CD003481-bbs2-0043" title="DesfrereL , ZoharS , MorvilleP , BrunhesA , ChevretS , PonsG , et al. Dose‐finding study of ibuprofen in patent ductus arteriosus using the continual reassessment method. Journal of Clinical Pharmacy and Therapeutics2005;30(2):121‐32. [DOI: 10.1111/j.1365‐2710.2005.00630.x; PUBMED: 15811164] ">Desfrere 2005</a> was a dose‐finding study and <a href="./references#CD003481-bbs2-0044" title="KalaniM , ShariatM , KhalesiN , FarahaniZ , AhmadiS . A comparison of early ibuprofen and indomethacin administration to prevent intraventricular hemorrhage among preterm infants. Acta Medica Iranica2016;54(12):788‐92. [PUBMED: 28120591] ">Kalani 2016</a> compared early ibuprofen with indomethacin administration to prevent intraventricular haemorrhage among preterm infants. </p> </section> </section> <section id="CD003481-sec-0082"> <h3 class="title">Risk of bias in included studies</h3> <p>For details, see the 'Risk of bias' summary (<a href="#CD003481-fig-0004">Figure 4</a>) and 'Risk of bias' graph (<a href="#CD003481-fig-0005">Figure 5</a>). These were all randomised controlled trials, but whether the randomisation was concealed or not was not always clear. In several studies, the timing of the doses of ibuprofen and indomethacin did not coincide, and therefore, the caregivers would be aware of group assignment (for details see 'Risk of bias' tables). </p> <div class="figure" id="CD003481-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003481-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD003481-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD003481-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD003481-sec-0083"> <h4 class="title">Allocation</h4> <p>The random sequence was properly generated (low risk of bias) in 28% of the trials and was unclear in the remaining 72% of the trials. With regards to allocation concealment, there was low risk of bias in 56% of the trials, unclear risk in 41% and high risk of bias in 3% of the trials. </p> </section> <section id="CD003481-sec-0084"> <h4 class="title">Blinding</h4> <p>There was adequate blinding of personnel in 13% of the trials (low risk of bias). The blinding of personnel was unclear in 26% of the trials and there was high risk of bias in 62% of the trials. </p> <p>There was blinding of outcome assessments in 51% of the trials (low risk of bias). The risk of bias was unclear in 23% of the trials and the risk was high in 26% of the trials. </p> </section> <section id="CD003481-sec-0085"> <h4 class="title">Incomplete outcome data</h4> <p>There was low risk of bias in 87% of the trials, unclear risk in 5% of the trials and the risk of bias was high in 8% of the trials. </p> </section> <section id="CD003481-sec-0086"> <h4 class="title">Selective reporting</h4> <p>For most of the included studies, the protocol for the study was not available to us and for several studies for which the protocol was registered in a trials registry, the registration had occurred after the trials had been completed (retrospective registration). There was low risk of bias in 13% of the trials, unclear risk in 87%, and no trials had high risk of bias. </p> </section> <section id="CD003481-sec-0087"> <h4 class="title">Other potential sources of bias</h4> <p>We did not detect any other sources of potential bias in 90% of the studies (low risk of bias). There was unclear risk in 10% of the studies and no trials had high risk of other potential sources of bias. </p> </section> </section> <section id="CD003481-sec-0088"> <h3 class="title" id="CD003481-sec-0088">Effects of interventions</h3> <p>See: <a href="./full#CD003481-tbl-0001"><b>Summary of findings for the main comparison</b> </a>; <a href="./full#CD003481-tbl-0002"><b>Summary of findings 2</b> </a>; <a href="./full#CD003481-tbl-0003"><b>Summary of findings 3</b> </a>; <a href="./full#CD003481-tbl-0004"><b>Summary of findings 4</b> </a>; <a href="./full#CD003481-tbl-0005"><b>Summary of findings 5</b> </a> </p> <p>See: Summary of findings tables for the main comparisons: <a href="./full#CD003481-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD003481-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD003481-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD003481-tbl-0004">summary of findings Table 4</a>; <a href="./full#CD003481-tbl-0005">summary of findings Table 5</a>. </p> <p>When only one study is included in an analysis the test for heterogeneity is not applicable.</p> <section id="CD003481-sec-0089"> <h4 class="title">Intravenous ibuprofen versus placebo or no intervention (Comparison 1)</h4> <section id="CD003481-sec-0090"> <h5 class="title">Primary outcomes</h5> <section id="CD003481-sec-0091"> <h6 class="title">Failure to close a patent ductus arteriosus after three doses (Analysis 1.1)</h6> <p>There was a statistically significantly reduced typical RR for failure to close a PDA after three doses of ibuprofen versus placebo (two studies, 206 infants); typical relative risk (RR); 0.62 (95% CI 0.44 to 0.86); typical risk difference (RD); ‐0.18 (95% CI ‐0.30 to ‐0.06); NNTB 6 (95% CI 3 to 17); I<sup>2</sup> = 65% (moderate heterogeneity) for RR and I<sup>2</sup> = 0% (no heterogeneity) for RD (<a href="./references#CD003481-fig-0008" title="">Analysis 1.1</a>). The quality of the evidence was moderate according to GRADE. </p> </section> </section> <section id="CD003481-sec-0092"> <h5 class="title">Secondary outcomes</h5> <section id="CD003481-sec-0093"> <h6 class="title">Necrotising enterocolitis (Analysis 1.13)</h6> <p>There was no statistically significant difference in the incidence of NEC (two studies, 264 infants; typical RR 1.84, 95% CI 0.87 to 3.90; typical RD 0.06, 95% CI ‐0.01 to 0.13; <a href="./references#CD003481-fig-0020" title="">Analysis 1.13</a>). There was high heterogeneity for the RR (I<sup>2</sup> = 77%) and moderate heterogeneity for the RD (I<sup>2</sup> = 67%) (<a href="./references#CD003481-fig-0020" title="">Analysis 1.13</a>). The quality of the evidence was moderate according to GRADE. </p> <p>For the following outcomes, there was only one study included in each analysis and there was no significant difference between the IV ibuprofen group versus the placebo or no intervention group (for details for each outcome, see the specific analysis; tests for heterogeneity were not applicable); need for surgical ligation (<a href="./references#CD003481-fig-0009" title="">Analysis 1.2</a>); intraventricular haemorrhage (any grade) (<a href="./references#CD003481-fig-0010" title="">Analysis 1.3</a>); intraventricular haemorrhage (grades III and IV) (<a href="./references#CD003481-fig-0011" title="">Analysis 1.4</a>); periventricular leukomalacia (<a href="./references#CD003481-fig-0012" title="">Analysis 1.5</a>); pulmonary haemorrhage (<a href="./references#CD003481-fig-0013" title="">Analysis 1.6</a>); pulmonary hypertension (<a href="./references#CD003481-fig-0014" title="">Analysis 1.7</a>); retinopathy of prematurity (any stage) (<a href="./references#CD003481-fig-0015" title="">Analysis 1.8</a>); retinopathy of prematurity (stage 3 or 4) (<a href="./references#CD003481-fig-0016" title="">Analysis 1.9</a>); retinopathy of prematurity (plus disease) (<a href="./references#CD003481-fig-0017" title="">Analysis 1.10</a>); chronic lung disease (supplemental oxygen at 28 days of age) (<a href="./references#CD003481-fig-0018" title="">Analysis 1.11</a>); chronic lung disease (supplemental oxygen at 36 weeks' PMA) (<a href="./references#CD003481-fig-0019" title="">Analysis 1.12</a>); mortality by 28 days (<a href="./references#CD003481-fig-0021" title="">Analysis 1.14</a>); mortality during hospital stay (<a href="./references#CD003481-fig-0025" title="">Analysis 1.18</a>). </p> <p>For the following outcomes, there was only one study included in each analysis, but there were significant differences between the IV ibuprofen group versus the placebo or no intervention group: </p> </section> <section id="CD003481-sec-0094"> <h6 class="title">Oliguria (urine output less than 1 mL/kg/hour) (Analysis 1.15)</h6> <p>There was a statistically significant difference in the incidence of oliguria with a higher incidence in the ibuprofen group (one study, 134 infants; RR 39, 95% CI 2.40 to 633.01; RD 0.28, 95% CI 0.17 to 0.39; NNTH 4, 95% CI 3 to 6; <a href="./references#CD003481-fig-0022" title="">Analysis 1.15</a>). </p> </section> <section id="CD003481-sec-0095"> <h6 class="title">Creatinine after treatment (Analysis 1.16)</h6> <p>There was a statistically significantly higher creatinine level in the ibuprofen group (one study, 134 infants; MD 29.17 µmol/L, 95% CI 12.60 to 45.74; <a href="./references#CD003481-fig-0023" title="">Analysis 1.16</a>). </p> </section> <section id="CD003481-sec-0096"> <h6 class="title">Blood urea nitrogen after treatment (Analysis 1.17)</h6> <p>There was a statistically significantly higher BUN level in the ibuprofen group (one study, 134 infants; MD 18.45 µmol/L, 95% CI 12.76 to 24.14; <a href="./references#CD003481-fig-0024" title="">Analysis 1.17</a>). </p> <p>Since this review was first published, oral ibuprofen has been introduced to close a PDA. Therefore, we included additional comparisons that were not planned a priori. </p> </section> </section> </section> <section id="CD003481-sec-0097"> <h4 class="title">Oral ibuprofen versus placebo or no intervention (Comparison 2)</h4> <section id="CD003481-sec-0098"> <h5 class="title">Failure to close a patent ductus arteriosus after single or three doses of ibuprofen (Analysis 2.1) </h5> <p>One study reported on failure to close a PDA after single or three doses of ibuprofen (<a href="./references#CD003481-bbs2-0022" title="LinXZ , ChenHQ , ZhengZ , LiYD , LaiJD , HuangLH . Therapeutic effect of early administration of oral ibuprofen in very low birth weight infants with patent ductus arteriosus. Zhongguo Dang Dai Er Ke za Zhi [Chinese Journal of Contemporary Pediatrics]2012;14(7):502‐5. [PUBMED: 22809601] ">Lin 2012</a>). There was a significant reduction in the failure rate to close a PDA (64 infants; RR 0.26, 95% CI 0.11 to 0.62; RD ‐0.44, 95% CI ‐0.65 to ‐0.23; NNTB 2, 95% CI 2 to 4. (<a href="./references#CD003481-fig-0026" title="">Analysis 2.1</a>). </p> <p>The authors reported that the incidence of PVL and BPD were significantly lower in the ibuprofen group than in the placebo group (P value &lt; 0.05). The duration of mechanical ventilation and hospitalisation were significantly shorter in the ibuprofen group than in the placebo group (P value &lt; 0.05). There were no significant differences in the incidence of IVH, early pulmonary haemorrhage and NEC between the two groups (P value &gt; 0.05). Only the abstract was available to us and numbers for these outcomes were not reported in the abstract. We have written to the authors to try to obtain more information, but we have not received any feedback. </p> </section> </section> <section id="CD003481-sec-0099"> <h4 class="title">Intravenous or oral ibuprofen versus intravenous or oral indomethacin (Comparison 3) </h4> <p>We included 24 studies for one or more of the outcomes listed under this comparison.</p> <section id="CD003481-sec-0100"> <h5 class="title">Primary outcome</h5> <section id="CD003481-sec-0101"> <h6 class="title">Failure to close a patent ductus arteriosus after single or three doses (Analysis 3.1) </h6> <p>Twenty‐four studies reported failure rates for PDA closure after one or three doses of ibuprofen compared with indomethacin included in this comparison and none found a statistically significant difference between the groups. In the meta‐analysis, there was no statistically significant difference between the groups (1590 infants; typical RR 1.07, 95% CI 0.92 to 1.24; typical RD 0.02, 95% CI ‐0.02 to 0.06) (<a href="./references#CD003481-fig-0027" title="">Analysis 3.1</a>; <a href="#CD003481-fig-0006">Figure 6</a>; <a href="#CD003481-fig-0001">Figure 1</a>). There was no between‐study heterogeneity (I<sup>2</sup> = 0% for both RR and RD). The quality of the evidence was moderate according to GRADE. </p> <div class="figure" id="CD003481-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, outcome: 3.1 Failure to close a patent ductus arteriosus (after single or three doses)." data-id="CD003481-fig-0006" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, outcome: 3.1 Failure to close a patent ductus arteriosus (after single or three doses). </p> </div> </div> </div> </section> </section> <section id="CD003481-sec-0102"> <h5 class="title">Secondary outcomes</h5> <section id="CD003481-sec-0103"> <h6 class="title">All‐cause mortality (Analysis 3.2)</h6> <p>Ten studies reported on mortality that occurred at an unspecified time while in hospital and none found a statistically significant difference between the groups. The meta‐analysis showed no statistically significant difference between the groups (697 infants; typical RR 0.79, 95% CI 0.54 to 1.17; typical RD ‐0.03, 95% CI ‐0.08 to 0.02) (<a href="./references#CD003481-fig-0028" title="">Analysis 3.2</a>). There was no between‐study heterogeneity (I<sup>2</sup> = 0% for both RR and RD). </p> </section> <section id="CD003481-sec-0104"> <h6 class="title">Neonatal mortality (death during first 28/30 days of life) (Analysis 3.3)</h6> <p>Four studies reported on mortality by 28 or 30 days of age. There was no statistically significant difference between the groups in the individual studies or in the meta‐analysis (333 infants; typical RR 1.12, 95% CI 0.59 to 2.11; typical RD 0.01, 95% CI ‐0.05 to 0.08) (<a href="./references#CD003481-fig-0029" title="">Analysis 3.3</a>). There was no between‐study heterogeneity (I<sup>2</sup> = 0% for both RR and RD). </p> </section> <section id="CD003481-sec-0105"> <h6 class="title">Infant mortality (mortality during the first year of life)</h6> <p>None of the studies reported on infant mortality.</p> </section> <section id="CD003481-sec-0106"> <h6 class="title">Reopening of the ductus arteriosus (Analysis 3.4)</h6> <p>Seven studies reported on reopening of the PDA and none of the individual studies found a statistically significant difference between the groups. In the meta‐analysis, there was no statistically significant difference between the groups (305 infants; typical RR 1.57, 95% CI 0.83 to 2.99; typical RD 0.05, 95% CI ‐0.02 to 0.12) (<a href="./references#CD003481-fig-0030" title="">Analysis 3.4</a>). There was no between‐study heterogeneity (I<sup>2</sup> = 0% for both RR and RD). </p> </section> <section id="CD003481-sec-0107"> <h6 class="title">Need for surgical closure of the patent ductus arteriosus (Analysis 3.5)</h6> <p>Sixteen studies reported on need for surgical closure of the PDA and none found a statistically significant difference between the groups. In the meta‐analysis, there was no statistically significant difference between the groups (1275 infants; typical RR 1.06, 95% CI 0.81 to 1.39; typical RD 0.01, 95% CI ‐0.03 to 0.05) (<a href="./references#CD003481-fig-0031" title="">Analysis 3.5</a>). There was no between‐study heterogeneity (I<sup>2</sup> = 0% for both RR and RD). The quality of the evidence was moderate according to GRADE. </p> </section> <section id="CD003481-sec-0108"> <h6 class="title">Need for re‐treatment with indomethacin or ibuprofen to close the patent ductus arteriosus (Analysis 3.6) </h6> <p>Seven studies reported on need for re‐treatment with indomethacin or ibuprofen to close the PDA and none of the studies found a statistically significant difference between the groups. In the meta‐analysis, there was no statistically significant difference between the groups (241 infants; typical RR 1.20, 95% CI 0.76 to 1.90; typical RD 0.04, 95% CI ‐0.06 to 0.14) (<a href="./references#CD003481-fig-0032" title="">Analysis 3.6</a>). There was no between‐study heterogeneity (I<sup>2</sup> = 0% for both RR and RD). </p> </section> <section id="CD003481-sec-0109"> <h6 class="title">Duration of ventilator support (Analysis 3.7)</h6> <p>Six studies reported on duration of ventilator support. There was a statistically significant difference between the groups favouring ibuprofen (six studies, 471 infants; MD ‐2.35 days, 95% CI ‐3.71 to ‐0.99) (<a href="./references#CD003481-fig-0033" title="">Analysis 3.7</a>). There was no heterogeneity between the studies (I<sup>2</sup> = 19%). The quality of the evidence was moderate according to GRADE. </p> </section> <section id="CD003481-sec-0110"> <h6 class="title">Duration of supplementary oxygen (Analysis 3.8)</h6> <p>Six studies reported on duration of supplementary oxygen. There was no statistically significant difference between the groups (556 infants; MD ‐0.33 days, 95% CI ‐1.66 to 0.99) (<a href="./references#CD003481-fig-0034" title="">Analysis 3.8</a>). There was low between‐study heterogeneity for this outcome (I<sup>2</sup> = 46%). </p> </section> <section id="CD003481-sec-0111"> <h6 class="title">Pneumothorax</h6> <p>No study reported on pneumothorax.</p> <p>For the following outcomes, there were no statistically significant differences between the groups (for details see the corresponding analyses); pulmonary haemorrhage (<a href="./references#CD003481-fig-0035" title="">Analysis 3.9</a>); pulmonary hypertension (<a href="./references#CD003481-fig-0036" title="">Analysis 3.10</a>); chronic lung disease (at 28 days) (<a href="./references#CD003481-fig-0037" title="">Analysis 3.11</a>); chronic lung disease at 36 weeks' PMA (<a href="./references#CD003481-fig-0038" title="">Analysis 3.12</a>); chronic lung disease (age not stated) (<a href="./references#CD003481-fig-0039" title="">Analysis 3.13</a>); intraventricular haemorrhage (grades I to IV) (<a href="./references#CD003481-fig-0040" title="">Analysis 3.14</a>); intraventricular haemorrhage (grades III and IV) (<a href="./references#CD003481-fig-0041" title="">Analysis 3.15</a>); periventricular leukomalacia (<a href="./references#CD003481-fig-0042" title="">Analysis 3.16</a>); intestinal perforation (<a href="./references#CD003481-fig-0044" title="">Analysis 3.18</a>); gastrointestinal bleed (<a href="./references#CD003481-fig-0045" title="">Analysis 3.19</a>); time to full enteral feeds (<a href="./references#CD003481-fig-0046" title="">Analysis 3.20</a>); time to regain birth weight (<a href="./references#CD003481-fig-0047" title="">Analysis 3.21</a>); retinopathy of prematurity (according to the international classification of retinopathy of prematurity) (<a href="./references#CD003481-fig-0048" title="">Analysis 3.22</a>); sepsis (<a href="./references#CD003481-fig-0049" title="">Analysis 3.23</a>); duration of hospitalisation (<a href="./references#CD003481-fig-0053" title="">Analysis 3.27</a>). </p> </section> <section id="CD003481-sec-0112"> <h6 class="title">Necrotising enterocolitis (any stage) (Analysis 3.17)</h6> <p>Eighteen studies reported on NEC (any stage) and none of the studies found a statistically significant difference between the groups. In one study, the rates of NEC were exceptionally high in both groups (<a href="./references#CD003481-bbs2-0009" title="ChotigeatU , JirapapaK , LayangkoolT . A comparison of oral ibuprofen and intravenous indomethacin for closure of patent ductus arteriosus in preterm infants. Chotmaihet Thangphaet [Journal of the Medical Association of Thailand]2003;86(Suppl 3):S563‐9. [PUBMED: 14700149] ">Chotigeat 2003</a>). In the meta‐analysis, there was a statistically significant difference between the groups favouring the ibuprofen group (1292 infants; typical RR 0.68, 95% CI 0.49 to 0.94; typical RD ‐0.04, 95% CI ‐0.07 to ‐0.01; NNTB 25, 95% CI 14 to 100) (<a href="./references#CD003481-fig-0043" title="">Analysis 3.17</a>; <a href="#CD003481-fig-0007">Figure 7</a>; <a href="#CD003481-fig-0002">Figure 2</a>). There was no between‐study heterogeneity (I<sup>2</sup> = 0% for both RR and RD). The quality of the evidence was moderate according to GRADE. </p> <div class="figure" id="CD003481-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, outcome: 3.17 Necrotising enterocolitis (any stage)." data-id="CD003481-fig-0007" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, outcome: 3.17 Necrotising enterocolitis (any stage). </p> </div> </div> </div> </section> <section id="CD003481-sec-0113"> <h6 class="title">Oliguria (urine output less than 1 mL/kg/hr) (Analysis 3.24)</h6> <p>Six studies reported on oliguria. Two trials found a statistically significant decrease in the proportion of infants with oliguria in the ibuprofen group (<a href="./references#CD003481-bbs2-0020" title="LagoP , BettiolT , SalvadoriS , PitassiI , VianelloA , ChiandettiL , et al. Safety and efficacy of ibuprofen versus indomethacin in preterm infants treated for patent ductus arteriosus: a randomised controlled trial. European Journal of Pediatrics2002;161(4):202‐7. [PUBMED: 12014386] LagoP , SalvadoriS , BettiolT , PitassiI , ChiandettiL , SaiaOS . Effects of indomethacin and ibuprofen on renal function in preterm infants treated for patent ductus arteriosus: a randomized controlled trial. Pediatric Research2001;49:375A. ZanardoV , VedovatoS , LagoP , PivaD , FaggianD , ChiozzaL . Effects of ibuprofen and indomethacin on urinary antidiuretic hormone excretion in preterm infants treated for patent ductus arteriosus. Fetal Diagnosis and Therapy2005;20(6):534‐9. [DOI: 10.1159/000088046; PUBMED: 16260891] ">Lago 2002</a>; <a href="./references#CD003481-bbs2-0038" title="PezzatiM , VangiV , BiagiottiR , BertiniG , CianciulliD , RubaltelliFF . Effects of indomethacin and ibuprofen on mesenteric and renal blood flow in preterm infants with patent ductus arteriosus. Journal of Pediatrics1999;135(6):733‐8. [PUBMED: 10586177] VanOvermeireB , LanghendriesJP , VanhaesebrouckP , LecoutereD , Van deBroekH . Ibuprofen for early treatment of patent ductus arteriosus, a randomized multicentre trial. Pediatric Research1998;43:200A. VanOvermeireB , SmetsK , LecoutereD , Van deBroekH , WeylerJ , DeGrooteK , et al. A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus. New England Journal of Medicine2000;343(10):674‐81. [DOI: 10.1056/NEJM200009073431001; PUBMED: 10974130] ">Van Overmeire 2000</a>). In the meta‐analysis, there was a statistically significant reduction in the proportion of infants with oliguria in the ibuprofen group (576 infants; typical RR 0.28, 95% CI 0.14 to 0.54; typical RD ‐0.09, 95% CI ‐0.14 to ‐0.05; NNTB 11, 95% CI 7 to 20; <a href="./references#CD003481-fig-0050" title="">Analysis 3.24</a>). There was no between‐study heterogeneity for RR (I<sup>2</sup> = 21%) and moderate for RD (I<sup>2</sup> = 69%). Hammerman and colleagues reported no statistically significant differences in urine output between the ibuprofen and indomethacin groups at pretreatment and at 24 and 48 hours after treatment (<a href="./references#CD003481-bbs2-0019" title="HammermanC , ShchorsI , JacobsonS , SchimmelMS , BromikerR , KaplanM , et al. Ibuprofen versus continuous indomethacin in premature neonates with patent ductus arteriosus: is the difference in the mode of administration?. Pediatric Research2008;64(3):291‐7. [DOI: 10.1203/PDR.0b013e31817d9bb0; PUBMED: 18458658] ">Hammerman 2008</a>). The quality of the evidence was moderate according to GRADE. </p> </section> <section id="CD003481-sec-0114"> <h6 class="title">Serum/plasma creatinine levels 72 hours after treatment (Analysis 3.25)</h6> <p>Eleven studies (918 infants) reported on serum/plasma creatinine levels 72 hours after treatment in such a format that the data could be used to summarise the information. Four individual studies found statistically significant lower serum/plasma creatinine levels 72 hours after initiation of treatment in the ibuprofen group compared with the indomethacin group (<a href="./references#CD003481-bbs2-0009" title="ChotigeatU , JirapapaK , LayangkoolT . A comparison of oral ibuprofen and intravenous indomethacin for closure of patent ductus arteriosus in preterm infants. Chotmaihet Thangphaet [Journal of the Medical Association of Thailand]2003;86(Suppl 3):S563‐9. [PUBMED: 14700149] ">Chotigeat 2003</a>; <a href="./references#CD003481-bbs2-0013" title="El‐MashadAE , El‐MahdyH , ElAmrousyDE , ElgendyM . Comparative study of the efficacy and safety of paracetamol, ibuprofen, and indomethacin in closure of patent ductus arteriosus in preterm neonates. European Journal of Pediatrics2017;176(2):233‐40. [DOI: 10.1007/s00431‐016‐2830‐7; PUBMED: 28004188] ">El‐Mashad 2017</a>; <a href="./references#CD003481-bbs2-0020" title="LagoP , BettiolT , SalvadoriS , PitassiI , VianelloA , ChiandettiL , et al. Safety and efficacy of ibuprofen versus indomethacin in preterm infants treated for patent ductus arteriosus: a randomised controlled trial. European Journal of Pediatrics2002;161(4):202‐7. [PUBMED: 12014386] LagoP , SalvadoriS , BettiolT , PitassiI , ChiandettiL , SaiaOS . Effects of indomethacin and ibuprofen on renal function in preterm infants treated for patent ductus arteriosus: a randomized controlled trial. Pediatric Research2001;49:375A. ZanardoV , VedovatoS , LagoP , PivaD , FaggianD , ChiozzaL . Effects of ibuprofen and indomethacin on urinary antidiuretic hormone excretion in preterm infants treated for patent ductus arteriosus. Fetal Diagnosis and Therapy2005;20(6):534‐9. [DOI: 10.1159/000088046; PUBMED: 16260891] ">Lago 2002</a>; <a href="./references#CD003481-bbs2-0036" title="SupapannachartS , LimrungsikulA , KhowsathitP . Oral ibuprofen and indomethacin for treatment of patent ductus arteriosus in premature infants: a randomized trial at Ramathibodi Hospital. Chotmaihet Thangphaet [Journal of the Medical Association of Thailand]2002;85(Suppl 4):S1252‐8. [PUBMED: 12549803] ">Supapannachart 2002</a>). In the meta‐analysis, the serum/plasma creatinine levels 72 hours after initiation of treatment were statistically significantly lower in the ibuprofen group (eleven studies, 918 infants; MD ‐8.12 µmol/L, 95% CI ‐10.81 to ‐5.43; <a href="./references#CD003481-fig-0050" title="">Analysis 3.24</a>). There was high between‐study heterogeneity (I<sup>2</sup> = 83%). The quality of the evidence was low according to GRADE. </p> <p>Pezzati and coworkers noted significantly lower serum creatinine levels on day three in the ibuprofen group compared with the indomethacin group (P value &lt; 0.05; data provided in graph form only) (<a href="./references#CD003481-bbs2-0027" title="PezzatiM , BertiniG , VangiV , BiagiottiR , CianciulliD , RubaltelliFF . Mesenteric and renal perfusion in preterm infants with PDA: indomethacin vs ibuprofen. Pediatric Research1999;45:218A. PezzatiM , VangiV , BiagiottiR , BertiniG , CianciulliD , RubatelliFF . Effects of indomethacin and ibuprofen on mesenteric and renal blood flow in preterm infants with patent ductus arteriosus. Journal of Pediatrics1999;135(6):733‐8. [PUBMED: 10586177] ">Pezzati 1999</a>). Plavka and coworkers reported lower serum creatinine levels in the ibuprofen group compared with the indomethacin group in the first 96 hours of treatment (P value &lt; 0.01; data for the two groups not provided) (<a href="./references#CD003481-bbs2-0029" title="PlavkaR , SvihovecP , BorekI , BiolekJ , KostirovaM , LiskaK , et al. Ibuprofen vs. indomethacin in the treatment of patent ductus arteriosus (PDA) in very premature neonates. Pediatric Research2001;49:375A. ">Plavka 2001</a>). Van Overmeire and coworkers noted that the maximal difference in serum creatinine levels between the ibuprofen and the indomethacin groups occurred on day three (P value = 0.07; data provided in graph form only) (<a href="./references#CD003481-bbs2-0037" title="VanOvermeireB , FollensI , HartmannS , CretenWL , VanAckerKJ . Treatment of patent ductus arteriosus with ibuprofen. Archives of Disease in Childhood. Fetal and Neonatal Edition1997;76(3):F179‐84. [PUBMED: 9175948] VanOvermeireB , FollensI , HartmannS , MahieuL , VanReemptsPJ . Intravenous ibuprofen (IBU) for the treatment of patent ductus arteriosus (PDA) in preterm infants with respiratory distress syndrome (RDS). Pediatric Research1996;39:250A. ">Van Overmeire 1997</a>). The lower levels were observed in the ibuprofen group. In their second trial, Van Overmeire and coworkers noted significantly lower serum creatinine levels in the ibuprofen group compared with the indomethacin group (P value = 0.04 overall; data provided in graph form only) (<a href="./references#CD003481-bbs2-0038" title="PezzatiM , VangiV , BiagiottiR , BertiniG , CianciulliD , RubaltelliFF . Effects of indomethacin and ibuprofen on mesenteric and renal blood flow in preterm infants with patent ductus arteriosus. Journal of Pediatrics1999;135(6):733‐8. [PUBMED: 10586177] VanOvermeireB , LanghendriesJP , VanhaesebrouckP , LecoutereD , Van deBroekH . Ibuprofen for early treatment of patent ductus arteriosus, a randomized multicentre trial. Pediatric Research1998;43:200A. VanOvermeireB , SmetsK , LecoutereD , Van deBroekH , WeylerJ , DeGrooteK , et al. A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus. New England Journal of Medicine2000;343(10):674‐81. [DOI: 10.1056/NEJM200009073431001; PUBMED: 10974130] ">Van Overmeire 2000</a>). Pourarian and coworkers reported that the MDs in serum creatinine before and after treatment were 0.35 mg/dL in the ibuprofen group and 0.45 mg/dL in the indomethacin group (SDs were not provided) (<a href="./references#CD003481-bbs2-0030" title="PourarianSH , PishvaN , MadaniA , RastegariM . Comparison of oral ibuprofen and indomethacin on closure of patent ductus arteriosus in preterm infants. Eastern Mediterranean Health Journal2008;14(2):360‐5. [PUBMED: 18561728] ">Pourarian 2008</a>). </p> </section> <section id="CD003481-sec-0115"> <h6 class="title">Increase in serum/plasma creatinine levels 72 hours after treatment (Analysis 3.26)</h6> <p>One study reported on the increase in serum/plasma creatinine levels 72 hours after treatment (<a href="./references#CD003481-bbs2-0004" title="AlyH , LotfyW , BadrawiN , GhawasM , Abdel‐MeguidIE , HammadTA . Oral ibuprofen and ductus arteriosus in premature infants: a randomized pilot study. American Journal of Perinatology2007;24(5):267‐70. [PUBMED: 17484080] LotfyW , BadrawiN , GhawasM , EhsanE , AlyH . Oral ibuprofen solution (O) is efficacious for the treatment of patent ductus arteriosus (PDA) in premature infants: a randomized controlled trial. Pediatric Academic Societies Annual Meeting; 2005 May 14‐17; Washington DC, United States. 2005. [PAS2005:1410] ">Aly 2007</a>). The increase in serum creatinine levels was significantly lower in the ibuprofen group compared with the indomethacin group (21 infants; MD ‐15.91 µmol/L, 95% CI ‐31.78 to ‐0.04) (<a href="./references#CD003481-fig-0052" title="">Analysis 3.26</a>). </p> </section> <section id="CD003481-sec-0116"> <h6 class="title">Significant decrease in urine output (&gt; 20% decrease in urine output after starting therapy) (Analysis 3.28) </h6> <p>One study reported a significant decrease in urine output after starting therapy. There was a lower risk of this outcome in the ibuprofen group compared with the indomethacin group (144 infants; RR 0.51, 95% CI 0.30 to 0.87; RD ‐0.20, 95% CI ‐0.35 to ‐0.05; NNTB 5, 95% CI 3 to 20) (<a href="./references#CD003481-fig-0054" title="">Analysis 3.28</a>). </p> </section> <section id="CD003481-sec-0117"> <h6 class="title">Daily urine output (mL/kg/hr) after treatment (Analysis 3.29)</h6> <p>One study reported significantly higher urine output in the ibuprofen group compared with indomethacin group (200 infants; MD 0.59 mL/kg/hr, 95% CI 0.45 to 0.73) (<a href="./references#CD003481-fig-0055" title="">Analysis 3.29</a>). </p> </section> <section id="CD003481-sec-0118"> <h6 class="title">Serum bilirubin (µmol/L) after treatment (Analysis 3.30)</h6> <p>One study reported on significantly higher serum bilirubin in the ibuprofen group compared with indomethacin group (200 infants; MD 12.65 µmol/L, 95% CI 9.96 to 15.34) (<a href="./references#CD003481-fig-0056" title="">Analysis 3.30</a>). </p> </section> <section id="CD003481-sec-0119"> <h6 class="title">Platelet count (x10<sup>9</sup>/L) after treatment (Analysis 3.31) </h6> <p>One study reported a significantly higher platelet count in the ibuprofen group compared with indomethacin group (200 infants; MD 72.00 x10<sup>9</sup>/L, 95% CI 58.07 to 85.93) (<a href="./references#CD003481-fig-0057" title="">Analysis 3.31</a>). </p> </section> <section id="CD003481-sec-0120"> <h6 class="title">Neurodevelopmental outcome (neurodevelopmental outcome assessed by a standardised and validated assessment tool or a child developmental specialist, or both) at any age reported (no analysis) </h6> <p>No long‐term outcome data were reported on neurodevelopmental outcome.</p> <p>The effects on cerebral blood flow velocity or cerebral blood flow were not included as predetermined outcomes in this review. However, several authors reported on these outcomes. All results favoured the ibuprofen group with less reduction in cerebral blood flow velocity or cerebral blood flow. </p> </section> </section> </section> <section id="CD003481-sec-0121"> <h4 class="title">Oral ibuprofen versus intravenous or oral indomethacin (Comparison 4)</h4> <section id="CD003481-sec-0122"> <h5 class="title">Failure to close a patent ductus arteriosus (after three doses) (Analysis 4.1)</h5> <p>Eight trials reported on failure to close a PDA. There was no statistically significant difference for oral ibuprofen versus IV or oral indomethacin (272 infants; typical RR 0.96, 95% CI 0.73 to 1.27; typical RD ‐0.01, 95% CI ‐0.12 to 0.09) (<a href="./references#CD003481-fig-0058" title="">Analysis 4.1</a>). There was no heterogeneity for this outcome (I<sup>2</sup> = 0% for both RR and RD). The quality of the evidence was low according to GRADE. </p> </section> <section id="CD003481-sec-0123"> <h5 class="title">All‐cause mortality (during hospital stay) (Analysis 4.2)</h5> <p>Four studies reported on all‐cause mortality. There was no statistically significant difference in any of the trials comparing oral ibuprofen with indomethacin and the meta‐analysis showed a difference of borderline statistical significance (165 infants; typical RR 0.41, 95% CI 0.17 to 1.00; typical RD ‐0.10, 95% CI ‐0.20 to ‐0.00; P value = 0.05 for both RR and RD) (<a href="./references#CD003481-fig-0059" title="">Analysis 4.2</a>). There was no heterogeneity for this outcome (I<sup>2</sup> = 0% for both RR and RD). </p> </section> <section id="CD003481-sec-0124"> <h5 class="title">Neonatal mortality (during first 28/30 days of life) (Analysis 4.3)</h5> <p>Two studies reported on neonatal mortality. There was no statistically significant difference in either of the trials comparing oral ibuprofen with indomethacin and the meta‐analysis showed no statistically significant difference (66 infants; typical RR 1.33, 95% CI 0.33 to 5.39; typical RD 0.03, 95% CI ‐0.12 to 0.18) (<a href="./references#CD003481-fig-0060" title="">Analysis 4.3</a>). There was no heterogeneity for this outcome (I<sup>2</sup> = 0% for both RR and RD). </p> </section> <section id="CD003481-sec-0125"> <h5 class="title">Reopening of the ductus arteriosus (Analysis 4.4)</h5> <p>One study reported on reopening of the ductus arteriosus. There was no case of reopening of the ductus in either of the groups (20 infants; RR not estimable; RD 0.00, 95% CI ‐0.17 to 0.17) (<a href="./references#CD003481-fig-0061" title="">Analysis 4.4</a>). </p> </section> <section id="CD003481-sec-0126"> <h5 class="title">Need for surgical closure of the patent ductus arteriosus (Analysis 4.5)</h5> <p>Four studies reported on need for surgical closure of the PDA. There was no statistically significant difference in any of the trials comparing oral ibuprofen with indomethacin and the meta‐analysis showed no statistically significant difference (174 infants; typical RR 0.93, 95% CI 0.50 to 1.74; typical RD ‐0.01, 95% CI ‐0.13 to 0.10) (<a href="./references#CD003481-fig-0062" title="">Analysis 4.5</a>). There was no heterogeneity for this outcome (I<sup>2</sup> = 0% for both RR and RD). The quality of the evidence was low according to GRADE. </p> </section> <section id="CD003481-sec-0127"> <h5 class="title">Necrotising enterocolitis (any stage) (Analysis 4.13)</h5> <p>Seven trials reported on NEC. There was no statistically significant difference in any of the trials comparing oral ibuprofen with indomethacin but the meta‐analysis showed a statistically significant difference in favour of oral ibuprofen (249 infants; typical RR 0.41, 95% CI 0.23 to 0.73; typical RD ‐0.13, 95% CI ‐0.22 to ‐0.05; NNTB 8, 95% CI 5 to 20) (<a href="./references#CD003481-fig-0070" title="">Analysis 4.13</a>). There was no heterogeneity for this outcome (I<sup>2</sup> = 0% for both RR and RD). The quality of the evidence was low according to GRADE. </p> <p>For the following outcomes, there were no statistically significant differences between the oral ibuprofen versus IV or oral indomethacin (for details see the corresponding analyses); pulmonary haemorrhage (<a href="./references#CD003481-fig-0063" title="">Analysis 4.6</a>); pulmonary hypertension (<a href="./references#CD003481-fig-0064" title="">Analysis 4.7</a>); chronic lung disease (at 28 days) (<a href="./references#CD003481-fig-0065" title="">Analysis 4.8</a>); chronic lung disease (age not stated) (<a href="./references#CD003481-fig-0066" title="">Analysis 4.9</a>); intraventricular haemorrhage (grades I to IV) (<a href="./references#CD003481-fig-0067" title="">Analysis 4.10</a>); intraventricular haemorrhage (grades III and IV) ( <a href="./references#CD003481-fig-0068" title="">Analysis 4.11</a>); periventricular leukomalacia (<a href="./references#CD003481-fig-0069" title="">Analysis 4.12</a>); intestinal perforation (<a href="./references#CD003481-fig-0071" title="">Analysis 4.14</a>); gastrointestinal bleed (<a href="./references#CD003481-fig-0072" title="">Analysis 4.15</a>); retinopathy of prematurity ( <a href="./references#CD003481-fig-0073" title="">Analysis 4.16</a>); sepsis (<a href="./references#CD003481-fig-0074" title="">Analysis 4.17</a>); oliguria (less than 1 mL/kg/hour) (<a href="./references#CD003481-fig-0075" title="">Analysis 4.18</a>); serum/plasma creatinine levels 72 hours after treatment (the quality of the evidence was very low according to GRADE) (<a href="./references#CD003481-fig-0076" title="">Analysis 4.19</a>); duration of hospital stay (<a href="./references#CD003481-fig-0077" title="">Analysis 4.20</a>). </p> </section> <section id="CD003481-sec-0128"> <h5 class="title">Chronic lung disease (36 weeks' postmenstrual age)</h5> <p>No trial reported on CLD at 36 weeks' PMA.</p> </section> </section> <section id="CD003481-sec-0129"> <h4 class="title">Oral ibuprofen versus intravenous ibuprofen (Comparison 5)</h4> <section id="CD003481-sec-0130"> <h5 class="title">Primary outcome</h5> <section id="CD003481-sec-0131"> <h6 class="title">Failure to close a patent ductus arteriosus (after three doses) (Analysis 5.1)</h6> <p>Five studies reported on failure to close a PDA. The meta‐analysis showed a statistically significant difference favouring the oral ibuprofen group (406 infants; typical RR 0.38, 95% CI 0.26 to 0.56; typical RD ‐0.22, 95% CI ‐0.31 to ‐0.14; NNTB 5, 95% CI 3 to 7) (<a href="./references#CD003481-fig-0078" title="">Analysis 5.1</a>). There was no heterogeneity for this outcome (I<sup>2</sup> = 0% for both RR and RD). The quality of the evidence was moderate according to GRADE. </p> </section> </section> <section id="CD003481-sec-0132"> <h5 class="title">Secondary outcomes</h5> <section id="CD003481-sec-0133"> <h6 class="title">Mortality (during first 28/30 days of life) (Analysis 5.2)</h6> <p>One study reported on mortality during the first 28/30 days of life. There was no significant difference comparing oral ibuprofen with IV ibuprofen (64 infants; RR 1.13, 95% CI 0.50 to 2.55; RD 0.03, 95% CI ‐0.19 to 0.25) (<a href="./references#CD003481-fig-0079" title="">Analysis 5.2</a>). </p> </section> <section id="CD003481-sec-0134"> <h6 class="title">Mortality (during hospital stay) (Analysis 5.3)</h6> <p>Two studies reported on mortality during hospital stay. There was no significant difference comparing oral ibuprofen with IV ibuprofen in either of the two studies and the meta‐analysis showed no statistically significant difference (188 infants; typical RR 0.83, 95% CI 0.38 to 1.82; typical RD ‐0.02, 95% CI ‐0.11 to 0.07) (<a href="./references#CD003481-fig-0080" title="">Analysis 5.3</a>). There was no heterogeneity for this outcome (I<sup>2</sup> = 0% for both RR and RD). </p> </section> <section id="CD003481-sec-0135"> <h6 class="title">Plasma cystatin‐C after treatment (Analysis 5.4)</h6> <p>One study reported on plasma cystatin‐C after treatment. There was a statistically significant difference comparing oral ibuprofen with IV ibuprofen (102 infants; MD ‐0.25 mg/dL, 95% CI ‐0.37 to ‐0.13) (<a href="./references#CD003481-fig-0081" title="">Analysis 5.4</a>). </p> </section> <section id="CD003481-sec-0136"> <h6 class="title">Need for surgical closure of the ductus (Analysis 5.5)</h6> <p>Five studies reported on need for surgical closure of the ductus. The meta‐analysis showed no statistically significant difference between the two groups (406 infants; typical RR 0.41, 95% CI 0.14 to 1.21; typical RD ‐0.03, 95% CI ‐0.07 to 0.01) (<a href="./references#CD003481-fig-0082" title="">Analysis 5.5</a>). There was no heterogeneity for this outcome (RR: I<sup>2</sup> = 0%; RD: I<sup>2</sup> = 22%). The quality of the evidence was moderate according to GRADE. </p> </section> <section id="CD003481-sec-0137"> <h6 class="title">Serum/plasma creatinine levels 72 hours after treatment (Analysis 5.19)</h6> <p>Two studies reported on serum/plasma creatinine levels 72 hours after treatment. There was a statistically significant reduction with oral ibuprofen compared with IV ibuprofen (170 infants; MD ‐22.47 μmol/L, 95% CI ‐32.40 to ‐12.53; <a href="./references#CD003481-fig-0096" title="">Analysis 5.19</a>). There was high heterogeneity for this outcome (I<sup>2</sup> = 81%). The quality of the evidence was low according to GRADE. </p> <p>For the following outcomes, there were no statistically significant differences between the two groups (for details see the corresponding analyses); duration of ventilatory support (<a href="./references#CD003481-fig-0083" title="">Analysis 5.6</a>) (the quality of the evidence was low according to GRADE); duration of hospitalisation (<a href="./references#CD003481-fig-0084" title="">Analysis 5.7</a>); pneumothorax (<a href="./references#CD003481-fig-0085" title="">Analysis 5.8</a>); pulmonary haemorrhage (<a href="./references#CD003481-fig-0086" title="">Analysis 5.9</a>); pulmonary hypertension (<a href="./references#CD003481-fig-0087" title="">Analysis 5.10</a>); chronic lung disease (at 36 weeks' postmenstrual age or at discharge) (<a href="./references#CD003481-fig-0088" title="">Analysis 5.11</a>); intraventricular haemorrhage (grades I to IV) (<a href="./references#CD003481-fig-0089" title="">Analysis 5.12</a>); periventricular leukomalacia (<a href="./references#CD003481-fig-0090" title="">Analysis 5.13</a>); necrotising enterocolitis (<a href="./references#CD003481-fig-0091" title="">Analysis 5.14</a>); intestinal perforation (<a href="./references#CD003481-fig-0092" title="">Analysis 5.15</a>); gastrointestinal bleed (<a href="./references#CD003481-fig-0093" title="">Analysis 5.16</a>); sepsis (<a href="./references#CD003481-fig-0094" title="">Analysis 5.17</a>); retinopathy of prematurity that required laser treatment (<a href="./references#CD003481-fig-0095" title="">Analysis 5.18</a>); and oliguria (<a href="./references#CD003481-fig-0097" title="">Analysis 5.20</a>) (the quality of the evidence was low according to GRADE) </p> <p>No study reported on the following outcomes; chronic lung disease (at 28 days); chronic lung disease (age not stated); intraventricular haemorrhage (grades III and IV). </p> </section> <section id="CD003481-sec-0138"> <h6 class="title">Mental Developmental Index (Bayley II) at 18 to 24 months (Analysis 5.21)</h6> <p>One study reported on the Mental Developmental Index (Bayley II) at 18 to 24 months. There was no statistically significant difference between oral ibuprofen and IV ibuprofen (57 infants; MD ‐9.00, 95% CI ‐23.89 to 5.89) (<a href="./references#CD003481-fig-0098" title="">Analysis 5.21</a>). </p> </section> <section id="CD003481-sec-0139"> <h6 class="title">Psychomotor Developmental Index (Bayley II) at 18 to 24 months (Analysis 5.22)</h6> <p>One study reported on the Psychomotor Developmental Index (Bayley II) at 18 to 24 months. There was no statistically significant difference between oral ibuprofen and IV ibuprofen (57 infants; MD 5.00, 95% CI ‐7.67 to 17.67) (<a href="./references#CD003481-fig-0099" title="">Analysis 5.22</a>). </p> </section> <section id="CD003481-sec-0140"> <h6 class="title">Moderate/severe cerebral palsy at 18 to 24 months (Analysis 5.23)</h6> <p>One study reported on moderate/severe cerebral palsy at 18 to 24 months. There was no statistically significant difference between oral ibuprofen and IV ibuprofen (57 infants; RR 1.35, 95% CI 0.24 to 7.48; RD 0.03, 95% CI ‐0.12 to 0.17) (<a href="./references#CD003481-fig-0100" title="">Analysis 5.23</a>). </p> </section> <section id="CD003481-sec-0141"> <h6 class="title">Blindness at 18 to 24 months (Analysis 5.24)</h6> <p>One study reported on blindness at 18 to 24 months. There was no case of blindness either in the oral ibuprofen group or the IV ibuprofen group (57 infants; RR not estimable; RD 0.00, 95% CI ‐0.07 to 0.07) (<a href="./references#CD003481-fig-0101" title="">Analysis 5.24</a>). </p> </section> <section id="CD003481-sec-0142"> <h6 class="title">Deafness at 18 to 24 months (Analysis 5.25)</h6> <p>One study reported on deafness at 18 to 24 months. There was no case of deafness either in the oral ibuprofen group or the IV ibuprofen group (57 infants; RR not estimable; RD 0.00, 95% CI ‐0.07 to 0.07; <a href="./references#CD003481-fig-0102" title="">Analysis 5.25</a>). </p> </section> </section> </section> <section id="CD003481-sec-0143"> <h4 class="title">High‐dose ibuprofen (oral or IV) versus standard‐dose regimen of ibuprofen (oral or IV) (Comparison 6) </h4> <p>Three studies compared a high‐dose of ibuprofen (20‐10‐10 mg/kg/day) (<a href="./references#CD003481-bbs2-0010" title="DaniC , VangiV , BertiniG , PratesiS , LoriI , FavelliF , et al. High‐dose ibuprofen for patent ductus arteriosus in extremely preterm infants: a randomized controlled study. Clinical Pharmacology and Therapeutics2012;91(4):590‐6. [PUBMED: 22089267] ">Dani 2012</a>; <a href="./references#CD003481-bbs2-0031" title="PourarianS , TakmilF , CherikiS , AmoozgarH . The effect of oral high‐dose ibuprofen on patent ductus arteriosus closure in preterm infants. American Journal of Perinatology2015;32(12):1158‐63. [DOI: 10.1055/s‐0035‐1551671; PUBMED: 26007314] ">Pourarian 2015</a>) or (15‐7.5‐7.5 mg/kg/day) (<a href="./references#CD003481-bbs2-0016" title="FesharakiHJ , NayeriFS , AsbaqPA , AminiE , SedagatM . Different doses of ibuprofen in the treatment of patent ductus arteriosus: a randomized controlled trial. Tehran University Medical Journal2012;70(8):488‐93. ">Fesharaki 2012</a>) versus standard‐dose of ibuprofen (10‐5‐5 mg/kg/day). </p> <p>The study by <a href="./references#CD003481-bbs2-0010" title="DaniC , VangiV , BertiniG , PratesiS , LoriI , FavelliF , et al. High‐dose ibuprofen for patent ductus arteriosus in extremely preterm infants: a randomized controlled study. Clinical Pharmacology and Therapeutics2012;91(4):590‐6. [PUBMED: 22089267] ">Dani 2012</a> randomised 95 infants. We reported on the outcomes included by the authors and these included 70 infants for all reported outcomes, except for mortality during hospital stay, which included 95 infants (all infants randomised) (a total of 25 infants were excluded because of 20 deaths and five infants with incomplete data). The study by <a href="./references#CD003481-bbs2-0016" title="FesharakiHJ , NayeriFS , AsbaqPA , AminiE , SedagatM . Different doses of ibuprofen in the treatment of patent ductus arteriosus: a randomized controlled trial. Tehran University Medical Journal2012;70(8):488‐93. ">Fesharaki 2012</a> randomised 60 infants. The only outcome that was reported by the three studies was failure to close a PDA. The study by <a href="./references#CD003481-bbs2-0031" title="PourarianS , TakmilF , CherikiS , AmoozgarH . The effect of oral high‐dose ibuprofen on patent ductus arteriosus closure in preterm infants. American Journal of Perinatology2015;32(12):1158‐63. [DOI: 10.1055/s‐0035‐1551671; PUBMED: 26007314] ">Pourarian 2015</a> randomised 60 infants and outcomes were reported for all randomised infants. </p> <section id="CD003481-sec-0144"> <h5 class="title">Failure to close a patent ductus arteriosus (after three doses) (Analysis 6.1)</h5> <p>Three studies reported on failure to close a PDA. There was a significant reduction in favour of high‐dose ibuprofen versus standard‐dose ibuprofen (190 infants; typical RR 0.37, 95% CI 0.22 to 0.61; typical RD ‐0.26, 95% CI ‐0.38 to ‐0.15; NNTB 4, 95% CI 3 to 7) (<a href="./references#CD003481-fig-0103" title="">Analysis 6.1</a>). There was no heterogeneity for RR (I<sup>2</sup> = 4%) nor for RD (I<sup>2</sup> = 0%). The quality of the evidence was moderate according to GRADE. </p> </section> <section id="CD003481-sec-0145"> <h5 class="title">Reopening after a second course of ibuprofen (Analysis 6.2)</h5> <p>One study reported on reopening after a second course of ibuprofen. There was no significant difference between high‐dose ibuprofen and standard‐dose ibuprofen (70 infants; RR 2.00, 95% CI 0.39 to 10.22; RD 0.06, 95% CI ‐0.07 to 0.19) (<a href="./references#CD003481-fig-0104" title="">Analysis 6.2</a>). </p> </section> <section id="CD003481-sec-0146"> <h5 class="title">Need for surgical closure (Analysis 6.3)</h5> <p>One study reported on need for surgical closure. There was no significant difference between high‐dose ibuprofen and standard‐dose ibuprofen (70 infants; RR 1.00, 95% CI 0.15 to 6.71; RD 0.00, 95% CI ‐0.11 to 0.11) (<a href="./references#CD003481-fig-0105" title="">Analysis 6.3</a>). </p> </section> <section id="CD003481-sec-0147"> <h5 class="title">Mortality during hospital stay (Analysis 6.4)</h5> <p>Two studies reported on mortality during hospital stay. There was no significant difference between high‐dose ibuprofen and standard‐dose ibuprofen (95 infants; RR 1.02, 95% CI 0.58 to 1.79; RD 0.00, 95% CI ‐0.12 to 0.13) (<a href="./references#CD003481-fig-0106" title="">Analysis 6.4</a>). There was no heterogeneity for this outcome (I<sup>2</sup> = 0 % for both RR and RD). </p> </section> <section id="CD003481-sec-0148"> <h5 class="title">Urine output on day three of treatment (Analysis 6.5)</h5> <p>Two studies reported on urine output on day three. There was no significant difference between high‐dose ibuprofen and standard‐dose ibuprofen (130 infants; MD 0.21, 95% CI ‐0.43 to 0.85; <a href="./references#CD003481-fig-0107" title="">Analysis 6.5</a>). There was no heterogeneity for this outcome (I<sup>2</sup> = 0 % for both RR and RD). </p> </section> <section id="CD003481-sec-0149"> <h5 class="title">Oliguria (less than 1 mL/kg/hour during 24 hours) after onset of treatment (Analysis 6.6) </h5> <p>One study reported on oliguria (less than 1 mL/kg/hour). There was no significant difference in the incidence of oliguria between high‐dose ibuprofen and standard‐dose ibuprofen (70 infants; RR 1.50, 95% CI 0.27 to 8.43; RD 0.03, 95% CI ‐0.09 to 0.15) (<a href="./references#CD003481-fig-0108" title="">Analysis 6.6</a>). </p> <p>For the following outcomes, there were no statistically significant differences between high‐dose ibuprofen and standard‐dose ibuprofen (for details see the corresponding analyses); intraventricular haemorrhage (all grades) (<a href="./references#CD003481-fig-0109" title="">Analysis 6.7</a>); intraventricular haemorrhage (grades III and IV) (<a href="./references#CD003481-fig-0110" title="">Analysis 6.8</a>); periventricular leukomalacia (<a href="./references#CD003481-fig-0111" title="">Analysis 6.9</a>); retinopathy of prematurity (all stages) (<a href="./references#CD003481-fig-0112" title="">Analysis 6.10</a>); retinopathy of prematurity (stage 3 or 4) (<a href="./references#CD003481-fig-0113" title="">Analysis 6.11</a>); necrotising enterocolitis (the quality of the evidence was low according to GRADE) (<a href="./references#CD003481-fig-0114" title="">Analysis 6.12</a>); chronic lung disease (at 36 weeks' PMA) (<a href="./references#CD003481-fig-0115" title="">Analysis 6.13</a>); sepsis (<a href="./references#CD003481-fig-0116" title="">Analysis 6.14</a>); hospital stay (<a href="./references#CD003481-fig-0117" title="">Analysis 6.15</a>); oliguria (&lt; 0.5 mL/kg/hr) (<a href="./references#CD003481-fig-0118" title="">Analysis 6.16</a>) (The quality of the evidence was low according to GRADE); gastrointestinal bleed (<a href="./references#CD003481-fig-0119" title="">Analysis 6.17</a>); platelet count (x10<sup>9</sup>/L) <a href="./references#CD003481-fig-0120" title="">Analysis 6.18</a>; serum creatinine after treatment (<a href="./references#CD003481-fig-0121" title="">Analysis 6.19</a>). </p> </section> </section> <section id="CD003481-sec-0150"> <h4 class="title">Early versus expectant administration of intravenous ibuprofen (Comparison 7)</h4> <p>Only one study compared early versus expectant administration of ibuprofen (<a href="./references#CD003481-bbs2-0033" title="SosenkoIR , FajardoMF , ClaureN , BancalariE . Timing of patent ductus arteriosus treatment and respiratory outcome in premature infants: a double‐blind randomized controlled trial. Journal of Pediatrics2012;160(6):929‐35. [PUBMED: 22284563] ">Sosenko 2012</a>). The study enrolled 105 infants. We reported on the outcomes included by the authors and these included 105 infants for all reported outcomes. As only one study was included for each of the outcomes, tests for heterogeneity were not applicable. </p> <section id="CD003481-sec-0151"> <h5 class="title">Primary outcome</h5> <section id="CD003481-sec-0152"> <h6 class="title">Days on supplemental oxygen during the first 28 days (Analysis 7.1)</h6> <p>There was a statistically significant difference between early and expectant administration favouring expectant administration of ibuprofen (105 infants; MD 2.00 days, 95% CI 0.04 to 3.96; P value = 0.05) (<a href="./references#CD003481-fig-0122" title="">Analysis 7.1</a>). </p> </section> </section> <section id="CD003481-sec-0153"> <h5 class="title">Secondary outcomes</h5> <p>For the following outcomes, there were no statistically significant differences between early and expectant administration of IV ibuprofen (for details see the corresponding analyses); days on supplemental oxygen (<a href="./references#CD003481-fig-0123" title="">Analysis 7.2</a>); days on mechanical ventilation first 28 days (<a href="./references#CD003481-fig-0124" title="">Analysis 7.3</a>); days on mechanical ventilation (<a href="./references#CD003481-fig-0125" title="">Analysis 7.4</a>); chronic lung disease (at 36 weeks' PMA) (<a href="./references#CD003481-fig-0126" title="">Analysis 7.5</a>); mortality or chronic lung disease (at 36 weeks' postmenstrual age) (<a href="./references#CD003481-fig-0127" title="">Analysis 7.6</a>); mortality during hospital stay (<a href="./references#CD003481-fig-0128" title="">Analysis 7.7</a>); pneumothorax (<a href="./references#CD003481-fig-0129" title="">Analysis 7.8</a>); intraventricular haemorrhage (grades III and IV) (<a href="./references#CD003481-fig-0130" title="">Analysis 7.9</a>); periventricular leukomalacia (<a href="./references#CD003481-fig-0131" title="">Analysis 7.10</a>); necrotising enterocolitis (requiring surgery) (<a href="./references#CD003481-fig-0132" title="">Analysis 7.11</a>); intestinal perforation (<a href="./references#CD003481-fig-0133" title="">Analysis 7.12</a>); sepsis (<a href="./references#CD003481-fig-0134" title="">Analysis 7.13</a>); retinopathy of prematurity (<a href="./references#CD003481-fig-0135" title="">Analysis 7.14</a>). </p> </section> </section> <section id="CD003481-sec-0154"> <h4 class="title">Echocardiographically guided intravenous ibuprofen versus standard intravenous ibuprofen (Comparison 8) </h4> <p>Only one study reported on this comparison (<a href="./references#CD003481-bbs2-0007" title="BravoMC , CabaňasF , RieraJ , Pérez‐FernándezE , QueroJ , Pérez‐RodriguezJ , et al. Randomized controlled clinical trial of standard versus echocardiographically guided ibuprofen treatment for patent ductus arteriosus in preterm infants: a pilot study. Journal of Maternal‐Fetal &amp; Neonatal Medicine2014;27(9):904‐9. [DOI: 10.3109/14767058.2013.846312; PUBMED: 24047189] ">Bravo 2014</a>). As only one study was included for any of the outcome analyses listed below, tests for heterogeneity were not applicable. </p> <section id="CD003481-sec-0155"> <h5 class="title">Primary outcome</h5> <section id="CD003481-sec-0156"> <h6 class="title">Failure to close a patent ductus arteriosus (Analysis 8.1)</h6> <p>There was no statistically significant difference between ECHO‐guided IV ibuprofen and standard IV ibuprofen for failure to close a PDA (49 infants; RR 1.31, 95% CI 0.44 to 3.91; RD 0.06, 95% CI ‐0.17 to 0.29) (<a href="./references#CD003481-fig-0136" title="">Analysis 8.1</a>). </p> </section> </section> <section id="CD003481-sec-0157"> <h5 class="title">Secondary outcomes</h5> <section id="CD003481-sec-0158"> <h6 class="title">Reopening of patent ductus arteriosus (Analysis 8.2)</h6> <p>There was no statistically significant difference between ECHO‐guided IV ibuprofen and standard IV ibuprofen for reopening of PDA (49 infants; RR 2.25, 95% CI 0.25 to 20.13; RD 0.06, 95% CI ‐0.09 to 0.21) (<a href="./references#CD003481-fig-0137" title="">Analysis 8.2</a>). </p> </section> <section id="CD003481-sec-0159"> <h6 class="title">Number of ibuprofen doses (Analysis 8.3)</h6> <p>There was a statistically significant difference between ECHO‐guided IV ibuprofen and standard IV ibuprofen for number of ibuprofen doses favouring ECHO‐guided IV ibuprofen (49 infants; MD ‐1.25 doses, 95% CI ‐1.70 to ‐0.80) (<a href="./references#CD003481-fig-0138" title="">Analysis 8.3</a>). </p> </section> <section id="CD003481-sec-0160"> <h6 class="title">Need for surgical ligation</h6> <p>The study did not report on need for surgical ligation.</p> </section> <section id="CD003481-sec-0161"> <h6 class="title">Mortality during hospital stay (Analysis 8.4)</h6> <p>There was no statistically significant difference between ECHO‐guided IV ibuprofen and standard IV ibuprofen for mortality during hospital stay (49 infants; RR 0.56, 95% CI 0.14 to 2.25; RD ‐0.08, 95% CI ‐0.29 to 0.12; <a href="./references#CD003481-fig-0139" title="">Analysis 8.4</a>). </p> <p>For the following outcomes, there were no statistically significant differences between ECHO‐guided IV ibuprofen and standard IV ibuprofen (for details see the corresponding analyses); bronchopulmonary dysplasia (supplemental oxygen at 36 weeks' PMA) (<a href="./references#CD003481-fig-0140" title="">Analysis 8.5</a>); necrotising enterocolitis (<a href="./references#CD003481-fig-0141" title="">Analysis 8.6</a>); intraventricular haemorrhage (grade II and III) (<a href="./references#CD003481-fig-0142" title="">Analysis 8.7</a>); white matter damage (<a href="./references#CD003481-fig-0143" title="">Analysis 8.8</a>); oliguria (urine output less than 1 mL/kg/hour) (<a href="./references#CD003481-fig-0144" title="">Analysis 8.9</a>); serum/plasma creatinine after treatment (<a href="./references#CD003481-fig-0145" title="">Analysis 8.10</a>); laser therapy for retinopathy of prematurity (<a href="./references#CD003481-fig-0146" title="">Analysis 8.11</a>). </p> </section> </section> </section> <section id="CD003481-sec-0162"> <h4 class="title">Continuous intravenous infusion of ibuprofen versus standard intravenous ibuprofen (boluses) (Comparison 9) </h4> <p>Only one study reported on this comparison (<a href="./references#CD003481-bbs2-0021" title="LagoP , SalvadoriS , OpocherF , RicatoS , ChiandettiL , FrigoAC . Continuous infusion of ibuprofen for treatment of patent ductus arteriosus in very low birth weight infants. Neonatology2014;105(1):46‐54. [DOI: 10.1159/000355679; PUBMED: 24281435] ">Lago 2014</a>). As only one study was included for any of the outcome analyses listed below, tests for heterogeneity were not applicable. </p> <section id="CD003481-sec-0163"> <h5 class="title">Primary outcome</h5> <section id="CD003481-sec-0164"> <h6 class="title">Failure to close a patent ductus arteriosus after one course of ibuprofen (Analysis 9.1) </h6> <p>There was no statistically significant difference between continuous infusion of ibuprofen and intermittent boluses of ibuprofen for failure to close a PDA after one course of ibuprofen (111 infants; RR 1.18, 95% CI 0.88 to 1.58; RD 0.10, 95% CI ‐0.08 to 0.28) (<a href="./references#CD003481-fig-0147" title="">Analysis 9.1</a>). </p> </section> </section> <section id="CD003481-sec-0165"> <h5 class="title">Secondary outcomes</h5> <section id="CD003481-sec-0166"> <h6 class="title">Reopening of patent ductus arteriosus (Analysis 9.2)</h6> <p>There was no statistically significant difference between continuous infusion of ibuprofen and intermittent boluses of ibuprofen for reopening of PDA (111 infants; RR 3.05, 95% CI 0.33 to 28.47; RD 0.04, 95% CI ‐0.03 to 0.11) (<a href="./references#CD003481-fig-0148" title="">Analysis 9.2</a>). </p> </section> <section id="CD003481-sec-0167"> <h6 class="title">Need for surgical ligation (Analysis 9.3)</h6> <p>There was a statistically significant difference between continuous infusion of ibuprofen and intermittent boluses of ibuprofen for need for surgical ligation favouring the continuous infusion of ibuprofen group (111 infants; RR 0.28, 95% CI 0.08 to 0.94; RD ‐0.14, 95% CI ‐0.26 to ‐0.02; NNTB 7, 95% CI 4 to 50) (<a href="./references#CD003481-fig-0149" title="">Analysis 9.3</a>). </p> </section> <section id="CD003481-sec-0168"> <h6 class="title">Mortality (in hospital) (Analysis 9.4)</h6> <p>There was no statistically significant difference between the continuous infusion of ibuprofen and the intermittent boluses of ibuprofen for mortality (in hospital) (111 infants; RR 1.02, 95% CI 0.07 to 15.87; RD 0.00, 95% CI ‐0.05 to 0.05) (<a href="./references#CD003481-fig-0150" title="">Analysis 9.4</a>). </p> <p>For the following outcomes, there were no statistically significant differences between continuous IV infusion of ibuprofen and standard IV ibuprofen (for details see the corresponding analyses); Chronic lung disease (at 36 weeks' postmenstrual age) (<a href="./references#CD003481-fig-0151" title="">Analysis 9.5</a>); Retinopathy of prematurity (any stage) (<a href="./references#CD003481-fig-0152" title="">Analysis 9.6</a>); Retinopathy of prematurity (stage 3 or 4) (<a href="./references#CD003481-fig-0153" title="">Analysis 9.7</a>); Intraventricular haemorrhage (any grade) (<a href="./references#CD003481-fig-0154" title="">Analysis 9.8</a>); Intraventricular haemorrhage (grade III and IV) (<a href="./references#CD003481-fig-0155" title="">Analysis 9.9</a>); Cystic periventricular leukomalacia (<a href="./references#CD003481-fig-0156" title="">Analysis 9.10</a>); Necrotising enterocolitis (<a href="./references#CD003481-fig-0157" title="">Analysis 9.11</a>); Isolated intestinal perforation (<a href="./references#CD003481-fig-0158" title="">Analysis 9.12</a>); Oliguria (1 mL/kg/hour or less) (<a href="./references#CD003481-fig-0159" title="">Analysis 9.13</a>); Serum/plasma creatinine after treatment (<a href="./references#CD003481-fig-0160" title="">Analysis 9.14</a>); Gastrointestinal haemorrhage (<a href="./references#CD003481-fig-0161" title="">Analysis 9.15</a>). </p> </section> </section> </section> <section id="CD003481-sec-0169"> <h4 class="title">Rectal ibuprofen versus oral ibuprofen (Comparison 10)</h4> <p>One study (<a href="./references#CD003481-bbs2-0011" title="DemirN , PekerE , EceI , BalahorogluR , TuncerO . Efficacy and safety of rectal ibuprofen for ductus arteriosus closure in very low birth weight infants. European Journal of Pediatrics2016;175(11):1705‐6. DemirN , PekerE , EceI , BalahorogluR , TuncerO . Efficacy and safety of rectal ibuprofen for patent ductus arteriosus closure in very low birth weight preterm infants. Journal of Maternal‐Fetal &amp; Neonatal Medicine2017;30(17):2119–25. [DOI: 10.1080/14767058.2016.1238897; PUBMED: 28052714] PekerE , DemirN , EceI , BalahorotluR , TuncerO . Efficacy and safety of rectal ibuprofen for ductus arteriosus closure in very low birth weight infants. Journal of Maternal‐Fetal &amp; Neonatal Medicine2016;29(Suppl 1):114. ">Demir 2017</a>) randomised 75 infants, but three infants (one in the rectal ibuprofen group and two in the oral ibuprofen group) died before they had completed treatment. The following outcomes were reported in 72 infants. As only one study was included in each analysis, tests for heterogeneity were not applicable. </p> <section id="CD003481-sec-0170"> <h5 class="title">Failure to close a patent ductus arteriosus (Analysis 10.1)</h5> <p>There was no statistically difference between rectal and oral ibuprofen for failure to close a PDA (72 infants; RR 0.83, 95% CI 0.28 to 2.49); RD ‐0.03, 95% CI ‐0.19 to 0.14) (<a href="./references#CD003481-fig-0162" title="">Analysis 10.1</a>). </p> </section> <section id="CD003481-sec-0171"> <h5 class="title">Need for surgical ligation (Analysis 10.2)</h5> <p>There was no statistically significant difference in the need for surgical ligation between rectal and oral ibuprofen (72 infants; RR 1.00, 95% CI 0.15 to 6.72; RD 0.00, 95% CI ‐0.11 to 0.11) (<a href="./references#CD003481-fig-0163" title="">Analysis 10.2</a>). </p> </section> <section id="CD003481-sec-0172"> <h5 class="title">Plasma creatinine (µmol/L) after treatment (Analysis 10.3)</h5> <p>The plasma creatinine was statistically significantly lower in the rectal versus the oral ibuprofen group (72 infants: MD ‐6.18 µmol/L, 95% CI ‐7.22 to ‐ 5.14) (<a href="./references#CD003481-fig-0164" title="">Analysis 10.3</a>). </p> </section> <section id="CD003481-sec-0173"> <h5 class="title">Plasma bilirubin (µmol/L)) after treatment (Analysis 10.4)</h5> <p>There was no statistically significant difference between the plasma bilirubin levels after treatment in the rectal versus the oral ibuprofen group (72 infants: MD 7.01 µmol/L, 95% CI ‐11.23 to 25.25) (<a href="./references#CD003481-fig-0165" title="">Analysis 10.4</a>). </p> </section> <section id="CD003481-sec-0174"> <h5 class="title">Urine output (mL/kg/hr) after treatment (Analysis 10.5)</h5> <p>There was no statistically significant difference between the urine output after treatment in the rectal versus the oral ibuprofen group (72 infants: MD ‐0.22 mL/kg/hr, 95% CI ‐0.45 to 0.01) (<a href="./references#CD003481-fig-0166" title="">Analysis 10.5</a>). </p> </section> </section> <section id="CD003481-sec-0175"> <h4 class="title">Subgroup analyses</h4> <p>We abandoned the prespecified subgroup analyses (excluding studies that used only one dose of medication and studies that were published as abstracts only for this and previous updates of the review). Only one study used a single dose and we identified only one abstract. The results of these studies were incorporated with the other studies. </p> <p>We found no randomised controlled trials on the use of mefenamic acid for the treatment or prevention of a PDA. </p> <section id="CD003481-sec-0176"> <h5 class="title">Funnel plots</h5> <p>To ascertain the possibility of publication bias, we conducted two funnel plots for the comparison 'intravenous or oral ibuprofen versus IV or oral indomethacin' for the primary outcome of 'failure to close a PDA (after single or three doses)' (<a href="#CD003481-fig-0001">Figure 1</a>), and for the same comparison for the secondary outcome of NEC (<a href="#CD003481-fig-0002">Figure 2</a>). Both funnel plots were quite symmetric indicating that there was no obvious indication of publication bias. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD003481-sec-0177" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD003481-sec-0177"></div> <section id="CD003481-sec-0178"> <h3 class="title" id="CD003481-sec-0178">Summary of main results</h3> <p>The 39 studies completed to date have reported on 2843 infants. We used the data from these studies and compared IV ibuprofen to placebo or no intervention (three studies); oral ibuprofen to placebo or no intervention (one study); IV or oral ibuprofen to IV or oral indomethacin (24 studies); oral ibuprofen to IV or oral indomethacin (8 studies); oral ibuprofen to IV ibuprofen (5 studies); high‐dose (oral or IV) ibuprofen to standard‐dose ibuprofen (oral or IV) (3 studies); early administration of ibuprofen to expectant administration of ibuprofen (one study); ECHO‐guided IV ibuprofen to standard IV ibuprofen (one study); continuous infusion of ibuprofen to intermittent boluses of ibuprofen (one study); and rectal ibuprofen to oral ibuprofen (one study). Some studies were included in more than one comparison. </p> <p>In this review, we have reported on the following comparisons. To avoid repetition, we included the GRADE score for the 'quality of evidence' for comparisons and outcomes that we have included in the 'Summary of findings' tables. </p> <p>Intravenous ibuprofen was significantly more effective in reducing the outcome 'failure to close a PDA after three doses than placebo or no intervention (moderate‐quality evidence) without any significant effect on NEC (moderate‐quality evidence). However, with IV ibuprofen there was an increased risk of oliguria, and increase in serum/plasma creatinine and blood urea nitrogen compared with placebo. Oral ibuprofen reduced the risk of 'failure to close a PDA after three doses' compared to placebo. </p> <p>There was no significant difference for intravenous or oral ibuprofen versus intravenous or oral indomethacin for the primary outcome of 'failure to close a PDA after three doses' (moderate‐quality evidence) or for the outcome of need for surgical closure of the PDA (moderate‐quality evidence). Duration of ventilator support was significantly reduced (moderate‐quality evidence) as were the outcomes of NEC (moderate‐quality evidence), and oliguria (urine output &lt; 1 ml/kg/hour) (moderate‐quality evidence) and serum/plasma creatinine (low‐quality evidence) was significantly lower in the ibuprofen versus the indomethacin group. </p> <p>For the comparison oral ibuprofen versus IV or oral indomethacin, there was no significant difference for the outcomes 'failure to close a PDA after three doses' (low‐quality evidence), need for surgical closure of the PDA (low‐quality evidence), but there was a significantly lower risk of NEC in the oral ibuprofen group (low‐quality evidence). There was no significant difference in the serum/plasma creatinine levels between the groups (very low‐quality evidence). </p> <p>There was a significantly lower risk of 'failure to close a PDA after three doses' of oral ibuprofen compared with IV ibuprofen (moderate‐quality evidence), but no significant difference for the outcome of need for surgical closure of the PDA (moderate‐quality evidence). The serum/plasma creatinine levels were significantly lower in the oral ibuprofen group compared with the IV ibuprofen group (low‐quality evidence), but there was no difference in the risk of oliguria (urine output &lt; 1 ml/kg/hour) (low‐quality evidence) between the two groups. </p> <p>For the comparison high‐dose oral or IV ibuprofen compared with standard‐dose oral or IV ibuprofen, there was a significantly decreased risk of 'failure to close a PDA after three doses' in the high‐dose group (moderate‐quality evidence) but there was no difference in the risk of NEC between the groups (low‐quality evidence). </p> <p>For the following comparisons, only one study was available for each of the included analyses and the number of included infants varied from 49 to 111 in the individual analyses. We did not perform 'summary of findings' tables for these comparisons. </p> <p>There were no significant differences in any of the outcomes for the comparison 'early versus expectant administration of IV ibuprofen'. </p> <p>For the comparison ECHO‐guided IV ibuprofen treatment versus standard IV ibuprofen treatment, the number of ibuprofen doses administered was significantly reduced in the ECHO‐guided IV ibuprofen treatment group. </p> <p>In the comparison continuous infusion of ibuprofen versus intermittent boluses of ibuprofen, the need for surgical ligation was significantly reduced in the continuous infusion group. </p> <p>In the comparison rectal ibuprofen versus oral ibuprofen, the plasma creatinine level was significantly reduced in the rectal ibuprofen group. </p> </section> <section id="CD003481-sec-0179"> <h3 class="title" id="CD003481-sec-0179">Overall completeness and applicability of evidence</h3> <p>Since first published in 2003 (<a href="./references#CD003481-bbs2-0106" title="OhlssonA , WaliaR , ShahS . Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database of Systematic Reviews2003, Issue 2. [DOI: 10.1002/14651858.CD003481] ">Ohlsson 2003</a>), the review has been regularly updated (<a href="./references#CD003481-bbs2-0107" title="OhlssonA , WaliaR , ShahS . Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database of Systematic Reviews2005, Issue 4. [DOI: 10.1002/14651858.CD003481.pub2] ">Ohlsson 2005</a>; <a href="./references#CD003481-bbs2-0108" title="OhlssonA , WaliaR , ShahS . Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database of Systematic Reviews2008, Issue 1. [DOI: 10.1002/14651858.CD003481.pub3] ">Ohlsson 2008</a>; <a href="./references#CD003481-bbs2-0109" title="OhlssonA , WaliaR , ShahS . Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database of Systematic Reviews2010, Issue 4. [DOI: 10.1002/14651858.CD003481.pub4] ">Ohlsson 2010</a>; <a href="./references#CD003481-bbs2-0110" title="OhlssonA , WaliaR , ShahS . Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database of Systematic Reviews2013, Issue 4. [DOI: 10.1002/14651858.CD003481.pub5] ">Ohlsson 2013</a>; <a href="./references#CD003481-bbs2-0111" title="OhlssonA , WaliaR , ShahSS . Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants. Cochrane Database of Systematic Reviews2015, Issue 2. [DOI: 10.1002/14651858.CD003481.pub6] ">Ohlsson 2015</a>), and this update, initiated in 2017, includes data from 39 studies with results reported on 2843 infants. There are currently 11 ongoing studies. </p> <p>Researchers have reported on additional comparisons that we did not include in the original review in 2003 (<a href="./references#CD003481-bbs2-0106" title="OhlssonA , WaliaR , ShahS . Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database of Systematic Reviews2003, Issue 2. [DOI: 10.1002/14651858.CD003481] ">Ohlsson 2003</a>), and we have added these comparisons. </p> <p>Ibuprofen is more effective than placebo in closure of a PDA. In the two trials that compared IV ibuprofen with placebo, the closure rates were 71% for ibuprofen versus 53% for placebo. </p> <p>There was moderate GRADE quality evidence that ibuprofen (IV or orally) is as effective as indomethacin (IV or orally) to close a PDA (24 studies; 1590 infants). None found a statistically significant difference in failure to close a PDA. In the meta‐analysis, there was no statistically significant difference between the groups (typical RR 1.07, 95% CI 0.92 to 1.24; typical RD 0.02, 95% CI ‐0.02 to 0.06) (<a href="#CD003481-fig-0006">Figure 6</a>). There was no between‐study heterogeneity (I<sup>2</sup> = 0% for both RR and RD). The CIs around the point estimates were very narrow for the primary outcome (<a href="#CD003481-fig-0006">Figure 6</a>). Likewise, there was moderate GRADE quality evidence that ibuprofen (IV or orally) compared with indomethacin (IV or orally) reduces the risk of NEC (18 studies, 1292 infants) (typical RR 0.68, 95% CI 0.49 to 0.94; typical RD ‐0.04, 95% CI ‐0.07 to ‐0.01; NNTB 24, 95% CI 14 to 100) (<a href="#CD003481-fig-0007">Figure 7</a>). There was no significant between‐study heterogeneity (I<sup>2</sup> = 0% for both RR and RD). The funnel plots for these two outcomes were symmetrical, suggesting that there was no publication bias (<a href="#CD003481-fig-0001">Figure 1</a>; <a href="#CD003481-fig-0002">Figure 2</a>). </p> <p>Data on long‐term follow‐up are still largely missing, which is a serious concern. Long‐term follow‐up of 18 to 24 months has been reported in only one study (<a href="./references#CD003481-bbs2-0018" title="ErasZ , GokmenT , ErdeveO , OzyurtBM , SaridasB , DilmenU . Impact of oral versus intravenous ibuprofen on neurodevelopmental outcome: a randomized controlled parallel study. American Journal of Perinatology2013;30(10):857‐62. [DOI: 10.1055/s‐0033‐1333667; PUBMED: 23359230] GokmenT , ErdeveO , AltugN , OguzSS , UrasN , DilmenU . Efficacy and safety of oral verus intravenous ibuprofen in very low birth weight infants with patent ductus arteriosus. Journal of Pediatrics2011;158(4):549‐54; Erratum in: Journal of Pediatrics; 2012;160(1):181. [10.1016/j.jpeds.2010.10.008; PUBMED: 21094951] ">Gokmen 2011</a>) of oral versus IV ibuprofen. Only 57 of the original cohort of 102 infants were assessed at follow‐up. To date, no long‐term follow‐up studies have been published for the other comparisons included in this review. As mentioned in the <a href="#CD003481-sec-0037">Background</a>, prophylactic use of indomethacin does reduce the risk of severe IVH and surgical duct ligation but does not confer any significant advantages at 18 months' corrected age with regards to intact survival (<a href="./references#CD003481-bbs2-0068" title="FowliePW , DavisPG , McGuireW . Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. Cochrane Database of Systematic Reviews2010, Issue 7. [DOI: 10.1002/14651858.CD000174.pub2] ">Fowlie 2010</a>; <a href="./references#CD003481-bbs2-0096" title="SchmidtB , DavisP , ModdemanD , OhlssonA , RobertsRS , SaigalS , et al. Trial of Indomethacin Prophylaxis in Preterms Investigators. Long‐term effect of indomethacin prophylaxis in extremely‐low‐birth‐weight infants. New England Journal of Medicine2001;344(26):1966‐72. [DOI: 10.1056/NEJM200106283442602; PUBMED: 11430325] ">Schmidt 2001</a>). There were no significant differences in the outcomes of IVH (any grade and grade II‐IV) in any of the comparisons. </p> <p>One study of the prophylactic use of ibuprofen was stopped after 135 infants had been enrolled (<a href="./references#CD003481-bbs2-0069" title="GournayV , SavagnerC , ThirezG , KusterA , RozeJC . Pulmonary hypertension after ibuprofen prophylaxis in very preterm infants. Lancet2002;359(9316):1486‐8. [PUBMED: 11988250] ">Gournay 2002</a>). Three infants developed severe hypoxaemia in the ibuprofen group. Hypoxaemia was thought to be due to pulmonary hypertension, as ECHO showed severely decreased pulmonary blood flow. Hypoxaemia resolved quickly on inhaled nitric oxide (<a href="./references#CD003481-bbs2-0069" title="GournayV , SavagnerC , ThirezG , KusterA , RozeJC . Pulmonary hypertension after ibuprofen prophylaxis in very preterm infants. Lancet2002;359(9316):1486‐8. [PUBMED: 11988250] ">Gournay 2002</a>). The authors postulated that this could be due to early administration of ibuprofen (less than six hours) preventing the normal fall in pulmonary vascular resistance, acidification of their ibuprofen solution (buffered with tromethamine) causing precipitation and micro embolism in the lungs, or due to a specific effect of ibuprofen. This adverse effect has not been reported in other trials using ibuprofen for prophylaxis of PDA (<a href="./references#CD003481-bbs2-0089" title="OhlssonA , ShahSS . Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database of Systematic Reviews2011, Issue 7. [DOI: 10.1002/14651858.CD004213.pub3] ">Ohlsson 2011</a>). In the 2007 update of the review (<a href="./references#CD003481-bbs2-0108" title="OhlssonA , WaliaR , ShahS . Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database of Systematic Reviews2008, Issue 1. [DOI: 10.1002/14651858.CD003481.pub3] ">Ohlsson 2008</a>), one randomised controlled trial reported one case of pulmonary hypertension in the ibuprofen group (<a href="./references#CD003481-bbs2-0001" title="AdamskaE , HelwichE , RutkowskaM , ZacharskaE , PiotrowskaA . Comparison of the efficacy of ibuprofen and indomethacin in the treatment of patent ductus arteriosus in prematurely born infants [Porownanie ibuprofenu i indometacyny w leczeniu przetrwalego przewodu tetniczego u noworodkow urodzonych przedwczesnie]. Medycyna Wieku Rozwojowego2005;9(3 Pt 1):335‐54. [PUBMED: 16547381] ">Adamska 2005</a>). In the 2010 update, there were three cases of pulmonary hypertension reported in the study by Aranda and coworkers (<a href="./references#CD003481-bbs2-0005" title="ArandaJV . Multicentre randomized double‐blind placebo controlled trial of ibuprofen L‐Lysine intravenous solution (IV Ibuprofen) in premature infants for the early treatment of patent ductus arteriosus (PDA). Pediatric Academic Societies Annual Meeting; 2005 May 14‐17; Washington DC, United States. 2005. ArandaJV , ClymanR , CoxB , VanOvermeireB , WozniakP , SosenkoI , et al. A randomized, double‐blind, placebo‐controlled trial of intravenous ibuprofen L‐lysine for the early closure of non‐symptomatic patent ductus arteriosus within 72 hours of birth in extremely low‐birth‐weight infants. American Journal of Perinatology2009;26(3):235‐45. [DOI: 10.1055/s‐0028‐1103515; PUBMED: 19067286] ">Aranda 2009</a>); two in the ibuprofen group and one in the placebo group. </p> <p>In an extensive search of the literature, including study designs other than randomised controlled trials, one additional case report following L‐lysine ibuprofen therapy in a preterm infant with a PDA (<a href="./references#CD003481-bbs2-0057" title="BelliniC , CamponeF , SerraG . Pulmonary hypertension following L‐lysine ibuprofen therapy in a preterm infant with patent ductus arteriosus. Canadian Medical Association Journal2006;174(13):1843‐4. [DOI: 10.1503/cmaj.051446; PUBMED: 16785458] ">Bellini 2006</a>) was identified in the 2008 update of the review (<a href="./references#CD003481-bbs2-0108" title="OhlssonA , WaliaR , ShahS . Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database of Systematic Reviews2008, Issue 1. [DOI: 10.1002/14651858.CD003481.pub3] ">Ohlsson 2008</a>). A repeat literature search in 2010 did not identify any new case of pulmonary hypertension associated with the treatment of a PDA in neonates (<a href="./references#CD003481-bbs2-0109" title="OhlssonA , WaliaR , ShahS . Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database of Systematic Reviews2010, Issue 4. [DOI: 10.1002/14651858.CD003481.pub4] ">Ohlsson 2010</a>). For the 2013 update (<a href="./references#CD003481-bbs2-0110" title="OhlssonA , WaliaR , ShahS . Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database of Systematic Reviews2013, Issue 4. [DOI: 10.1002/14651858.CD003481.pub5] ">Ohlsson 2013</a>), the literature was searched in July 2012 and three additional case reports of pulmonary hypertension in preterm infants treated with ibuprofen were identified (<a href="./references#CD003481-bbs2-0056" title="AmendoliaB , LynnM , BhatV , RitzSB , AghaiZH . Severe pulmonary hypertension with therapeutic L‐lysine ibuprofen in 2 preterm infants. Pediatrics2012;129(5):e1360‐3. [DOI: 10.1542/peds.2011‐0117; PUBMED: 22492771] ">Amendolia 2012</a>; <a href="./references#CD003481-bbs2-0098" title="SehgalA , KumarshingriPS . Pulmonary hypertension in an infant treated with ibuprofen. Indian Journal of Pediatrics2013;80(8):697‐9 (Epub 2012 Jul 29). [DOI: 10.1007/s12098‐012‐0829‐2; PUBMED: 22843343] ">Sehgal 2013</a>). A repeat PubMed search in July 2014 did not identify any additional cases of pulmonary hypertension following ibuprofen treatment. For this update, we identified additional studies that reported on 35 cases of pulmonary hypertension associated with ibuprofen treatment for PDA (<a href="./references#CD003481-bbs2-0058" title="BravoMC , CordeiroM , DeirosL , Pérez‐RodríguezJ . Lethal pulmonary hypertension associated with ibuprofen treatment in a very low birth weight infant. Journal of Paediatrics and Child Health2014;50(1):85‐6. [DOI: 10.1111/jpc.12445; PUBMED: 24397458] ">Bravo 2014a</a>; <a href="./references#CD003481-bbs2-0066" title="ElHassanNO , BirdTM , KingAJ , AmbadwarPB , JaquissRD , KaiserJR , et al. Variation and comparative effectiveness of patent ductus arteriosus pharmacotherapy in extremely low birth weight infants. Journal of Neonatal‐Perinatal Medicine2014;7(3):229‐35. [DOI: 10.3233/NPM‐14814015; PUBMED: 25322995] ">ElHassan 2014</a>; <a href="./references#CD003481-bbs2-0081" title="MalikiwiA , RoufaeilC , TanK , SehgalA . Indomethacin vs ibuprofen: comparison of efficacy in the setting of conservative therapeutic approach. European Journal of Pediatrics2015;174(5):615‐20. [DOI: 10.1007/s00431‐014‐2441‐0; PUBMED: 25344763] ">Malikiwi 2015</a>; <a href="./references#CD003481-bbs2-0094" title="Rodriguez‐CastanoMJ , AleoE , ArruzaL . Oral sildenafil for severe pulmonary hypertension developing after ibuprofen use in a neonate. Indian Pediatrics2016;53(4):349‐50. [PUBMED: 27156554] ">Rodriguez‐Castano 2016</a>; <a href="./references#CD003481-bbs2-0078" title="KimSY , ShinSH , KimHS , JungYH , KimEK , ChoiJH . Pulmonary arterial hypertension after ibuprofen treatment for patent ductus arteriosus in very low birth weight infants. Journal of Pediatrics2016;179:49‐53.e1. [DOI: 10.1016/j.jpeds.2016.08.103; PUBMED: 27692860] ">Kim 2016</a>). In the study by <a href="./references#CD003481-bbs2-0066" title="ElHassanNO , BirdTM , KingAJ , AmbadwarPB , JaquissRD , KaiserJR , et al. Variation and comparative effectiveness of patent ductus arteriosus pharmacotherapy in extremely low birth weight infants. Journal of Neonatal‐Perinatal Medicine2014;7(3):229‐35. [DOI: 10.3233/NPM‐14814015; PUBMED: 25322995] ">ElHassan 2014</a>, data were extracted from the Pediatric Health Information System; extremely low birth weight infants (ELBW) infants born between January 1, 2007 and December 31, 2010 and admitted on day of life 0 were eligible for inclusion. Seven hundred thirty‐two infants had a PDA diagnosis and met inclusion criteria. Persistent pulmonary hypertension of the newborn (PPHN) occurred in 19 of 306 infants in the ibuprofen group (6%) and in 32 of 426 infants in the indomethacin group (8%) (<a href="./references#CD003481-bbs2-0066" title="ElHassanNO , BirdTM , KingAJ , AmbadwarPB , JaquissRD , KaiserJR , et al. Variation and comparative effectiveness of patent ductus arteriosus pharmacotherapy in extremely low birth weight infants. Journal of Neonatal‐Perinatal Medicine2014;7(3):229‐35. [DOI: 10.3233/NPM‐14814015; PUBMED: 25322995] ">ElHassan 2014</a>). </p> <p>In the 2008 update of this review (<a href="./references#CD003481-bbs2-0108" title="OhlssonA , WaliaR , ShahS . Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database of Systematic Reviews2008, Issue 1. [DOI: 10.1002/14651858.CD003481.pub3] ">Ohlsson 2008</a>), we stated, "In view of the lack of long‐term outcome data and potential side effects for both drugs, one drug cannot be recommended over the other as the therapy of choice for a PDA". In the 2010 update of the review, we found a significant reduction in the incidence of NEC in the ibuprofen versus indomethacin group (<a href="./references#CD003481-bbs2-0109" title="OhlssonA , WaliaR , ShahS . Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database of Systematic Reviews2010, Issue 4. [DOI: 10.1002/14651858.CD003481.pub4] ">Ohlsson 2010</a>). As the closure rates for PDA by ibuprofen and indomethacin are similar, the reduced rate of NEC is an important finding and favours the use of ibuprofen over indomethacin for the treatment of a PDA. Kidney function is less affected by ibuprofen. In the update in 2014, the closure rates for ibuprofen versus indomethacin were identical with no heterogeneity and the risk of NEC remained reduced as did the risk of adverse effects on the kidneys. This update confirms these findings in larger samples. Some results favoured oral ibuprofen over IV ibuprofen. Oral ibuprofen is more readily available in some countries. For the comparisons 'high‐dose versus standard‐dose ibuprofen'; 'early versus expectant administration of ibuprofen' , 'ECHO‐guided IV ibuprofen treatment versus standard IV treatment', 'continuous infusion of ibuprofen versus intermittent boluses of ibuprofen' and for 'rectal ibuprofen versus oral ibuprofen', evidence is lacking on which treatment is preferable. </p> </section> <section id="CD003481-sec-0180"> <h3 class="title" id="CD003481-sec-0180">Quality of the evidence</h3> <p>Study quality was variable and the results of this review were based on small to moderately large trials. As can be seen in <a href="#CD003481-fig-0004">Figure 4</a>, 'Risk of bias summary: review authors' judgements about each risk of bias item for each included study' and in <a href="#CD003481-fig-0005">Figure 5</a>, 'Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies', we identified concerns about bias in most individual studies and therefore for the group of studies included as well. The main concerns were the lack of blinding and unclear information about concealed allocation to the treatment groups. As stated in above under 'Summary of main results' most outcomes in the 'summary of findings' tables were rated as of moderate quality according to GRADE. The sample sizes varied from 16 (<a href="./references#CD003481-bbs2-0024" title="MoscaF , BrayM , LattanzioM , FumagalliM , ColnaghiM , CastoldiF , et al. Comparison of the effects of ibuprofen and indomethacin on PDA closure and cerebral perfusion and oxygenation. Pediatric Research1997;41:165A. MoscaF , BrayM , LattanzioM , FumagalliM , ColnaghiMR , CompagnoniG . Comparison of the effects of indomethacin (INDO) and ibuprofen (IBU) on cerebral perfusion and oxygenation in preterm infants. Pediatric Research1996;39:231A. MoscaF , BrayM , LattanzioM , FumagalliM , TosettoC . Comparative evaluation of the effects of indomethacin and ibuprofen on cerebral perfusion and oxygenation in preterm infants with patent ductus arteriosus. Journal of Pediatrics1997;131(4):549‐54. [PUBMED: 9386657] ">Mosca 1997</a>) to 200 (<a href="./references#CD003481-bbs2-0013" title="El‐MashadAE , El‐MahdyH , ElAmrousyDE , ElgendyM . Comparative study of the efficacy and safety of paracetamol, ibuprofen, and indomethacin in closure of patent ductus arteriosus in preterm neonates. European Journal of Pediatrics2017;176(2):233‐40. [DOI: 10.1007/s00431‐016‐2830‐7; PUBMED: 28004188] ">El‐Mashad 2017</a>) infants enrolled. For many of the outcomes, the sample size lacked power to detect a significant difference and the estimates were imprecise. The studies were conducted in 18 different countries (Albania, Belgium, China, Czech Republic, Egypt, India, Iran, Israel, Italy, Poland, Qatar, Spain, Taiwan, Thailand, Tunisia, Turkey, the UK, the US), which increases the applicability of the results internationally. There was no heterogeneity for the primary outcome of 'failure to close a PDA' in any of the comparisons or for NEC in the comparisons of ibuprofen versus indomethacin. These findings increased the validity of these results. In addition, the funnel plot for the primary outcome 'failure to close a PDA' was symmetrical, with no obvious absence of smaller studies having a protective effect of ibuprofen versus indomethacin (<a href="#CD003481-fig-0001">Figure 1</a>). For the important secondary outcome of 'NEC', the funnel plot was also symmetrical (<a href="#CD003481-fig-0002">Figure 2</a>). </p> </section> <section id="CD003481-sec-0181"> <h3 class="title" id="CD003481-sec-0181">Potential biases in the review process</h3> <p>We are not aware of any potential biases in the review process.</p> </section> <section id="CD003481-sec-0182"> <h3 class="title" id="CD003481-sec-0182">Agreements and disagreements with other studies or reviews</h3> <p>Indomethacin decreases cerebral blood flow in a preterm infant with a PDA (<a href="./references#CD003481-bbs2-0087" title="OhlssonA , BottuJ , GovanJ , RyanML , FongK , MyhrT . The effect of indomethacin on cerebral blood flow velocities in very low birth weight neonates with patent ductus arteriosus. Developmental Pharmacology and Therapeutics1993;20(1‐2):100‐6. [PUBMED: 7924757] ">Ohlsson 1993</a>), while ibuprofen has some neuro protective effects in animal models (<a href="./references#CD003481-bbs2-0059" title="ChemtobS , BeharyK , RexJ , VarmaDR , ArandaJV . Prostanoids determine the range of cerebral blood flow autoregulation of newborn piglets. Stroke1990;21(5):777‐84. [PUBMED: 2339458] ">Chemtob 1990</a>; <a href="./references#CD003481-bbs2-0092" title="PellicerA , AparicioM , CabanasF , ValverdeE , QueroJ , StirisTA . Effect of the cyclo‐oxygenase blocker ibuprofen on cerebral blood volume and cerebral blood flow during normocarbia and hypercarbia in newborn piglets. Acta Pediatrica1999;88(1):82‐8. [PUBMED: 10090554] ">Pellicer 1999</a>). Future studies comparing the two drugs should include long‐term follow‐up (intact survival) to at least 18 months of age. Sample size calculations could be based on this review and two related Cochrane reviews (<a href="./references#CD003481-bbs2-0068" title="FowliePW , DavisPG , McGuireW . Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. Cochrane Database of Systematic Reviews2010, Issue 7. [DOI: 10.1002/14651858.CD000174.pub2] ">Fowlie 2010</a>; <a href="./references#CD003481-bbs2-0089" title="OhlssonA , ShahSS . Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database of Systematic Reviews2011, Issue 7. [DOI: 10.1002/14651858.CD004213.pub3] ">Ohlsson 2011</a>). </p> <p>Coceani and coworkers suggested that a membrane‐bound prostaglandin E synthase inhibitor, once developed for therapeutic use, could become the agent of choice for PDA treatment, particularly when preterm birth is complicated by infectious or inflammatory conditions (<a href="./references#CD003481-bbs2-0062" title="CoceaniF , BarogiS , BrizzaF , AckerleyC , SeidlitzE , KelseyL , et al. Cyclooxygenase isoenzymes and patency of ductus arteriosus. Prostaglandins, Leukotrienes, and Essential Fatty Acids2005;72(2):71‐7. [DOI: 10.1016/j.plefa.2004.10.004; PUBMED: 15626588] ">Coceani 2005</a>). </p> <p>One systematic review that used meta‐analytic techniques, but included fewer trials, has come to similar conclusions as us (<a href="./references#CD003481-bbs2-0085" title="NeumannR , SchulzkeSM , BührerC . Oral ibuprofen versus intravenous ibuprofen or intravenous indomethacin for the treatment of patent ductus arteriosus in preterm infants: a systematic review and meta‐analysis. Neonatology2012;102(1):9‐15. [DOI: 10.1159/000335332; PUBMED: 22414850] ">Neumann 2012</a>). Likewise, one narrative review by <a href="./references#CD003481-bbs2-0091" title="OncelMY , ErdeveO . Oral medications regarding their safety and efficacy in the management of patent ductus arteriosus. World Journal of Clinical Pediatrics2016;5(1):75‐81. [DOI: 10.5409/wjcp.v5.i1.75; PUBMED: 26862505] ">Oncel 2016</a> reported similar findings to ours. <a href="./references#CD003481-bbs2-0083" title="MitraS , FlorezID , TamayoME , AuneD , MbuagbawL , VeronikiAA , et al. Effectiveness and safety of treatments used for the management of patent ductus arteriosus (PDA) in preterm infants: a protocol for a systematic review and network meta‐analysis. BMJ Open2016;6(7):e011271. [DOI: 10.1136/bmjopen‐2016‐011271; PUBMED: 27456327] ">Mitra 2016</a> and coworkers have published a protocol for a systematic review and network meta‐analysis of the effectiveness and safety of treatments used for the management of PDA in preterm infants. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD003481-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, outcome: 3.1 Failure to close a patent ductus arteriosus (PDA) (after single or 3 doses)." data-id="CD003481-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Funnel plot of comparison: 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, outcome: 3.1 Failure to close a patent ductus arteriosus (PDA) (after single or 3 doses). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/full#CD003481-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, outcome: 3.17 Necrotising enterocolitis (any stage)." data-id="CD003481-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Funnel plot of comparison: 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, outcome: 3.17 Necrotising enterocolitis (any stage). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/full#CD003481-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram: review update" data-id="CD003481-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Study flow diagram: review update</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/full#CD003481-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003481-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/full#CD003481-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD003481-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/full#CD003481-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, outcome: 3.1 Failure to close a patent ductus arteriosus (after single or three doses)." data-id="CD003481-fig-0006" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, outcome: 3.1 Failure to close a patent ductus arteriosus (after single or three doses). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/full#CD003481-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, outcome: 3.17 Necrotising enterocolitis (any stage)." data-id="CD003481-fig-0007" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Forest plot of comparison: 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, outcome: 3.17 Necrotising enterocolitis (any stage). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/full#CD003481-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intravenous ibuprofen versus placebo, Outcome 1 Failure to close a patent ductus arteriosus (after 3 doses)." data-id="CD003481-fig-0008" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Intravenous ibuprofen versus placebo, Outcome 1 Failure to close a patent ductus arteriosus (after 3 doses). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intravenous ibuprofen versus placebo, Outcome 2 Need for surgical ligation." data-id="CD003481-fig-0009" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Intravenous ibuprofen versus placebo, Outcome 2 Need for surgical ligation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intravenous ibuprofen versus placebo, Outcome 3 Intraventricular haemorrhage (any grade)." data-id="CD003481-fig-0010" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Intravenous ibuprofen versus placebo, Outcome 3 Intraventricular haemorrhage (any grade). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intravenous ibuprofen versus placebo, Outcome 4 Intraventricular haemorrhage (grades III and IV)." data-id="CD003481-fig-0011" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Intravenous ibuprofen versus placebo, Outcome 4 Intraventricular haemorrhage (grades III and IV). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intravenous ibuprofen versus placebo, Outcome 5 Periventricular leukomalacia." data-id="CD003481-fig-0012" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Intravenous ibuprofen versus placebo, Outcome 5 Periventricular leukomalacia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intravenous ibuprofen versus placebo, Outcome 6 Pulmonary haemorrhage." data-id="CD003481-fig-0013" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Intravenous ibuprofen versus placebo, Outcome 6 Pulmonary haemorrhage.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intravenous ibuprofen versus placebo, Outcome 7 Pulmonary hypertension." data-id="CD003481-fig-0014" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Intravenous ibuprofen versus placebo, Outcome 7 Pulmonary hypertension.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intravenous ibuprofen versus placebo, Outcome 8 Retinopathy of prematurity (any stage)." data-id="CD003481-fig-0015" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Intravenous ibuprofen versus placebo, Outcome 8 Retinopathy of prematurity (any stage). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intravenous ibuprofen versus placebo, Outcome 9 Retinopathy of prematurity (stage 3 or 4)." data-id="CD003481-fig-0016" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Intravenous ibuprofen versus placebo, Outcome 9 Retinopathy of prematurity (stage 3 or 4). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intravenous ibuprofen versus placebo, Outcome 10 Retinopathy of prematurity (plus disease)." data-id="CD003481-fig-0017" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Intravenous ibuprofen versus placebo, Outcome 10 Retinopathy of prematurity (plus disease). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intravenous ibuprofen versus placebo, Outcome 11 Chronic lung disease (supplemental oxygen at 28 days of age)." data-id="CD003481-fig-0018" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Intravenous ibuprofen versus placebo, Outcome 11 Chronic lung disease (supplemental oxygen at 28 days of age). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intravenous ibuprofen versus placebo, Outcome 12 Chronic lung disease (supplemental oxygen at 36 weeks' postmenstrual age (PMA))." data-id="CD003481-fig-0019" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Intravenous ibuprofen versus placebo, Outcome 12 Chronic lung disease (supplemental oxygen at 36 weeks' postmenstrual age (PMA)). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intravenous ibuprofen versus placebo, Outcome 13 Necrotising enterocolitis." data-id="CD003481-fig-0020" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Intravenous ibuprofen versus placebo, Outcome 13 Necrotising enterocolitis.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intravenous ibuprofen versus placebo, Outcome 14 Mortality by 28 days of life." data-id="CD003481-fig-0021" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Intravenous ibuprofen versus placebo, Outcome 14 Mortality by 28 days of life. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intravenous ibuprofen versus placebo, Outcome 15 Oliguria (urine output &lt; 1 mL/kg/hour)." data-id="CD003481-fig-0022" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Intravenous ibuprofen versus placebo, Outcome 15 Oliguria (urine output &lt; 1 mL/kg/hour). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intravenous ibuprofen versus placebo, Outcome 16 Creatinine (µmol/L) after treatment." data-id="CD003481-fig-0023" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 Intravenous ibuprofen versus placebo, Outcome 16 Creatinine (µmol/L) after treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intravenous ibuprofen versus placebo, Outcome 17 Blood urea nitrogen (µmol/L)." data-id="CD003481-fig-0024" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 Intravenous ibuprofen versus placebo, Outcome 17 Blood urea nitrogen (µmol/L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-001-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-001-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intravenous ibuprofen versus placebo, Outcome 18 Mortality." data-id="CD003481-fig-0025" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-001-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1 Intravenous ibuprofen versus placebo, Outcome 18 Mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-001-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oral ibuprofen versus placebo, Outcome 1 Failure to close a patent ductus arteriosus after single or 3 doses." data-id="CD003481-fig-0026" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Oral ibuprofen versus placebo, Outcome 1 Failure to close a patent ductus arteriosus after single or 3 doses. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-003-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, Outcome 1 Failure to close a patent ductus arteriosus (PDA) (after single or 3 doses)." data-id="CD003481-fig-0027" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, Outcome 1 Failure to close a patent ductus arteriosus (PDA) (after single or 3 doses). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, Outcome 2 All‐cause mortality." data-id="CD003481-fig-0028" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, Outcome 2 All‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, Outcome 3 Neonatal mortality (during first 28/30 days of life)." data-id="CD003481-fig-0029" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, Outcome 3 Neonatal mortality (during first 28/30 days of life). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, Outcome 4 Reopening of the ductus arteriosus." data-id="CD003481-fig-0030" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, Outcome 4 Reopening of the ductus arteriosus. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, Outcome 5 Need for surgical closure of the PDA." data-id="CD003481-fig-0031" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, Outcome 5 Need for surgical closure of the PDA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, Outcome 6 Need for re‐treatment with indomethacin or ibuprofen to close the PDA." data-id="CD003481-fig-0032" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, Outcome 6 Need for re‐treatment with indomethacin or ibuprofen to close the PDA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, Outcome 7 Duration of ventilator support (days)." data-id="CD003481-fig-0033" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, Outcome 7 Duration of ventilator support (days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, Outcome 8 Duration of need for supplementary oxygen (days)." data-id="CD003481-fig-0034" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, Outcome 8 Duration of need for supplementary oxygen (days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-003-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-003-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, Outcome 9 Pulmonary haemorrhage." data-id="CD003481-fig-0035" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-003-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, Outcome 9 Pulmonary haemorrhage. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-003-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-003-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-003-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, Outcome 10 Pulmonary hypertension." data-id="CD003481-fig-0036" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-003-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, Outcome 10 Pulmonary hypertension. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-003-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-003-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-003-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, Outcome 11 Chronic lung disease (at 28 days)." data-id="CD003481-fig-0037" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-003-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, Outcome 11 Chronic lung disease (at 28 days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-003-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-003-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-003-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, Outcome 12 Chronic lung disease (at 36 weeks' postmenstrual age)." data-id="CD003481-fig-0038" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-003-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.12</div> <div class="figure-caption"> <p>Comparison 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, Outcome 12 Chronic lung disease (at 36 weeks' postmenstrual age). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-003-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-003-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-003-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, Outcome 13 Chronic lung disease (age not stated)." data-id="CD003481-fig-0039" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-003-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.13</div> <div class="figure-caption"> <p>Comparison 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, Outcome 13 Chronic lung disease (age not stated). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-003-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-003-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-003-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, Outcome 14 Intraventricular haemorrhage (any grade)." data-id="CD003481-fig-0040" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-003-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.14</div> <div class="figure-caption"> <p>Comparison 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, Outcome 14 Intraventricular haemorrhage (any grade). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-003-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-003-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-003-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, Outcome 15 Intraventricular haemorrhage (grades III and IV)." data-id="CD003481-fig-0041" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-003-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.15</div> <div class="figure-caption"> <p>Comparison 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, Outcome 15 Intraventricular haemorrhage (grades III and IV). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-003-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-003-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-003-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, Outcome 16 Periventricular leukomalacia (cystic)." data-id="CD003481-fig-0042" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-003-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.16</div> <div class="figure-caption"> <p>Comparison 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, Outcome 16 Periventricular leukomalacia (cystic). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-003-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-003-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-003-17.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, Outcome 17 Necrotising enterocolitis (any stage)." data-id="CD003481-fig-0043" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-003-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.17</div> <div class="figure-caption"> <p>Comparison 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, Outcome 17 Necrotising enterocolitis (any stage). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-003-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-003-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-003-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, Outcome 18 Intestinal perforation." data-id="CD003481-fig-0044" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-003-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.18</div> <div class="figure-caption"> <p>Comparison 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, Outcome 18 Intestinal perforation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-003-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-003-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-003-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, Outcome 19 Gastrointestinal bleed." data-id="CD003481-fig-0045" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-003-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.19</div> <div class="figure-caption"> <p>Comparison 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, Outcome 19 Gastrointestinal bleed. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-003-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-003-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-003-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, Outcome 20 Time to full enteral feeds." data-id="CD003481-fig-0046" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-003-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.20</div> <div class="figure-caption"> <p>Comparison 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, Outcome 20 Time to full enteral feeds. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-003-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-003-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-003-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, Outcome 21 Time to regain birth weight (days)." data-id="CD003481-fig-0047" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-003-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.21</div> <div class="figure-caption"> <p>Comparison 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, Outcome 21 Time to regain birth weight (days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-003-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-003-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-003-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, Outcome 22 Retinopathy of prematurity." data-id="CD003481-fig-0048" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-003-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.22</div> <div class="figure-caption"> <p>Comparison 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, Outcome 22 Retinopathy of prematurity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-003-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-003-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-003-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, Outcome 23 Sepsis." data-id="CD003481-fig-0049" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-003-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.23</div> <div class="figure-caption"> <p>Comparison 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, Outcome 23 Sepsis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-003-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-003-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-003-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, Outcome 24 Oliguria (urine output &lt; 1 mL/kg/hour)." data-id="CD003481-fig-0050" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-003-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.24</div> <div class="figure-caption"> <p>Comparison 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, Outcome 24 Oliguria (urine output &lt; 1 mL/kg/hour). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-003-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-003-25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-003-25.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, Outcome 25 Serum/plasma creatinine levels (μmol/L) 72 hours after treatment." data-id="CD003481-fig-0051" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-003-25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.25</div> <div class="figure-caption"> <p>Comparison 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, Outcome 25 Serum/plasma creatinine levels (μmol/L) 72 hours after treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-003-25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-003-26" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-003-26.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, Outcome 26 Increase in serum/plasma creatinine levels (mg/dL) following treatment." data-id="CD003481-fig-0052" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-003-26.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.26</div> <div class="figure-caption"> <p>Comparison 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, Outcome 26 Increase in serum/plasma creatinine levels (mg/dL) following treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-003-26.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-003-27" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-003-27.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, Outcome 27 Duration of hospitalisation (days)." data-id="CD003481-fig-0053" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-003-27.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.27</div> <div class="figure-caption"> <p>Comparison 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, Outcome 27 Duration of hospitalisation (days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-003-27.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-003-28" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-003-28.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, Outcome 28 Significant decrease in urine output (&gt; 20% decrease in urine output after starting therapy)." data-id="CD003481-fig-0054" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-003-28.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.28</div> <div class="figure-caption"> <p>Comparison 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, Outcome 28 Significant decrease in urine output (&gt; 20% decrease in urine output after starting therapy). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-003-28.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-003-29" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-003-29.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, Outcome 29 Daily urine output mL/kg/hr." data-id="CD003481-fig-0055" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-003-29.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.29</div> <div class="figure-caption"> <p>Comparison 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, Outcome 29 Daily urine output mL/kg/hr. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-003-29.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-003-30" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-003-30.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, Outcome 30 Serum bilirubin (µmol/L) after treatment." data-id="CD003481-fig-0056" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-003-30.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.30</div> <div class="figure-caption"> <p>Comparison 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, Outcome 30 Serum bilirubin (µmol/L) after treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-003-30.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-003-31" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-003-31.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, Outcome 31 Platelet count (x109/L)." data-id="CD003481-fig-0057" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-003-31.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.31</div> <div class="figure-caption"> <p>Comparison 3 Intravenous or oral ibuprofen versus intravenous or oral indomethacin, Outcome 31 Platelet count (x10<sup>9</sup>/L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-003-31.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Oral ibuprofen versus intravenous (IV) or oral indomethacin, Outcome 1 Failure to close a patent ductus arteriosus (PDA) (after 3 doses)." data-id="CD003481-fig-0058" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Oral ibuprofen versus intravenous (IV) or oral indomethacin, Outcome 1 Failure to close a patent ductus arteriosus (PDA) (after 3 doses). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Oral ibuprofen versus intravenous (IV) or oral indomethacin, Outcome 2 All‐cause mortality." data-id="CD003481-fig-0059" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Oral ibuprofen versus intravenous (IV) or oral indomethacin, Outcome 2 All‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Oral ibuprofen versus intravenous (IV) or oral indomethacin, Outcome 3 Neonatal mortality (during first 28/30 days of life)." data-id="CD003481-fig-0060" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Oral ibuprofen versus intravenous (IV) or oral indomethacin, Outcome 3 Neonatal mortality (during first 28/30 days of life). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Oral ibuprofen versus intravenous (IV) or oral indomethacin, Outcome 4 Reopening of the ductus arteriosus." data-id="CD003481-fig-0061" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Oral ibuprofen versus intravenous (IV) or oral indomethacin, Outcome 4 Reopening of the ductus arteriosus. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Oral ibuprofen versus intravenous (IV) or oral indomethacin, Outcome 5 Need for surgical closure of the PDA." data-id="CD003481-fig-0062" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Oral ibuprofen versus intravenous (IV) or oral indomethacin, Outcome 5 Need for surgical closure of the PDA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Oral ibuprofen versus intravenous (IV) or oral indomethacin, Outcome 6 Pulmonary haemorrhage." data-id="CD003481-fig-0063" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 Oral ibuprofen versus intravenous (IV) or oral indomethacin, Outcome 6 Pulmonary haemorrhage. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-004-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-004-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Oral ibuprofen versus intravenous (IV) or oral indomethacin, Outcome 7 Pulmonary hypertension." data-id="CD003481-fig-0064" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-004-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4 Oral ibuprofen versus intravenous (IV) or oral indomethacin, Outcome 7 Pulmonary hypertension. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-004-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-004-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-004-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Oral ibuprofen versus intravenous (IV) or oral indomethacin, Outcome 8 Chronic lung disease (at 28 days)." data-id="CD003481-fig-0065" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-004-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4 Oral ibuprofen versus intravenous (IV) or oral indomethacin, Outcome 8 Chronic lung disease (at 28 days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-004-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-004-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-004-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Oral ibuprofen versus intravenous (IV) or oral indomethacin, Outcome 9 Chronic lung disease (age not stated)." data-id="CD003481-fig-0066" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-004-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.9</div> <div class="figure-caption"> <p>Comparison 4 Oral ibuprofen versus intravenous (IV) or oral indomethacin, Outcome 9 Chronic lung disease (age not stated). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-004-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-004-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-004-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Oral ibuprofen versus intravenous (IV) or oral indomethacin, Outcome 10 Intraventricular haemorrhage (any grade)." data-id="CD003481-fig-0067" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-004-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.10</div> <div class="figure-caption"> <p>Comparison 4 Oral ibuprofen versus intravenous (IV) or oral indomethacin, Outcome 10 Intraventricular haemorrhage (any grade). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-004-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-004-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-004-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Oral ibuprofen versus intravenous (IV) or oral indomethacin, Outcome 11 Intraventricular haemorrhage (grades III and IV)." data-id="CD003481-fig-0068" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-004-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.11</div> <div class="figure-caption"> <p>Comparison 4 Oral ibuprofen versus intravenous (IV) or oral indomethacin, Outcome 11 Intraventricular haemorrhage (grades III and IV). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-004-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-004-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-004-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Oral ibuprofen versus intravenous (IV) or oral indomethacin, Outcome 12 Periventricular leukomalacia (cystic)." data-id="CD003481-fig-0069" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-004-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.12</div> <div class="figure-caption"> <p>Comparison 4 Oral ibuprofen versus intravenous (IV) or oral indomethacin, Outcome 12 Periventricular leukomalacia (cystic). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-004-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-004-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-004-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Oral ibuprofen versus intravenous (IV) or oral indomethacin, Outcome 13 Necrotising enterocolitis (any stage)." data-id="CD003481-fig-0070" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-004-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.13</div> <div class="figure-caption"> <p>Comparison 4 Oral ibuprofen versus intravenous (IV) or oral indomethacin, Outcome 13 Necrotising enterocolitis (any stage). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-004-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-004-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-004-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Oral ibuprofen versus intravenous (IV) or oral indomethacin, Outcome 14 Intestinal perforation." data-id="CD003481-fig-0071" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-004-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.14</div> <div class="figure-caption"> <p>Comparison 4 Oral ibuprofen versus intravenous (IV) or oral indomethacin, Outcome 14 Intestinal perforation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-004-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-004-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-004-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Oral ibuprofen versus intravenous (IV) or oral indomethacin, Outcome 15 Gastrointestinal bleed." data-id="CD003481-fig-0072" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-004-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.15</div> <div class="figure-caption"> <p>Comparison 4 Oral ibuprofen versus intravenous (IV) or oral indomethacin, Outcome 15 Gastrointestinal bleed. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-004-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-004-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-004-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Oral ibuprofen versus intravenous (IV) or oral indomethacin, Outcome 16 Retinopathy of prematurity." data-id="CD003481-fig-0073" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-004-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.16</div> <div class="figure-caption"> <p>Comparison 4 Oral ibuprofen versus intravenous (IV) or oral indomethacin, Outcome 16 Retinopathy of prematurity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-004-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-004-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-004-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Oral ibuprofen versus intravenous (IV) or oral indomethacin, Outcome 17 Sepsis." data-id="CD003481-fig-0074" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-004-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.17</div> <div class="figure-caption"> <p>Comparison 4 Oral ibuprofen versus intravenous (IV) or oral indomethacin, Outcome 17 Sepsis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-004-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-004-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-004-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Oral ibuprofen versus intravenous (IV) or oral indomethacin, Outcome 18 Oliguria (urine output &lt; 1 mL/kg/hour)." data-id="CD003481-fig-0075" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-004-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.18</div> <div class="figure-caption"> <p>Comparison 4 Oral ibuprofen versus intravenous (IV) or oral indomethacin, Outcome 18 Oliguria (urine output &lt; 1 mL/kg/hour). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-004-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-004-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-004-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Oral ibuprofen versus intravenous (IV) or oral indomethacin, Outcome 19 Serum/plasma creatinine levels (µmol/L) 72 hours after treatment." data-id="CD003481-fig-0076" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-004-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.19</div> <div class="figure-caption"> <p>Comparison 4 Oral ibuprofen versus intravenous (IV) or oral indomethacin, Outcome 19 Serum/plasma creatinine levels (µmol/L) 72 hours after treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-004-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-004-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-004-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Oral ibuprofen versus intravenous (IV) or oral indomethacin, Outcome 20 Duration of hospital stay (days)." data-id="CD003481-fig-0077" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-004-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.20</div> <div class="figure-caption"> <p>Comparison 4 Oral ibuprofen versus intravenous (IV) or oral indomethacin, Outcome 20 Duration of hospital stay (days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-004-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Oral ibuprofen versus intravenous (IV) ibuprofen, Outcome 1 Failure to close a patent ductus arteriosus (after single or 3 doses)." data-id="CD003481-fig-0078" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Oral ibuprofen versus intravenous (IV) ibuprofen, Outcome 1 Failure to close a patent ductus arteriosus (after single or 3 doses). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Oral ibuprofen versus intravenous (IV) ibuprofen, Outcome 2 Mortality (during first 28/30 days of life)." data-id="CD003481-fig-0079" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Oral ibuprofen versus intravenous (IV) ibuprofen, Outcome 2 Mortality (during first 28/30 days of life). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Oral ibuprofen versus intravenous (IV) ibuprofen, Outcome 3 Mortality (during hospital stay)." data-id="CD003481-fig-0080" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Oral ibuprofen versus intravenous (IV) ibuprofen, Outcome 3 Mortality (during hospital stay). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Oral ibuprofen versus intravenous (IV) ibuprofen, Outcome 4 Mean plasma cystatin‐C (mg/L) after treatment." data-id="CD003481-fig-0081" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 Oral ibuprofen versus intravenous (IV) ibuprofen, Outcome 4 Mean plasma cystatin‐C (mg/L) after treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-005-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-005-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Oral ibuprofen versus intravenous (IV) ibuprofen, Outcome 5 Need for surgical closure of the ductus." data-id="CD003481-fig-0082" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-005-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5 Oral ibuprofen versus intravenous (IV) ibuprofen, Outcome 5 Need for surgical closure of the ductus. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-005-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-005-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-005-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Oral ibuprofen versus intravenous (IV) ibuprofen, Outcome 6 Duration of ventilatory support." data-id="CD003481-fig-0083" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-005-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5 Oral ibuprofen versus intravenous (IV) ibuprofen, Outcome 6 Duration of ventilatory support. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-005-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-005-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-005-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Oral ibuprofen versus intravenous (IV) ibuprofen, Outcome 7 Duration of hospitalisation (days)." data-id="CD003481-fig-0084" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-005-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5 Oral ibuprofen versus intravenous (IV) ibuprofen, Outcome 7 Duration of hospitalisation (days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-005-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-005-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-005-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Oral ibuprofen versus intravenous (IV) ibuprofen, Outcome 8 Pneumothorax." data-id="CD003481-fig-0085" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-005-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.8</div> <div class="figure-caption"> <p>Comparison 5 Oral ibuprofen versus intravenous (IV) ibuprofen, Outcome 8 Pneumothorax.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-005-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0086"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-005-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-005-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Oral ibuprofen versus intravenous (IV) ibuprofen, Outcome 9 Pulmonary haemorrhage." data-id="CD003481-fig-0086" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-005-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.9</div> <div class="figure-caption"> <p>Comparison 5 Oral ibuprofen versus intravenous (IV) ibuprofen, Outcome 9 Pulmonary haemorrhage. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0086">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-005-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0087"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-005-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-005-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Oral ibuprofen versus intravenous (IV) ibuprofen, Outcome 10 Pulmonary hypertension." data-id="CD003481-fig-0087" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-005-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.10</div> <div class="figure-caption"> <p>Comparison 5 Oral ibuprofen versus intravenous (IV) ibuprofen, Outcome 10 Pulmonary hypertension. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0087">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-005-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0088"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-005-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-005-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Oral ibuprofen versus intravenous (IV) ibuprofen, Outcome 11 Chronic lung disease (at 36 weeks' postmenstrual age or at discharge)." data-id="CD003481-fig-0088" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-005-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.11</div> <div class="figure-caption"> <p>Comparison 5 Oral ibuprofen versus intravenous (IV) ibuprofen, Outcome 11 Chronic lung disease (at 36 weeks' postmenstrual age or at discharge). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0088">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-005-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0089"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-005-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-005-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Oral ibuprofen versus intravenous (IV) ibuprofen, Outcome 12 Intraventricular haemorrhage (any grade)." data-id="CD003481-fig-0089" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-005-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.12</div> <div class="figure-caption"> <p>Comparison 5 Oral ibuprofen versus intravenous (IV) ibuprofen, Outcome 12 Intraventricular haemorrhage (any grade). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0089">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-005-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0090"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-005-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-005-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Oral ibuprofen versus intravenous (IV) ibuprofen, Outcome 13 Periventricular leukomalacia." data-id="CD003481-fig-0090" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-005-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.13</div> <div class="figure-caption"> <p>Comparison 5 Oral ibuprofen versus intravenous (IV) ibuprofen, Outcome 13 Periventricular leukomalacia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0090">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-005-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0091"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-005-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-005-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Oral ibuprofen versus intravenous (IV) ibuprofen, Outcome 14 Necrotising enterocolitis (any stage)." data-id="CD003481-fig-0091" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-005-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.14</div> <div class="figure-caption"> <p>Comparison 5 Oral ibuprofen versus intravenous (IV) ibuprofen, Outcome 14 Necrotising enterocolitis (any stage). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0091">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-005-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0092"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-005-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-005-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Oral ibuprofen versus intravenous (IV) ibuprofen, Outcome 15 Intestinal perforation." data-id="CD003481-fig-0092" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-005-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.15</div> <div class="figure-caption"> <p>Comparison 5 Oral ibuprofen versus intravenous (IV) ibuprofen, Outcome 15 Intestinal perforation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0092">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-005-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0093"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-005-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-005-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Oral ibuprofen versus intravenous (IV) ibuprofen, Outcome 16 Gastrointestinal bleed." data-id="CD003481-fig-0093" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-005-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.16</div> <div class="figure-caption"> <p>Comparison 5 Oral ibuprofen versus intravenous (IV) ibuprofen, Outcome 16 Gastrointestinal bleed. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0093">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-005-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0094"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-005-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-005-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Oral ibuprofen versus intravenous (IV) ibuprofen, Outcome 17 Sepsis." data-id="CD003481-fig-0094" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-005-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.17</div> <div class="figure-caption"> <p>Comparison 5 Oral ibuprofen versus intravenous (IV) ibuprofen, Outcome 17 Sepsis.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0094">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-005-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0095"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-005-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-005-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Oral ibuprofen versus intravenous (IV) ibuprofen, Outcome 18 Retinopathy of prematurity that required laser treatment." data-id="CD003481-fig-0095" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-005-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.18</div> <div class="figure-caption"> <p>Comparison 5 Oral ibuprofen versus intravenous (IV) ibuprofen, Outcome 18 Retinopathy of prematurity that required laser treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0095">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-005-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0096"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-005-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-005-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Oral ibuprofen versus intravenous (IV) ibuprofen, Outcome 19 Serum/plasma creatinine levels (μmol/L) after treatment." data-id="CD003481-fig-0096" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-005-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.19</div> <div class="figure-caption"> <p>Comparison 5 Oral ibuprofen versus intravenous (IV) ibuprofen, Outcome 19 Serum/plasma creatinine levels (μmol/L) after treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0096">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-005-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0097"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-005-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-005-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Oral ibuprofen versus intravenous (IV) ibuprofen, Outcome 20 Oliguria (Urine output &lt; 1 mL/kg/hour)." data-id="CD003481-fig-0097" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-005-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.20</div> <div class="figure-caption"> <p>Comparison 5 Oral ibuprofen versus intravenous (IV) ibuprofen, Outcome 20 Oliguria (Urine output &lt; 1 mL/kg/hour). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0097">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-005-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0098"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-005-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-005-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Oral ibuprofen versus intravenous (IV) ibuprofen, Outcome 21 Mental Developmental Index (Bayley II) at 18‐24 months." data-id="CD003481-fig-0098" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-005-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.21</div> <div class="figure-caption"> <p>Comparison 5 Oral ibuprofen versus intravenous (IV) ibuprofen, Outcome 21 Mental Developmental Index (Bayley II) at 18‐24 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0098">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-005-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0099"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-005-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-005-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Oral ibuprofen versus intravenous (IV) ibuprofen, Outcome 22 Psychomotor Developmental Index at 18‐24 months." data-id="CD003481-fig-0099" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-005-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.22</div> <div class="figure-caption"> <p>Comparison 5 Oral ibuprofen versus intravenous (IV) ibuprofen, Outcome 22 Psychomotor Developmental Index at 18‐24 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0099">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-005-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0100"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-005-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-005-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Oral ibuprofen versus intravenous (IV) ibuprofen, Outcome 23 Moderate/severe cerebral palsy at 18‐24 months." data-id="CD003481-fig-0100" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-005-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.23</div> <div class="figure-caption"> <p>Comparison 5 Oral ibuprofen versus intravenous (IV) ibuprofen, Outcome 23 Moderate/severe cerebral palsy at 18‐24 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0100">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-005-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0101"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-005-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-005-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Oral ibuprofen versus intravenous (IV) ibuprofen, Outcome 24 Blindness at 18‐24 months." data-id="CD003481-fig-0101" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-005-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.24</div> <div class="figure-caption"> <p>Comparison 5 Oral ibuprofen versus intravenous (IV) ibuprofen, Outcome 24 Blindness at 18‐24 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0101">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-005-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0102"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-005-25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-005-25.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Oral ibuprofen versus intravenous (IV) ibuprofen, Outcome 25 Deafness at 18‐24 months." data-id="CD003481-fig-0102" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-005-25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.25</div> <div class="figure-caption"> <p>Comparison 5 Oral ibuprofen versus intravenous (IV) ibuprofen, Outcome 25 Deafness at 18‐24 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0102">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-005-25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0103"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 High‐dose (oral or IV) versus standard‐dose ibuprofen (oral or IV), Outcome 1 Failure to close a patent ductus arteriosus after 3 doses of ibuprofen." data-id="CD003481-fig-0103" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 High‐dose (oral or IV) versus standard‐dose ibuprofen (oral or IV), Outcome 1 Failure to close a patent ductus arteriosus after 3 doses of ibuprofen. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0103">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0104"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 High‐dose (oral or IV) versus standard‐dose ibuprofen (oral or IV), Outcome 2 Reopening after second course of ibuprofen." data-id="CD003481-fig-0104" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 High‐dose (oral or IV) versus standard‐dose ibuprofen (oral or IV), Outcome 2 Reopening after second course of ibuprofen. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0104">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0105"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 High‐dose (oral or IV) versus standard‐dose ibuprofen (oral or IV), Outcome 3 Need for surgical closure." data-id="CD003481-fig-0105" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 High‐dose (oral or IV) versus standard‐dose ibuprofen (oral or IV), Outcome 3 Need for surgical closure. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0105">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0106"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-006-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-006-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 High‐dose (oral or IV) versus standard‐dose ibuprofen (oral or IV), Outcome 4 Mortality during hospital stay." data-id="CD003481-fig-0106" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-006-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6 High‐dose (oral or IV) versus standard‐dose ibuprofen (oral or IV), Outcome 4 Mortality during hospital stay. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0106">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-006-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0107"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-006-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-006-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 High‐dose (oral or IV) versus standard‐dose ibuprofen (oral or IV), Outcome 5 Urine output on day 3 of treatment (mL/kg/hour)." data-id="CD003481-fig-0107" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-006-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6 High‐dose (oral or IV) versus standard‐dose ibuprofen (oral or IV), Outcome 5 Urine output on day 3 of treatment (mL/kg/hour). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0107">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-006-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0108"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-006-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-006-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 High‐dose (oral or IV) versus standard‐dose ibuprofen (oral or IV), Outcome 6 Oliguria (&lt; 1 mL/kg/hour during 24 hours)." data-id="CD003481-fig-0108" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-006-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6 High‐dose (oral or IV) versus standard‐dose ibuprofen (oral or IV), Outcome 6 Oliguria (&lt; 1 mL/kg/hour during 24 hours). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0108">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-006-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0109"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-006-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-006-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 High‐dose (oral or IV) versus standard‐dose ibuprofen (oral or IV), Outcome 7 Intraventricular haemorrhage (any grade)." data-id="CD003481-fig-0109" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-006-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.7</div> <div class="figure-caption"> <p>Comparison 6 High‐dose (oral or IV) versus standard‐dose ibuprofen (oral or IV), Outcome 7 Intraventricular haemorrhage (any grade). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0109">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-006-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0110"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-006-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-006-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 High‐dose (oral or IV) versus standard‐dose ibuprofen (oral or IV), Outcome 8 Intraventricular haemorrhage (grades III and IV)." data-id="CD003481-fig-0110" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-006-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.8</div> <div class="figure-caption"> <p>Comparison 6 High‐dose (oral or IV) versus standard‐dose ibuprofen (oral or IV), Outcome 8 Intraventricular haemorrhage (grades III and IV). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0110">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-006-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0111"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-006-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-006-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 High‐dose (oral or IV) versus standard‐dose ibuprofen (oral or IV), Outcome 9 Periventricular leukomalacia." data-id="CD003481-fig-0111" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-006-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.9</div> <div class="figure-caption"> <p>Comparison 6 High‐dose (oral or IV) versus standard‐dose ibuprofen (oral or IV), Outcome 9 Periventricular leukomalacia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0111">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-006-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0112"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-006-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-006-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 High‐dose (oral or IV) versus standard‐dose ibuprofen (oral or IV), Outcome 10 Retinopathy of prematurity (any stage)." data-id="CD003481-fig-0112" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-006-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.10</div> <div class="figure-caption"> <p>Comparison 6 High‐dose (oral or IV) versus standard‐dose ibuprofen (oral or IV), Outcome 10 Retinopathy of prematurity (any stage). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0112">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-006-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0113"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-006-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-006-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 High‐dose (oral or IV) versus standard‐dose ibuprofen (oral or IV), Outcome 11 Retinopathy of prematurity (stage 3 or 4)." data-id="CD003481-fig-0113" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-006-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.11</div> <div class="figure-caption"> <p>Comparison 6 High‐dose (oral or IV) versus standard‐dose ibuprofen (oral or IV), Outcome 11 Retinopathy of prematurity (stage 3 or 4). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0113">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-006-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0114"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-006-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-006-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 High‐dose (oral or IV) versus standard‐dose ibuprofen (oral or IV), Outcome 12 Necrotising enterocolitis." data-id="CD003481-fig-0114" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-006-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.12</div> <div class="figure-caption"> <p>Comparison 6 High‐dose (oral or IV) versus standard‐dose ibuprofen (oral or IV), Outcome 12 Necrotising enterocolitis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0114">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-006-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0115"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-006-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-006-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 High‐dose (oral or IV) versus standard‐dose ibuprofen (oral or IV), Outcome 13 Chronic lung disease (at 36 weeks' postmenstrual age)." data-id="CD003481-fig-0115" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-006-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.13</div> <div class="figure-caption"> <p>Comparison 6 High‐dose (oral or IV) versus standard‐dose ibuprofen (oral or IV), Outcome 13 Chronic lung disease (at 36 weeks' postmenstrual age). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0115">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-006-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0116"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-006-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-006-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 High‐dose (oral or IV) versus standard‐dose ibuprofen (oral or IV), Outcome 14 Sepsis." data-id="CD003481-fig-0116" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-006-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.14</div> <div class="figure-caption"> <p>Comparison 6 High‐dose (oral or IV) versus standard‐dose ibuprofen (oral or IV), Outcome 14 Sepsis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0116">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-006-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0117"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-006-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-006-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 High‐dose (oral or IV) versus standard‐dose ibuprofen (oral or IV), Outcome 15 Hospital stay (days)." data-id="CD003481-fig-0117" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-006-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.15</div> <div class="figure-caption"> <p>Comparison 6 High‐dose (oral or IV) versus standard‐dose ibuprofen (oral or IV), Outcome 15 Hospital stay (days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0117">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-006-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0118"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-006-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-006-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 High‐dose (oral or IV) versus standard‐dose ibuprofen (oral or IV), Outcome 16 Oliguria (&lt; 0.5 mL/kg/hour) after onset of treatment." data-id="CD003481-fig-0118" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-006-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.16</div> <div class="figure-caption"> <p>Comparison 6 High‐dose (oral or IV) versus standard‐dose ibuprofen (oral or IV), Outcome 16 Oliguria (&lt; 0.5 mL/kg/hour) after onset of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0118">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-006-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0119"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-006-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-006-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 High‐dose (oral or IV) versus standard‐dose ibuprofen (oral or IV), Outcome 17 Gastrointestinal bleed." data-id="CD003481-fig-0119" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-006-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.17</div> <div class="figure-caption"> <p>Comparison 6 High‐dose (oral or IV) versus standard‐dose ibuprofen (oral or IV), Outcome 17 Gastrointestinal bleed. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0119">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-006-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0120"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-006-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-006-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 High‐dose (oral or IV) versus standard‐dose ibuprofen (oral or IV), Outcome 18 Platelet count (x 109/L) after treatment." data-id="CD003481-fig-0120" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-006-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.18</div> <div class="figure-caption"> <p>Comparison 6 High‐dose (oral or IV) versus standard‐dose ibuprofen (oral or IV), Outcome 18 Platelet count (x 10<sup>9</sup>/L) after treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0120">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-006-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0121"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-006-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-006-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 High‐dose (oral or IV) versus standard‐dose ibuprofen (oral or IV), Outcome 19 Serum creatinine (µmol/L) after treatment." data-id="CD003481-fig-0121" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-006-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.19</div> <div class="figure-caption"> <p>Comparison 6 High‐dose (oral or IV) versus standard‐dose ibuprofen (oral or IV), Outcome 19 Serum creatinine (µmol/L) after treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0121">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-006-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0122"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Early versus expectant administration of intravenous ibuprofen, Outcome 1 Days on supplemental oxygen during the first 28 days." data-id="CD003481-fig-0122" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Early versus expectant administration of intravenous ibuprofen, Outcome 1 Days on supplemental oxygen during the first 28 days. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0122">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0123"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-007-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-007-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Early versus expectant administration of intravenous ibuprofen, Outcome 2 Days on supplemental oxygen." data-id="CD003481-fig-0123" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-007-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 Early versus expectant administration of intravenous ibuprofen, Outcome 2 Days on supplemental oxygen. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0123">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-007-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0124"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-007-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-007-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Early versus expectant administration of intravenous ibuprofen, Outcome 3 Days on mechanical ventilation first 28 days." data-id="CD003481-fig-0124" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-007-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7 Early versus expectant administration of intravenous ibuprofen, Outcome 3 Days on mechanical ventilation first 28 days. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0124">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-007-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0125"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-007-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-007-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Early versus expectant administration of intravenous ibuprofen, Outcome 4 Days on mechanical ventilation." data-id="CD003481-fig-0125" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-007-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7 Early versus expectant administration of intravenous ibuprofen, Outcome 4 Days on mechanical ventilation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0125">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-007-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0126"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-007-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-007-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Early versus expectant administration of intravenous ibuprofen, Outcome 5 Chronic lung disease (at 36 weeks' postmenstrual age (PMA))." data-id="CD003481-fig-0126" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-007-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.5</div> <div class="figure-caption"> <p>Comparison 7 Early versus expectant administration of intravenous ibuprofen, Outcome 5 Chronic lung disease (at 36 weeks' postmenstrual age (PMA)). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0126">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-007-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0127"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-007-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-007-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Early versus expectant administration of intravenous ibuprofen, Outcome 6 Mortality or chronic lung disease (at 36 weeks' PMA)." data-id="CD003481-fig-0127" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-007-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.6</div> <div class="figure-caption"> <p>Comparison 7 Early versus expectant administration of intravenous ibuprofen, Outcome 6 Mortality or chronic lung disease (at 36 weeks' PMA). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0127">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-007-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0128"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-007-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-007-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Early versus expectant administration of intravenous ibuprofen, Outcome 7 Mortality during hospital stay." data-id="CD003481-fig-0128" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-007-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.7</div> <div class="figure-caption"> <p>Comparison 7 Early versus expectant administration of intravenous ibuprofen, Outcome 7 Mortality during hospital stay. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0128">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-007-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0129"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-007-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-007-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Early versus expectant administration of intravenous ibuprofen, Outcome 8 Pneumothorax." data-id="CD003481-fig-0129" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-007-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.8</div> <div class="figure-caption"> <p>Comparison 7 Early versus expectant administration of intravenous ibuprofen, Outcome 8 Pneumothorax. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0129">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-007-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0130"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-007-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-007-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Early versus expectant administration of intravenous ibuprofen, Outcome 9 Intraventricular haemorrhage (grades III and IV)." data-id="CD003481-fig-0130" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-007-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.9</div> <div class="figure-caption"> <p>Comparison 7 Early versus expectant administration of intravenous ibuprofen, Outcome 9 Intraventricular haemorrhage (grades III and IV). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0130">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-007-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0131"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-007-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-007-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Early versus expectant administration of intravenous ibuprofen, Outcome 10 Periventricular leukomalacia." data-id="CD003481-fig-0131" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-007-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.10</div> <div class="figure-caption"> <p>Comparison 7 Early versus expectant administration of intravenous ibuprofen, Outcome 10 Periventricular leukomalacia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0131">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-007-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0132"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-007-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-007-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Early versus expectant administration of intravenous ibuprofen, Outcome 11 Necrotising enterocolitis (requiring surgery)." data-id="CD003481-fig-0132" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-007-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.11</div> <div class="figure-caption"> <p>Comparison 7 Early versus expectant administration of intravenous ibuprofen, Outcome 11 Necrotising enterocolitis (requiring surgery). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0132">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-007-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0133"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-007-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-007-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Early versus expectant administration of intravenous ibuprofen, Outcome 12 Intestinal perforation." data-id="CD003481-fig-0133" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-007-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.12</div> <div class="figure-caption"> <p>Comparison 7 Early versus expectant administration of intravenous ibuprofen, Outcome 12 Intestinal perforation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0133">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-007-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0134"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-007-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-007-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Early versus expectant administration of intravenous ibuprofen, Outcome 13 Sepsis." data-id="CD003481-fig-0134" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-007-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.13</div> <div class="figure-caption"> <p>Comparison 7 Early versus expectant administration of intravenous ibuprofen, Outcome 13 Sepsis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0134">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-007-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0135"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-007-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-007-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Early versus expectant administration of intravenous ibuprofen, Outcome 14 Retinopathy of prematurity (stage 3 or 4)." data-id="CD003481-fig-0135" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-007-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.14</div> <div class="figure-caption"> <p>Comparison 7 Early versus expectant administration of intravenous ibuprofen, Outcome 14 Retinopathy of prematurity (stage 3 or 4). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0135">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-007-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0136"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Echocardiographically (ECHO)‐guided intravenous ibuprofen treatment versus standard intravenous ibuprofen treatment, Outcome 1 Failure to close a patent ductus arteriosus (PDA)." data-id="CD003481-fig-0136" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 Echocardiographically (ECHO)‐guided intravenous ibuprofen treatment versus standard intravenous ibuprofen treatment, Outcome 1 Failure to close a patent ductus arteriosus (PDA). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0136">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0137"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-008-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-008-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Echocardiographically (ECHO)‐guided intravenous ibuprofen treatment versus standard intravenous ibuprofen treatment, Outcome 2 Reopening of PDA." data-id="CD003481-fig-0137" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-008-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8 Echocardiographically (ECHO)‐guided intravenous ibuprofen treatment versus standard intravenous ibuprofen treatment, Outcome 2 Reopening of PDA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0137">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-008-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0138"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-008-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-008-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Echocardiographically (ECHO)‐guided intravenous ibuprofen treatment versus standard intravenous ibuprofen treatment, Outcome 3 Number of ibuprofen doses." data-id="CD003481-fig-0138" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-008-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8 Echocardiographically (ECHO)‐guided intravenous ibuprofen treatment versus standard intravenous ibuprofen treatment, Outcome 3 Number of ibuprofen doses. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0138">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-008-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0139"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-008-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-008-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Echocardiographically (ECHO)‐guided intravenous ibuprofen treatment versus standard intravenous ibuprofen treatment, Outcome 4 Mortality during hospital stay." data-id="CD003481-fig-0139" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-008-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.4</div> <div class="figure-caption"> <p>Comparison 8 Echocardiographically (ECHO)‐guided intravenous ibuprofen treatment versus standard intravenous ibuprofen treatment, Outcome 4 Mortality during hospital stay. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0139">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-008-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0140"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-008-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-008-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Echocardiographically (ECHO)‐guided intravenous ibuprofen treatment versus standard intravenous ibuprofen treatment, Outcome 5 Bronchopulmonary dysplasia (supplemental oxygen at 36 weeks' postmenstrual age)." data-id="CD003481-fig-0140" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-008-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.5</div> <div class="figure-caption"> <p>Comparison 8 Echocardiographically (ECHO)‐guided intravenous ibuprofen treatment versus standard intravenous ibuprofen treatment, Outcome 5 Bronchopulmonary dysplasia (supplemental oxygen at 36 weeks' postmenstrual age). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0140">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-008-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0141"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-008-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-008-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Echocardiographically (ECHO)‐guided intravenous ibuprofen treatment versus standard intravenous ibuprofen treatment, Outcome 6 Necrotising enterocolitis." data-id="CD003481-fig-0141" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-008-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.6</div> <div class="figure-caption"> <p>Comparison 8 Echocardiographically (ECHO)‐guided intravenous ibuprofen treatment versus standard intravenous ibuprofen treatment, Outcome 6 Necrotising enterocolitis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0141">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-008-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0142"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-008-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-008-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Echocardiographically (ECHO)‐guided intravenous ibuprofen treatment versus standard intravenous ibuprofen treatment, Outcome 7 Intraventricular haemorrhage (grade II and III)." data-id="CD003481-fig-0142" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-008-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.7</div> <div class="figure-caption"> <p>Comparison 8 Echocardiographically (ECHO)‐guided intravenous ibuprofen treatment versus standard intravenous ibuprofen treatment, Outcome 7 Intraventricular haemorrhage (grade II and III). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0142">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-008-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0143"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-008-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-008-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Echocardiographically (ECHO)‐guided intravenous ibuprofen treatment versus standard intravenous ibuprofen treatment, Outcome 8 White matter damage." data-id="CD003481-fig-0143" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-008-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.8</div> <div class="figure-caption"> <p>Comparison 8 Echocardiographically (ECHO)‐guided intravenous ibuprofen treatment versus standard intravenous ibuprofen treatment, Outcome 8 White matter damage. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0143">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-008-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0144"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-008-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-008-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Echocardiographically (ECHO)‐guided intravenous ibuprofen treatment versus standard intravenous ibuprofen treatment, Outcome 9 Oliguria (urine output &lt; 1 mL/kg/hour)." data-id="CD003481-fig-0144" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-008-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.9</div> <div class="figure-caption"> <p>Comparison 8 Echocardiographically (ECHO)‐guided intravenous ibuprofen treatment versus standard intravenous ibuprofen treatment, Outcome 9 Oliguria (urine output &lt; 1 mL/kg/hour). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0144">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-008-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0145"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-008-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-008-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Echocardiographically (ECHO)‐guided intravenous ibuprofen treatment versus standard intravenous ibuprofen treatment, Outcome 10 Serum/plasma creatinine (µmol/L) after treatment." data-id="CD003481-fig-0145" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-008-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.10</div> <div class="figure-caption"> <p>Comparison 8 Echocardiographically (ECHO)‐guided intravenous ibuprofen treatment versus standard intravenous ibuprofen treatment, Outcome 10 Serum/plasma creatinine (µmol/L) after treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0145">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-008-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0146"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-008-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-008-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Echocardiographically (ECHO)‐guided intravenous ibuprofen treatment versus standard intravenous ibuprofen treatment, Outcome 11 Laser therapy for retinopathy of prematurity." data-id="CD003481-fig-0146" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-008-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.11</div> <div class="figure-caption"> <p>Comparison 8 Echocardiographically (ECHO)‐guided intravenous ibuprofen treatment versus standard intravenous ibuprofen treatment, Outcome 11 Laser therapy for retinopathy of prematurity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0146">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-008-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0147"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-009-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-009-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Continuous infusion of ibuprofen versus intermittent boluses of ibuprofen, Outcome 1 Failure to close a patent ductus arteriosus (PDA) after 1 course of ibuprofen." data-id="CD003481-fig-0147" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-009-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9 Continuous infusion of ibuprofen versus intermittent boluses of ibuprofen, Outcome 1 Failure to close a patent ductus arteriosus (PDA) after 1 course of ibuprofen. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0147">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-009-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0148"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-009-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-009-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Continuous infusion of ibuprofen versus intermittent boluses of ibuprofen, Outcome 2 Reopening of PDA." data-id="CD003481-fig-0148" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-009-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9 Continuous infusion of ibuprofen versus intermittent boluses of ibuprofen, Outcome 2 Reopening of PDA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0148">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-009-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0149"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-009-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-009-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Continuous infusion of ibuprofen versus intermittent boluses of ibuprofen, Outcome 3 Need for surgical ligation." data-id="CD003481-fig-0149" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-009-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.3</div> <div class="figure-caption"> <p>Comparison 9 Continuous infusion of ibuprofen versus intermittent boluses of ibuprofen, Outcome 3 Need for surgical ligation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0149">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-009-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0150"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-009-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-009-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Continuous infusion of ibuprofen versus intermittent boluses of ibuprofen, Outcome 4 Mortality (in hospital)." data-id="CD003481-fig-0150" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-009-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.4</div> <div class="figure-caption"> <p>Comparison 9 Continuous infusion of ibuprofen versus intermittent boluses of ibuprofen, Outcome 4 Mortality (in hospital). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0150">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-009-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0151"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-009-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-009-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Continuous infusion of ibuprofen versus intermittent boluses of ibuprofen, Outcome 5 Chronic lung disease (at 36 weeks' postmenstrual age)." data-id="CD003481-fig-0151" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-009-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.5</div> <div class="figure-caption"> <p>Comparison 9 Continuous infusion of ibuprofen versus intermittent boluses of ibuprofen, Outcome 5 Chronic lung disease (at 36 weeks' postmenstrual age). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0151">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-009-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0152"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-009-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-009-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Continuous infusion of ibuprofen versus intermittent boluses of ibuprofen, Outcome 6 Retinopathy of prematurity (any stage)." data-id="CD003481-fig-0152" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-009-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.6</div> <div class="figure-caption"> <p>Comparison 9 Continuous infusion of ibuprofen versus intermittent boluses of ibuprofen, Outcome 6 Retinopathy of prematurity (any stage). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0152">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-009-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0153"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-009-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-009-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Continuous infusion of ibuprofen versus intermittent boluses of ibuprofen, Outcome 7 Retinopathy of prematurity (stage 3 or 4)." data-id="CD003481-fig-0153" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-009-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.7</div> <div class="figure-caption"> <p>Comparison 9 Continuous infusion of ibuprofen versus intermittent boluses of ibuprofen, Outcome 7 Retinopathy of prematurity (stage 3 or 4). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0153">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-009-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0154"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-009-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-009-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Continuous infusion of ibuprofen versus intermittent boluses of ibuprofen, Outcome 8 Intraventricular haemorrhage (any grade)." data-id="CD003481-fig-0154" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-009-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.8</div> <div class="figure-caption"> <p>Comparison 9 Continuous infusion of ibuprofen versus intermittent boluses of ibuprofen, Outcome 8 Intraventricular haemorrhage (any grade). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0154">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-009-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0155"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-009-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-009-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Continuous infusion of ibuprofen versus intermittent boluses of ibuprofen, Outcome 9 Intraventricular haemorrhage (grade III and IV)." data-id="CD003481-fig-0155" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-009-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.9</div> <div class="figure-caption"> <p>Comparison 9 Continuous infusion of ibuprofen versus intermittent boluses of ibuprofen, Outcome 9 Intraventricular haemorrhage (grade III and IV). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0155">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-009-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0156"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-009-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-009-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Continuous infusion of ibuprofen versus intermittent boluses of ibuprofen, Outcome 10 Periventricular leukomalacia (cystic)." data-id="CD003481-fig-0156" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-009-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.10</div> <div class="figure-caption"> <p>Comparison 9 Continuous infusion of ibuprofen versus intermittent boluses of ibuprofen, Outcome 10 Periventricular leukomalacia (cystic). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0156">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-009-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0157"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-009-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-009-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Continuous infusion of ibuprofen versus intermittent boluses of ibuprofen, Outcome 11 Necrotising enterocolitis." data-id="CD003481-fig-0157" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-009-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.11</div> <div class="figure-caption"> <p>Comparison 9 Continuous infusion of ibuprofen versus intermittent boluses of ibuprofen, Outcome 11 Necrotising enterocolitis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0157">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-009-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0158"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-009-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-009-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Continuous infusion of ibuprofen versus intermittent boluses of ibuprofen, Outcome 12 Isolated intestinal perforation." data-id="CD003481-fig-0158" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-009-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.12</div> <div class="figure-caption"> <p>Comparison 9 Continuous infusion of ibuprofen versus intermittent boluses of ibuprofen, Outcome 12 Isolated intestinal perforation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0158">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-009-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0159"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-009-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-009-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Continuous infusion of ibuprofen versus intermittent boluses of ibuprofen, Outcome 13 Oliguria (urine output ≤ 1 mL/kg/hour)." data-id="CD003481-fig-0159" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-009-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.13</div> <div class="figure-caption"> <p>Comparison 9 Continuous infusion of ibuprofen versus intermittent boluses of ibuprofen, Outcome 13 Oliguria (urine output ≤ 1 mL/kg/hour). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0159">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-009-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0160"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-009-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-009-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Continuous infusion of ibuprofen versus intermittent boluses of ibuprofen, Outcome 14 Serum/plasma creatinine after treatment (µmol/L)." data-id="CD003481-fig-0160" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-009-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.14</div> <div class="figure-caption"> <p>Comparison 9 Continuous infusion of ibuprofen versus intermittent boluses of ibuprofen, Outcome 14 Serum/plasma creatinine after treatment (µmol/L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0160">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-009-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0161"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-009-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-009-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Continuous infusion of ibuprofen versus intermittent boluses of ibuprofen, Outcome 15 Gastrointestinal haemorrhage." data-id="CD003481-fig-0161" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-009-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.15</div> <div class="figure-caption"> <p>Comparison 9 Continuous infusion of ibuprofen versus intermittent boluses of ibuprofen, Outcome 15 Gastrointestinal haemorrhage. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0161">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-009-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0162"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-010-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-010-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Rectal ibuprofen versus oral ibuprofen, Outcome 1 Failure to close a PDA after 3 doses." data-id="CD003481-fig-0162" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-010-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10 Rectal ibuprofen versus oral ibuprofen, Outcome 1 Failure to close a PDA after 3 doses. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0162">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-010-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0163"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-010-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-010-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Rectal ibuprofen versus oral ibuprofen, Outcome 2 Need for surgical ligation." data-id="CD003481-fig-0163" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-010-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10 Rectal ibuprofen versus oral ibuprofen, Outcome 2 Need for surgical ligation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0163">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-010-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0164"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-010-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-010-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Rectal ibuprofen versus oral ibuprofen, Outcome 3 Plasma creatinine (µmol/L." data-id="CD003481-fig-0164" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-010-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.3</div> <div class="figure-caption"> <p>Comparison 10 Rectal ibuprofen versus oral ibuprofen, Outcome 3 Plasma creatinine (µmol/L. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0164">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-010-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0165"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-010-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-010-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Rectal ibuprofen versus oral ibuprofen, Outcome 4 Plasma bilirubin (µmol/L) after treatment." data-id="CD003481-fig-0165" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-010-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.4</div> <div class="figure-caption"> <p>Comparison 10 Rectal ibuprofen versus oral ibuprofen, Outcome 4 Plasma bilirubin (µmol/L) after treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0165">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-010-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003481-fig-0166"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/urn:x-wiley:14651858:media:CD003481:CD003481-CMP-010-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_t/tCD003481-CMP-010-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Rectal ibuprofen versus oral ibuprofen, Outcome 5 Urine output (mL/kg/hr) after treatment." data-id="CD003481-fig-0166" src="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-010-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.5</div> <div class="figure-caption"> <p>Comparison 10 Rectal ibuprofen versus oral ibuprofen, Outcome 5 Urine output (mL/kg/hr) after treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-fig-0166">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/media/CDSR/CD003481/image_n/nCD003481-CMP-010-05.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD003481-tbl-0001"> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Intravenous ibuprofen compared with placebo for patent ductus arteriosus</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population: preterm infants with patent ductus arteriosus</b> </p> <p><b>Settings: NICU</b> </p> <p><b>Intervention: intravenous ibuprofen</b> </p> <p><b>Comparison: placebo</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>IV ibuprofen</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Failure to close a patent ductus arteriosus (after 3 doses)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.62</b> (0.44 to 0.86) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>206<br/> (2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bias: there was unclear bias for random sequence generation and allocation concealment in the two included studies. The blinding of personnel was unclear in both studies and the blinding of outcome assessments was low risk in one study and unclear in the other study. We did not downgrade the evidence. </p> <p>Heterogeneity/consistency: we noted moderate heterogeneity (65%) for RR but no heterogeneity (0%) for RD. We downgraded the evidence by one step. </p> <p>Directness of evidence: studies were conducted in the target population.</p> <p>Precision: the confidence intervals around the point estimates for RR and RD were quite narrow </p> <p>Presence of publication bias: this category was not applicable as only two studies were included in the analysis. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>471 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>294 per 1000</b><br/> 29 to 432 </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Necrotising enterocolitis</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.84</b> (0.87 to 3.90) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>264<br/> (2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bias: the information about random sequence generation, allocation concealment, blinding of personnel and blinding of outcome assessments was unclear in one of the two studies. In the second study there were no concerns about these items. We did not downgrade the evidence. </p> <p>Heterogeneity/consistency: we noted high heterogeneity (77%) for RR and moderate heterogeneity (67%) for RD. We downgraded the evidence by one step. </p> <p>Directness of evidence: studies were conducted in the target population.</p> <p>Precision: the confidence intervals around the point estimates for RR and RD were quite narrow. </p> <p>Presence of publication bias: this category was not applicable as only two studies were included in the analysis. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>68 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>129 per 1000</b><br/> (119 to 139) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>IV:</b> intravenous; <b>NICU:</b> Neonatal intensive care unit: <b>RD:</b> risk difference; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-title"></span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/full#CD003481-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003481-tbl-0002"> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Intravenous or oral ibuprofen compared with intravenous or oral indomethacin for patent ductus arteriosus</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population: preterm infants with patent ductus arteriosus</b> </p> <p><b>Settings: NICU</b> </p> <p><b>Intervention: intravenous or oral ibuprofen</b> </p> <p><b>Comparison: intravenous or oral indomethacin</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Indomethacin (IV or oral)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Ibuprofen (IV or oral)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Failure to close a patent ductus arteriosus (PDA) (after single or 3 doses)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.07</b> (0.92 to 1.24) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1590<br/> (24) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bias: there was low risk of bias for random sequence generation in 7 of the studies and there was unclear risk in the remaining 17 studies.There was low risk of bias for allocation concealment in 13 studies, high risk of bias in one study and unclear risk in the remaining 10 studies. The blinding of personnel was adequate in three studies, unclear in six studies and there was high risk of bias in 15 studies. Blinding of outcome assessments was at low risk of bias in 11 studies, unclear in six studies and there was high risk of bias in seven studies. We downgraded the evidence by one step. </p> <p>Heterogeneity/consistency: there was no heterogeneity (0%) for either RR or for RD.</p> <p>Directness of evidence: studies were conducted in the target population.</p> <p>Precision: the confidence intervals around the point estimates for RR and RD were narrow. </p> <p>Presence of publication bias: the funnel plot was symmetric based on 24 studies.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>280 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>305 per 1000</b><br/> (0 to 708) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Need for surgical closure of the PDA</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.06</b> (0.81 to 1.39) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1275<br/> (16) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bias: there was low risk of bias for random sequence generation in seven of the studies and there was unclear risk in the remaining 9 studies.There was low risk of bias for allocation concealment in 10 studies, high risk of bias in one study and unclear risk in the remaining 5 studies. The blinding of personnel was adequate in three studies, unclear in two studies and there was high risk of bias in 11 studies. Blinding of outcome assessments was at low risk of bias in 9 studies, unclear in three studies and there was high risk of bias in four studies. We downgraded the evidence by one step. </p> <p>Heterogeneity/consistency: there was no heterogeneity (0%) for either RR or for RD.</p> <p>Directness of evidence: studies were conducted in the target population.</p> <p>Precision: the confidence intervals around the point estimates for RR and RD were narrow. </p> <p>Presence of publication bias: the funnel plot was symmetric based on 16 studies.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>135 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>144 per 1000</b><br/> (0 to 250) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of ventilator support (days)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean duration of ventilator support (days) ranged across control groups from 8 to 26 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean duration of ventilator support (days) in the intervention groups was 2.35 days lower (3.71 to 0.99 days lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD ‐2.35</b> (‐3.71 to ‐0.99) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>471<br/> (6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bias: there was low risk of bias for random sequence generation in two of the studies and there was unclear risk in the remaining four studies.There was low risk of bias for allocation concealment in five studies, and unclear risk in one study. The blinding of personnel was adequate in two studies, and there was high risk of bias in four studies. Blinding of outcome assessments was at low risk of bias in four studies, and unclear in two studies. We downgraded the evidence by one step. </p> <p>Heterogeneity/consistency: there was no heterogeneity (19%) for MD.</p> <p>Directness of evidence: studies were conducted in the target population.</p> <p>Precision: the confidence intervals around the point estimates for RR and RD were narrow. </p> <p>Presence of publication bias: only 6 studies were included in the analysis so a funnel plot was not constructed. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Necrotising enterocolitis (any stage)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.68</b> (0.49 to 0.94) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1292<br/> (18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bias: there was low risk of bias for random sequence generation in seven of the studies and there was unclear risk in the remaining 11 studies.There was low risk of bias for allocation concealment in eleven studies, high risk in one study and unclear risk in six studies. The blinding of personnel was adequate in two studies, and there was high risk of bias in 13 studies and an unclear risk of bias in three studies. Blinding of outcome assessments was at low risk of bias in ten studies, high risk of bias in five studies and unclear in three studies. We downgraded the evidence by one step. </p> <p>Heterogeneity/consistency: there was no heterogeneity (0%) for RR and RD.</p> <p>Directness of evidence: studies were conducted in the target population.</p> <p>Precision: the confidence intervals around the point estimates for RR and RD were narrow. </p> <p>Presence of publication bias: the funnel plot was symmetric based on 18 studies.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>111 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>73 per 1000</b><br/> (0 to 400) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Oliguria (urine output &lt; 1 mL/kg/hour)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.28</b> (0.14 to 0.54) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>576<br/> (6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bias: there was low risk of bias for random sequence generation in two of the studies and there was unclear risk in the remaining four studies.There was low risk of bias for allocation concealment in four studies, and unclear risk in two studies. The blinding of personnel was adequate in two studies, unclear in one study and there was high risk of bias in three studies. Blinding of outcome assessments was at low risk of bias in all six studies. We did not downgrade the evidence. </p> <p>Heterogeneity/consistency: there was no heterogeneity (24%) for RR and moderate for RD (69%). We downgraded the evidence by one step. </p> <p>Directness of evidence: studies were conducted in the target population.</p> <p>Precision: the confidence intervals around the point estimates for RR and RD were narrow. </p> <p>Presence of publication bias: only 6 studies were included in the analysis so a funnel plot was not constructed. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>124 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>34 per 1000</b><br/> (0 to 68) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serum/plasma creatinine levels (μmol/L) 72 hours after treatment</b> </p> <p>Normal values for male and female newborns 17.7 to 88.4 µmol/L</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean s<b>erum/plasma creatinine level</b> ranged across control groups from 45.97 to 147.63 <b>μmol/L</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean s<b>erum/plasma creatinine level</b> in the intervention groups was<br/> 8.12 <b>μmol/L lower (‐10.81 to ‐ 5.43 lower)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD ‐8.12 μmol/L (‐10.81 to ‐ 5.43)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>918<br/> (11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bias: there was low risk of bias for random sequence generation in four of the studies and there was unclear risk in the remaining seven studies.There was low risk of bias for allocation concealment in seven studies and unclear risk in four studies. The blinding of personnel was adequate in two studies, there was high risk of bias in seven studies, and the risk of bias was unclear in two studies. Blinding of outcome assessments was at low risk of bias in six studies but there was high risk of bias in 5 studies. We downgraded the evidence by one step. </p> <p>Heterogeneity/consistency: there was high heterogeneity (83%) for MD. We downgraded the evidence by one step. </p> <p>Directness of evidence: studies were conducted in the target population.</p> <p>Precision: the confidence intervals around the point estimates for MD were narrow.</p> <p>Presence of publication bias: the funnel plot was symmetric based on 11 studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>IV:</b> intravenous; <b>MD</b> : mean difference; <b>NICU:</b> Neonatal intensive care unit; <b>RD</b> : risk difference; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-title"></span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/full#CD003481-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003481-tbl-0003"> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Oral ibuprofen compared with intravenous or oral indomethacin for patent ductus arteriosus</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population: preterm infants with patent ductus arteriosus</b> </p> <p><b>Settings: NICU</b> </p> <p><b>Intervention: oral ibuprofen</b> </p> <p><b>Comparison: intravenous or oral indomethacin</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Intravenous or oral indomethacin</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Oral ibuprofen</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Failure to close a patent ductus arteriosus (PDA) (after 3 doses)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.96</b> (0.73 to 1.27) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>272<br/> (8) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bias: there was low risk of bias for random sequence generation in two of the studies and there was unclear risk in the remaining six studies.There was low risk of bias for allocation concealment in 3 studies, high risk of bias in one study and unclear risk in four studies. The blinding of personnel was inadequate in seven studies and unclear in one study. Blinding of outcome assessments was good in two of the studies but with high risk of bias in six studies. We downgraded the evidence by two steps. </p> <p>Heterogeneity/consistency: we noted no heterogeneity (0%) for RR and RD.</p> <p>Directness of evidence: studies were conducted in the target population.</p> <p>Precision: the confidence interval around the point estimates for MD was quite narrow</p> <p>Presence of publication bias: only 8 studies were included in the analysis so a funnel plot was not constructed. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>386 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>393 per 1000</b><br/> (0 to 708) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Need for surgical closure of the PDA</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.93</b> (0.50 to 1.74) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>174<br/> (4) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bias: there was low risk of bias for random sequence generation in two of the studies and there was unclear risk in two studies.There was low risk of bias for allocation concealment in one study, high risk of bias in one study and unclear risk in two studies. The blinding of personnel was inadequate in all four studies as was blinding of outcome assessments. We downgraded the evidence by two steps. </p> <p>Heterogeneity/consistency: we noted no heterogeneity (0%) for RR and RD.</p> <p>Directness of evidence: studies were conducted in the target population.</p> <p>Precision: the confidence interval around the point estimate for RR and RD was quite narrow. </p> <p>Presence of publication bias: only 4 studies were included in the analysis so a funnel plot was not constructed. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>188 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>181 per 1000</b><br/> (0 to250) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Necrotising enterocolitis (any stage)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.41</b> (0.23 to 0.73) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>249<br/> (7) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bias: there was low risk of bias for random sequence generation in two of the studies and there was unclear risk in the remaining five studies.There was low risk of bias for allocation concealment in 3 studies, high risk of bias in one study and unclear risk in three studies. The blinding of personnel was inadequate in six studies and unclear in one study. Blinding of outcome assessments was good in two of the studies but with high risk of bias in five studies. We downgraded the evidence by two steps. </p> <p>Heterogeneity/consistency: we noted no heterogeneity (0%) for RR and RD.</p> <p>Directness of evidence: studies were conducted in the target population.</p> <p>Precision: the confidence interval around the point estimates for MD was quite narrow.</p> <p>Presence of publication bias: only 7 studies were included in the analysis so a funnel plot was not constructed. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>224 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>83 per 1000</b><br/> (0 to 400) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serum/plasma creatinine levels (µmol/L) 72 hours after treatment</b> </p> <p>Normal values for male and female newborns 17.7 to 88.4 µmol/L</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>The mean serum/plasma creatinine levels ranged across control groups from 45.97 to 106.08 µmol/L</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean <b>serum/plasma creatinine level</b> in the intervention groups was 0.51 <b>µmol/L (‐6.04 to 5.01)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD ‐0.51</b> (‐6.04 to 5.01) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>190<br/> (5) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bias: there was low risk of bias for random sequence generation in one of the studies and there was unclear risk in the remaining 4 studies.There was low risk of bias for allocation concealment in 3 studies, and unclear risk in two studies The blinding of personnel was inadequate in four studies and unclear in one study. Blinding of outcome assessments was good in one of the studies but with high risk of bias in four studies. We downgraded the evidence by two steps. </p> <p>Heterogeneity/consistency: we noted moderate heterogeneity (72%) for MD. We downgraded the evidence by one step. </p> <p>Directness of evidence: studies were conducted in the target population.</p> <p>Precision: the confidence interval around the point estimates for MD was quite narrow.</p> <p>Presence of publication bias: only 5 studies were included in the analysis so a funnel plot was not constructed. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>MD:</b> Mean difference; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-title"></span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/full#CD003481-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003481-tbl-0004"> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Oral ibuprofen compared with intravenous ibuprofen for patent ductus arteriosus</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population: preterm infants with patent ductus arteriosus</b> </p> <p><b>Settings: NICU</b> </p> <p><b>Intervention: oral ibuprofen</b> </p> <p><b>Comparison: intravenous ibuprofen</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>intravenous ibuprofen</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>oral ibuprofen</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Failure to close a patent ductus arteriosus (after single or 3 doses)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.38</b> (0.26 to 0.56) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>406<br/> (5) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bias: there was unclear risk of bias for random sequence generation in all 5 studies. There was low risk of bias for allocation concealment in 4 studies, and unclear risk in one study. The blinding of personnel was inadequate in all five studies and blinding of outcome assessments was good in three studies but inadequate in two studies. We downgraded the evidence by one step. </p> <p>Heterogeneity/consistency: we noted no heterogeneity for RR and for RD (0%).</p> <p>Directness of evidence: studies were conducted in the target population.</p> <p>Precision: the confidence intervals around the point estimates for RR and RD were quite narrow. </p> <p>Presence of publication bias: only 5 studies were included in the analysis so a funnel plot was not constructed. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>363 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>139 per 1000</b><br/> (115 to 156) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Need for surgical closure of the ductus</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.41</b> (0.41 to 1.21) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>406<br/> (5) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bias: there was unclear risk of bias for random sequence generation in all 5 studies. There was low risk of bias for allocation concealment in 4 studies, and unclear risk in one study. The blinding of personnel was inadequate in all five studies and blinding of outcome assessments was good in three studies but inadequate in two studies We downgraded the evidence by one step. </p> <p>Heterogeneity/consistency: we noted no heterogeneity for RR and for RD (0%).</p> <p>Directness of evidence: studies were conducted in the target population.</p> <p>Precision: the confidence intervals around the point estimates for RR and RD were quite narrow. </p> <p>Presence of publication bias: only 5 studies were included in the analysis so a funnel plot was not constructed. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>51 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>19 per 1000</b><br/> (0 to 31) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Duration of ventilatory support</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>MD 0.54 (days)</b> (‐0.01 to 1.10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>134</p> <p>(2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Bias: there was unclear risk of bias for random sequence generation in both studies. There was low risk of bias for allocation concealment in one study, and unclear risk in one study. The blinding of personnel was inadequate in both studies and blinding of outcome assessments was good in one study but inadequate in two one study. We downgraded the evidence by one step. </p> <p>Heterogeneity/consistency: we noted no heterogeneity for MD (10%).</p> <p>Directness of evidence: studies were conducted in the target population.</p> <p>Precision: the confidence intervals around the point estimates for RR and RD were quite wide. We downgraded the evidence by one step. </p> <p>Presence of publication bias: only two studies were included in the analysis so a funnel plot was not constructed. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>The mean duration of ventilatory support (days) ranges across control groups from 3 to 5.1 days</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>The mean duration of ventilatory support was 0.54 (days) higher in the in the oral ibuprofen group (‐0.01 to 1.10)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serum/plasma creatinine levels (μmol/L) after treatment</b> </p> <p>Normal values for male and female newborns 17.7 to 88.4 µmol/L</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>The mean serum/plasma creatinine levels ranged across control groups from 69.84 to 76.02 (μmol/L)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>The mean serum/plasma creatinine level in the intervention groups was 22.47 (μmol/L) lower</b> (‐32.40 to ‐12.53) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 22.47</b> (μmol/L) (‐32.40 to ‐12.53) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>170<br/> (2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bias: there was unclear risk of bias for random sequence generation in both studies. There was low risk of bias for allocation concealment in one study, and unclear risk in one study. The blinding of personnel was inadequate in both studies and blinding of outcome assessments was good in one study but inadequate in the other study. We downgraded the evidence by one step. </p> <p>Heterogeneity/consistency: there was high heterogeneity for MD (81%). We downgraded the evidence by one step. </p> <p>Directness of evidence: studies were conducted in the target population.</p> <p>Precision: the confidence intervals around the point estimates for MD were quite narrow.</p> <p>Presence of publication bias: only 2 studies were included in the analysis so a funnel plot was not constructed. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Oliguria (Urine output &lt; 1 mL/kg/hour)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.14</b> (0.01 to 2.66) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>304<br/> (4) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bias: there was unclear risk of bias for random sequence generation in all 4 studies. There was low risk of bias for allocation concealment in three studies, and unclear risk in one study. The blinding of personnel was inadequate in all four studies and blinding of outcome assessments was good in three studies but inadequate in one study. We downgraded the evidence by one step. </p> <p>Heterogeneity/consistency: tests for heterogeneity were not applicable for RR as there were only outcomes in one group in one trial. We noted no heterogeneity for RD (19%). </p> <p>Directness of evidence: studies were conducted in the target population.</p> <p>Precision: the confidence interval around the point estimate for RR was quite wide. We downgraded the evidence by one step. </p> <p>Presence of publication bias: only 4 studies were included in the analysis so a funnel plot was not constructed. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>IV:</b> intravenous; <b>MD</b> : Mean difference; <b>NICU:</b> Neonatal intensive care unit; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-title"></span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/full#CD003481-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003481-tbl-0005"> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>High‐dose oral or intravenous ibuprofen compared with standard‐dose oral or intravenous ibuprofen for patent ductus arteriosus</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population: preterm infants</b> with patent ductus arteriosus </p> <p><b>Settings: NICU</b> </p> <p><b>Intervention: high‐dose oral or intravenous ibuprofen</b> </p> <p><b>Comparison: standard‐dose oral or intravenous ibuprofen</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Standard‐dose ibuprofen</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>High‐dose ibuprofen</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Failure to close a patent ductus arteriosus after 3 doses of ibuprofen</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.37</b> (0.22 to 0.61) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>190<br/> (3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bias: there was unclear risk of bias for random sequence generation in all three studies. The allocation was concealed in two of the studies and unclear in one study. The blinding of personnel was unclear in all three studies and blinding of outcome assessments was unclear in one of the three studies, with low risk of bias in the other two studies. We downgraded the evidence by one step. </p> <p>Heterogeneity/consistency: we noted no heterogeneity for RR (4%) or for RD (0%).</p> <p>Directness of evidence: studies were conducted in the target population.</p> <p>Precision: the confidence intervals around the point estimates for RR and RD were quite narrow. </p> <p>Presence of publication bias: only 3 studies were included in the analysis so a funnel plot was not constructed. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>411 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>147 per 1000</b><br/> (0 to 300) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Necrotising enterocolitis</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.00</b> (0.40 to 2.50) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>130<br/> (2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bias: there was unclear risk of bias for random sequence generation in both studies. The allocation was concealed in both studies. The blinding of personnel was unclear in both studies but there was low risk of bias for blinding of outcome assessments. We downgraded the evidence by one step. </p> <p>Heterogeneity/consistency: we noted no heterogeneity for RR or for RD (0% for both).</p> <p>Directness of evidence: studies were conducted in the target population.</p> <p>Precision: the confidence intervals around the point estimates for RR and RD were quite wide as the sample size was small. We downgraded the evidence by one step. </p> <p>Presence of publication bias: only 2 studies were included in the analysis so a funnel plot was not constructed. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>123 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>123 per 1000</b><br/> (114 to 133) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Oliguria</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 1.57</b> (0.44 to 5.63) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>120</p> <p>(2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Bias: there was unclear risk of bias for random sequence generation in both studies. The allocation was concealed in one study. The blinding of personnel was unclear in both studies but there was low risk of bias for blinding of outcome assessments (by cardiologist) in one study. We downgraded the evidence by one step. </p> <p>Heterogeneity/consistency: we noted no heterogeneity for RR or for RD (0% for both).</p> <p>Directness of evidence: studies were conducted in the target population.</p> <p>Precision: the confidence intervals around the point estimates for RR and RD were quite wide as the sample size was small. We downgraded the evidence by one step. </p> <p>Presence of publication bias: only 2 studies were included in the analysis so a funnel plot was not constructed. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>50 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>83 per 1000</p> <p>(33 to 133)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>NICU:</b> Neonatal intensive care unit; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-title"></span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/full#CD003481-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003481-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Intravenous ibuprofen versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Failure to close a patent ductus arteriosus (after 3 doses) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.44, 0.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Need for surgical ligation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.89 [0.91, 3.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Intraventricular haemorrhage (any grade) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.64, 1.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Intraventricular haemorrhage (grades III and IV) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.47, 2.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Periventricular leukomalacia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.01, 2.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Pulmonary haemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.03, 2.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Pulmonary hypertension <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.19, 21.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Retinopathy of prematurity (any stage) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.88, 1.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Retinopathy of prematurity (stage 3 or 4) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.38, 3.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Retinopathy of prematurity (plus disease) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.31, 5.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Chronic lung disease (supplemental oxygen at 28 days of age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.95, 1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Chronic lung disease (supplemental oxygen at 36 weeks' postmenstrual age (PMA)) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.88, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Necrotising enterocolitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.84 [0.87, 3.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Mortality by 28 days of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Oliguria (urine output &lt; 1 mL/kg/hour) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>39.0 [2.40, 633.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Creatinine (µmol/L) after treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>29.17 [12.60, 45.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Blood urea nitrogen (µmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>18.45 [12.76, 24.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.8 [0.34, 1.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Intravenous ibuprofen versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003481-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Oral ibuprofen versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Failure to close a patent ductus arteriosus after single or 3 doses <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.11, 0.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Oral ibuprofen versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003481-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Intravenous or oral ibuprofen versus intravenous or oral indomethacin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Failure to close a patent ductus arteriosus (PDA) (after single or 3 doses) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1590</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.92, 1.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>697</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.54, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Neonatal mortality (during first 28/30 days of life) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>333</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.59, 2.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Reopening of the ductus arteriosus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>305</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.57 [0.83, 2.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Need for surgical closure of the PDA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1275</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.81, 1.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Need for re‐treatment with indomethacin or ibuprofen to close the PDA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>241</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.76, 1.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Duration of ventilator support (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>471</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.35 [‐3.71, ‐0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Duration of need for supplementary oxygen (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>556</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.33 [‐1.66, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Pulmonary haemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>303</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.40, 2.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Pulmonary hypertension <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.53 [0.15, 81.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Chronic lung disease (at 28 days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>292</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.93, 1.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Chronic lung disease (at 36 weeks' postmenstrual age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>357</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.77, 1.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Chronic lung disease (age not stated) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.82, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Intraventricular haemorrhage (any grade) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>524</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.61, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Intraventricular haemorrhage (grades III and IV) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>798</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.68, 1.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Periventricular leukomalacia (cystic) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>573</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.67, 2.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Necrotising enterocolitis (any stage) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1292</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.49, 0.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Intestinal perforation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.20, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Gastrointestinal bleed <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>514</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.55, 1.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Time to full enteral feeds <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>413</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [‐1.89, 3.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Time to regain birth weight (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.18 [‐2.59, 2.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Retinopathy of prematurity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>581</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.60, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Sepsis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>735</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.84, 1.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 Oliguria (urine output &lt; 1 mL/kg/hour) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>576</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.14, 0.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25 Serum/plasma creatinine levels (μmol/L) 72 hours after treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>918</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.12 [‐10.81, ‐5.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26 Increase in serum/plasma creatinine levels (mg/dL) following treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐15.91 [‐31.78, ‐0.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">27 Duration of hospitalisation (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>368</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.69 [‐4.54, 3.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">28 Significant decrease in urine output (&gt; 20% decrease in urine output after starting therapy) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.30, 0.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">29 Daily urine output mL/kg/hr <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.45, 0.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">30 Serum bilirubin (µmol/L) after treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>12.65 [9.96, 15.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">31 Platelet count (x10<sup>9</sup>/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>72.0 [58.07, 85.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Intravenous or oral ibuprofen versus intravenous or oral indomethacin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003481-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Oral ibuprofen versus intravenous (IV) or oral indomethacin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Failure to close a patent ductus arteriosus (PDA) (after 3 doses) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>272</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.73, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.20, ‐0.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Neonatal mortality (during first 28/30 days of life) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.12, 0.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Reopening of the ductus arteriosus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.17, 0.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Need for surgical closure of the PDA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>174</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.50, 1.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Pulmonary haemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.22 [‐0.51, 0.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Pulmonary hypertension <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.05, 0.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Chronic lung disease (at 28 days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.07 [‐0.42, 0.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Chronic lung disease (age not stated) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.44, 0.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Intraventricular haemorrhage (any grade) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.03 [‐0.22, 0.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Intraventricular haemorrhage (grades III and IV) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.14, 0.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Periventricular leukomalacia (cystic) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.05 [‐0.18, 0.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Necrotising enterocolitis (any stage) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>249</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.23, 0.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Intestinal perforation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.25, 0.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Gastrointestinal bleed <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [‐0.05, 0.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Retinopathy of prematurity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.00 [‐0.18, 0.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Sepsis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.22, 0.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Oliguria (urine output &lt; 1 mL/kg/hour) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.10, 0.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Serum/plasma creatinine levels (µmol/L) 72 hours after treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.51 [‐6.04, 5.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Duration of hospital stay (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.55 [‐3.61, 12.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Oral ibuprofen versus intravenous (IV) or oral indomethacin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003481-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Oral ibuprofen versus intravenous (IV) ibuprofen</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Failure to close a patent ductus arteriosus (after single or 3 doses) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>406</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.26, 0.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mortality (during first 28/30 days of life) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.50, 2.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mortality (during hospital stay) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.38, 1.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Mean plasma cystatin‐C (mg/L) after treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.25 [‐0.37, ‐0.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Need for surgical closure of the ductus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>406</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.14, 1.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Duration of ventilatory support <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [‐0.01, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Duration of hospitalisation (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>236</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.51 [‐5.21, 0.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Pneumothorax <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.11, 1.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Pulmonary haemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.01, 2.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Pulmonary hypertension <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Chronic lung disease (at 36 weeks' postmenstrual age or at discharge) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>236</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.56, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Intraventricular haemorrhage (any grade) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.59, 2.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Periventricular leukomalacia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.15, 6.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Necrotising enterocolitis (any stage) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>236</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.35, 2.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Intestinal perforation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.01, 7.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Gastrointestinal bleed <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.89 [0.12, 69.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Sepsis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>236</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.54, 1.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Retinopathy of prematurity that required laser treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.26, 1.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Serum/plasma creatinine levels (μmol/L) after treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐22.47 [‐32.40, ‐12.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Oliguria (Urine output &lt; 1 mL/kg/hour) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>304</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.01, 2.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Mental Developmental Index (Bayley II) at 18‐24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐9.0 [‐23.89, 5.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Psychomotor Developmental Index at 18‐24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.0 [‐7.67, 17.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Moderate/severe cerebral palsy at 18‐24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.24, 7.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 Blindness at 18‐24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25 Deafness at 18‐24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Oral ibuprofen versus intravenous (IV) ibuprofen</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003481-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">High‐dose (oral or IV) versus standard‐dose ibuprofen (oral or IV)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Failure to close a patent ductus arteriosus after 3 doses of ibuprofen <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.22, 0.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Reopening after second course of ibuprofen <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.39, 10.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Need for surgical closure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.15, 6.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Mortality during hospital stay <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.58, 1.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Urine output on day 3 of treatment (mL/kg/hour) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [‐0.43, 0.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Oliguria (&lt; 1 mL/kg/hour during 24 hours) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.5 [0.27, 8.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Intraventricular haemorrhage (any grade) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.21, 2.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Intraventricular haemorrhage (grades III and IV) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.5 [0.10, 2.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Periventricular leukomalacia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.5 [0.27, 8.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Retinopathy of prematurity (any stage) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.27, 3.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Retinopathy of prematurity (stage 3 or 4) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.19, 21.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Necrotising enterocolitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.40, 2.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Chronic lung disease (at 36 weeks' postmenstrual age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.6 [0.85, 3.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Sepsis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.51, 1.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Hospital stay (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>21.0 [‐1.44, 43.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Oliguria (&lt; 0.5 mL/kg/hour) after onset of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.57 [0.44, 5.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Gastrointestinal bleed <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.5 [0.58, 3.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Platelet count (x 10<sup>9</sup>/L) after treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐29.0 [‐74.83, 16.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Serum creatinine (µmol/L) after treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.84 [‐4.41, 22.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">High‐dose (oral or IV) versus standard‐dose ibuprofen (oral or IV)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003481-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Early versus expectant administration of intravenous ibuprofen</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Days on supplemental oxygen during the first 28 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.04, 3.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Days on supplemental oxygen <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [‐8.20, 12.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Days on mechanical ventilation first 28 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [‐0.58, 4.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Days on mechanical ventilation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.0 [‐6.98, 4.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Chronic lung disease (at 36 weeks' postmenstrual age (PMA)) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.57, 1.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Mortality or chronic lung disease (at 36 weeks' PMA) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.59, 1.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Mortality during hospital stay <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.19, 2.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Pneumothorax <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.30, 5.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Intraventricular haemorrhage (grades III and IV) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.29, 2.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Periventricular leukomalacia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.30, 5.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Necrotising enterocolitis (requiring surgery) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.36 [0.48, 11.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Intestinal perforation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.09, 2.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Sepsis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.58, 1.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Retinopathy of prematurity (stage 3 or 4) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.58 [0.49, 5.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Early versus expectant administration of intravenous ibuprofen</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003481-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Echocardiographically (ECHO)‐guided intravenous ibuprofen treatment versus standard intravenous ibuprofen treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Failure to close a patent ductus arteriosus (PDA) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.44, 3.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Reopening of PDA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.25 [0.25, 20.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Number of ibuprofen doses <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.25 [‐1.70, ‐0.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Mortality during hospital stay <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.14, 2.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Bronchopulmonary dysplasia (supplemental oxygen at 36 weeks' postmenstrual age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.53, 3.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Necrotising enterocolitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.08, 1.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Intraventricular haemorrhage (grade II and III) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.5 [0.60, 3.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 White matter damage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.88 [0.40, 8.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Oliguria (urine output &lt; 1 mL/kg/hour) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.31 [0.29, 97.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Serum/plasma creatinine (µmol/L) after treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐11.49 [‐29.88, 6.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Laser therapy for retinopathy of prematurity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.25 [0.50, 10.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Echocardiographically (ECHO)‐guided intravenous ibuprofen treatment versus standard intravenous ibuprofen treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003481-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Continuous infusion of ibuprofen versus intermittent boluses of ibuprofen</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Failure to close a patent ductus arteriosus (PDA) after 1 course of ibuprofen <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.88, 1.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Reopening of PDA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.05 [0.33, 28.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Need for surgical ligation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.08, 0.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Mortality (in hospital) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.07, 15.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Chronic lung disease (at 36 weeks' postmenstrual age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.55, 2.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Retinopathy of prematurity (any stage) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.39, 1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Retinopathy of prematurity (stage 3 or 4) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.04, 3.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Intraventricular haemorrhage (any grade) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.25, 2.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Intraventricular haemorrhage (grade III and IV) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.01, 8.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Periventricular leukomalacia (cystic) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.05, 5.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Necrotising enterocolitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.12, 1.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Isolated intestinal perforation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.04 [0.19, 21.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Oliguria (urine output ≤ 1 mL/kg/hour) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.05, 5.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Serum/plasma creatinine after treatment (µmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.10 [‐4.92, 9.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Gastrointestinal haemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.16, 1.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Continuous infusion of ibuprofen versus intermittent boluses of ibuprofen</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003481-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Rectal ibuprofen versus oral ibuprofen</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Failure to close a PDA after 3 doses <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.28, 2.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Need for surgical ligation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.15, 6.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Plasma creatinine (µmol/L <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.18 [‐7.22, ‐5.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Plasma bilirubin (µmol/L) after treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.01 [‐11.23, 25.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Urine output (mL/kg/hr) after treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.22 [‐0.45, 0.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Rectal ibuprofen versus oral ibuprofen</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003481.pub8/references#CD003481-tbl-0015">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD003481.pub8&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD003481-note-0007">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD003481-note-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD003481-note-0005">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD003481-note-0009">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD003481-note-0004">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD003481-note-0006">Polski</a> </li> <li class="section-language"> <a class="" href="pt#CD003481-note-0003">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD003481-note-0002">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD003481-note-0014">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD003481-note-0008">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003481\x2epub8\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003481\x2epub8\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003481\x2epub8\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003481\x2epub8"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003481\x2epub8\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003481\x2epub8\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003481\x2epub8\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003481\x2epub8\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003481\x2epub8\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003481\x2epub8"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003481\x2epub8\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003481\x2epub8\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003481\x2epub8\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003481\x2epub8"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003481\x2epub8\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003481\x2epub8\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003481\x2epub8\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003481\x2epub8"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Ko3zGe0H&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003481.pub8&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003481.pub8';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD003481.pub8/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD003481.pub8/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003481.pub8%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740726073009"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003481.pub8/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740726073013"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003481.pub8/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e8abb9b399379',t:'MTc0MDcyNjA3My4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 